Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 1Clinical Study Protocol 
Drug Substance Durvalumab
Study Code D9100C00001
Version 4.0
Date 11March 2021
A Phase III, Randomized, Multi -Center, Double -Blind, Global Study to 
Determine the Efficacy and Safety of Durvalumab in Combination With and 
following Chemoradiotherapy Compared to Chemoradiotherapy Alone for 
Treatment in Women With Locally Advanced Cervical Cancer (CALLA)
Sponsor: [COMPANY_008] AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifying Number(s): [ADDRESS_768045] atin. To ensure appropriate balance between patients treated wi th 
cisplatin and carboplatin as the radiosensit izer across regions in the ongoing study , no 
further use of carboplat in as the radiosensit izer will be allowed in this study .
Section 1.1 Schedule of activities, Section 5.2 Exclusion Crit eria
Clarified requi rement to perform  ECG once during screening unless clinical abnormalit ies 
are present. 
Section [IP_ADDRESS] Standard of care
Separated sections for cisplatin and carboplatin as carboplat in is not a treatment option in 
this versi on 
Section 1.2 Synopsis, Section 3 Objectives and Endpoints, Section 6.1.1 Investigational 
products, Section 6.1.2 Dose and treatment regimens, Section 6.4 Concomitant 
therapy, Section 9.3 Populations for analyses, 9.3.3 PK analysis set; Section [IP_ADDRESS] 
Overall survi val in PD -L1 positive patients, Section 9.5.[ADDRESS_768046] between PFS and OS in this cohort
Section 1.2 Synopsis , Section 1.1 Schedule of activities, Section 4.1 Overall design, 9.7 
China cohort
Added details of China cohort, including number of pat ients requi red and potenti al to 
recrui t bey ond gl obal LSI
Section [IP_ADDRESS] Specific toxicity management and dose modification information –
durva lumab
Added informat ion that toxi city management gui delines (TMG) have been developed to 
assist invest igators with the recognition and management of toxicit ies associated with the 
use of the immune -checkpo int inhibitor durvalumab.
Section 9.[ADDRESS_768047] of the 
protocol .
Section 1.1. Schedule of activities, Appendix A7 Study and Site start and closure, 
Appendix B2 Definitions of serious adverse event, Appendix E Actions Required in 
Cases of Increases in Liver Biochemistry and Evaluation of Hy’s law, Appendix G12.[ADDRESS_768048] “maintenance” changed to “adjuvant” in these sect ions, as this i s a m ore accurate 
descript ion of the intent of the Durvalumab/Placebo treatment post CCRT for this patient 
popul ation.
Section 2.2.4 Treatment of cervical cancer
Rationale for the com pletion of  CCRT wi thin 56 days has been added
Section 2.2.4 Treatment of cervical cancer
Background informat ion for the treatm ent of cervical cancer has been updated
Table 1 Schedule of assessments for durvalumab/placebo ± chemoradiation therapy 
screening and treatment and retreatment periods (up to total of 24 dos es), Section 4.1 
Overall Design, Section 7.1.1 Procedures for discontinuation of study treatment, 
Section 8.1 Efficacy assessments
Clarified the rol e of pelvic examinat ion in the assessment of progressive disease. 
Table 1 Schedule of assessments for durva lumab/placebo ± chemoradiation therapy 
screening and treatment and retreatment periods (up to total of 24 doses), Table [ADDRESS_768049] ion added to provide rationale for stratification factors.
Section 5.1 Inclusion criteria 5.0 & multiple sections
Multiple secti ons of  CSP updated to emphasise that FIGO (2009) is used for this protocol. 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 6Section 5.2 Exclusion criteria
Added mucinous adenocarcino ma into excl usion criteria 1.0. 
Section [IP_ADDRESS] Durvalumab (MEDI4736), Section 6.1 .1.3 Placebo
Durvalumab blinding procedure updated to include the use of coloured infusio n sleeves.
Section [IP_ADDRESS] Durvalumab (MEDI4736) -Order of Adminsitration
Clarified SOC chemotherapy administration t iming post durvalumab/placebo 
administration from 24 hour to 1 cal endar day  
Removed “Cisplat in or carboplatin should co mmence wit hin the first 3 radiat ion 
treatm ents” as inconsistent with other sections.”
Section 6.1.[ADDRESS_768050] ion upd ated to provide clarit y on cri teria for treatm ent through progression 
Table 7 Prohibited concomitant medications
Added immunosuppressive, EGFR & TKI as additio nal prohibited medicat ions
Section [IP_ADDRESS] Administration of patient reported outcome questionnaires
This sect ion updated to allow
ePRO assessment can be performed post blood sample co llection, 
ePRO can be performed prior to C1D1 as long as first of dose of Durvalumab and 
CCRT i s given wi thin 3 days of ePRO co mpletion 
Added that illiterat e patients will not be required to complete the PRO assessments.
Section [IP_ADDRESS] Administration of health care resource assessment
Clarified that HOSPAD eCRF will be completed when there are hospi[INVESTIGATOR_3094]/hospi [INVESTIGATOR_584141] .
Section [IP_ADDRESS] Tumor sampl e collection
Clarificat ion provi ded on the screening tumor sample age requirement

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 7Addit ional sentence added request ing to refer specific instructions and guidelines 
refer to lab manual for tumor sample collection.
Section 8.8.2 Exploratory biomarkers
Previous sect ion [IP_ADDRESS] deleted and exploratory  tumor m arkers m oved to this 
section.
ctDNA sample co llection sect ion updated to provide more clarit y.
Added the information about Microsatellite instabilit y and tum or mutation burden 
and tumor markers.
Section [ADDRESS_768051] ion to strengthen the analysis plan for the OS endpoint. OS will be 
analysed at the time o f each PFS analysis, in the event that PFS is posit ive at the same 
timepo int.
Section [IP_ADDRESS] RECIST 1.1 -based endpoints, Section [IP_ADDRESS] Primary endpoint -
progressio n-free survival
This sect ion updated to clarify criteria and relat ionship between date of progression & 
physical exam
Section [IP_ADDRESS] Progression Free Survival (3 years), Section [IP_ADDRESS] Progression free 
survival in PD -L1 positive patients, Section [IP_ADDRESS] Progression Free Survival (3 year), 
Section [IP_ADDRESS] Progression free survival in PD -L1 positive patients, Table [ADDRESS_768052] ives
Section [IP_ADDRESS] EORTC QLQ CX24
Language for threshold value for clinically meaningful change and analysis plan for this 
PRO has been updated

Clinical Study Protocol -4.[ADDRESS_768053] ion in cervical cancer .......................................... 36
2.2.2 Staging of cervical cancer ................................................................................. 37
2.2.3 Lymph node status in cervical cancer ................................................................ 37
2.2.4 Treatment of cervical cancer ............................................................................. 38
2.2.5 Cervical cancer establishes an immunosuppressive environment ....................... 40
2.2.6 Previous checkpo int inhibitor therapy  in cervical cancer ................................... 41
2.2.7 Immunotherapi [INVESTIGATOR_014].............................................................................................. 41
2.2.8 Durval umab ...................................................................................................... 42
2.3 Benefit/risk assessment ..................................................................................... 43
2.3.1 Potenti al benefi ts.............................................................................................. 43
[IP_ADDRESS] Durvalumab as monotherapy  in cervical cancer ................................................ 43
[IP_ADDRESS] Concurrent immunotherapy and chemoradiotherapy  in cervical cancer ............. 44
2.3.2 Overal l risks..................................................................................................... 45
[IP_ADDRESS] Durvalumab ...................................................................................................... 46
2.3.3 Overall benefit/risk ........................................................................................... 46
3. OBJECTIVES AND ENDPOINTS ................................................................... 47
4. STUDY DESIGN ............................................................................................. 49
4.1 Overall design ................................................................................................... 49
4.2 Scientific rat ionale for study  design .................................................................. 51
4.2.1 Rationale for study  endpoints (efficacy) ............................................................ 51
4.2.2 Rationale for study  endpoints (other exploratory  endpoints) .............................. [ADDRESS_768054] igational products .................................................................................... 64
[IP_ADDRESS] Durvalumab (MEDI4736) ................................................................................. 67
[IP_ADDRESS] Standard of care ................................................................................................ 68
[IP_ADDRESS] Placebo ............................................................................................................. 69
6.1.2 Dose and treatment regimens ............................................................................ 69
[IP_ADDRESS] Durvalumab (MEDI4736) monotherapy ............................................................ 70
[IP_ADDRESS] Standard of care ................................................................................................ 70
6.1.3 Durati on of  treatm ent and cri teria for treatm ent through progression ................. 71
6.1.4 Storage ............................................................................................................. 72
6.2 Measures to minimize bias: randomization and blinding ................................... [ADDRESS_768055] to follow -up.............................................................................................. 81
7.3 Withdrawal fro m the study ................................................................................ 82
8. STUDY ASSESSMENTS AN D PROCEDURES ............................................. 82
8.1 Efficacy assessments ......................................................................................... 83
8.1.1 Central  reading of scans .................................................................................... 84
8.1.2 Survival assessments ......................................................................................... 85
8.1.3 Patient-reported Outcomes (PROs) ................................................................... 85
[IP_ADDRESS] EORTC QLQ -C30 and QLQ- CX24 .................................................................. 85
[IP_ADDRESS] PRO- CTCAE .................................................................................................... 86

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY [IP_ADDRESS] PGIC ................................................................................................................ 86
[IP_ADDRESS] PGIS ................................................................................................................. 86
[IP_ADDRESS] EuroQol  five-dimensio nal five-level  questi onnai re (EQ -5D- 5L) and visual 
analogue scale (VAS) ....................................................................................... 86
[IP_ADDRESS] Administrati on of  patient re ported outcome quest ionnaires ............................... 87
8.1.4 Health care resource use ................................................................................... 88
[IP_ADDRESS] Administrati on of  heal th care resource assessment ............................................ 88
8.2 Safety assessments ............................................................................................ 88
8.2.1 Physical examinat ions....................................................................................... 88
8.2.2 Vital signs ......................................................................................................... 89
8.2.3 Electrocardiograms ........................................................................................... 90
8.2.4 Clinical safet y laboratory  assessments ............................................................... 90
8.2.5 WHO/ECOG performance status ...................................................................... [ADDRESS_768056] ion............................................................................ 95
8.3.5 Causalit y collection ........................................................................................... 96
8.3.6 Adverse events based on signs and symptoms ................................................... 97
8.3.7 Adverse events based on examinat ions and tests ............................................... 97
8.3.8 Hy’s law ................................
........................................................................... [ADDRESS_768057] ..................................................................... 98
8.3.13 Safety data to be collected following the final Data Cutoff of the study........... 100
8.4 Safety repor ting and medical management ...................................................... 100
8.4.1 Reporting of serious adverse events ................................................................ 100
8.4.2 Pregnancy ....................................................................................................... 101
[IP_ADDRESS] Maternal exposure .......................................................................................... 101
8.4.3 Overdose ........................................................................................................ 102
[IP_ADDRESS] Durvalumab .................................................................................................... 102
[IP_ADDRESS] Standard of Care ............................................................................................. 102
8.4.4 Medicat ion error ............................................................................................. 102
8.4.5 Management of durvalumab -related toxi cities................................................. 103
[IP_ADDRESS] Specific toxicit y management and dose modificat ion informat ion -durvalumab103
[IP_ADDRESS] Spec ific toxicit y management and dose modificat ion informat ion -
chemoradiotherapy ......................................................................................... [ADDRESS_768058] ion of samples ...................................................................................... 104
[IP_ADDRESS] Collect ion of samples to measure for the presence of ant idrug ant ibodies ........ 104

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 128.5.2 Storage an d destructi on of  pharmacokinet ic/ant idrug antibody samples .......... 105
8.6 Pharmacodynamics ......................................................................................... 105
8.7 Genet ics.......................................................................................................... 105
8.7.1 Optional exploratory  genet ic sample ............................................................... 105
8.7.2 Storage and destruction of genet ic samples ..................................................... 106
8.8 Biomarkers ..................................................................................................... 106
8.8.1 Tumour sam ples: ............................................................................................ 106
[IP_ADDRESS] Tumor sam ple collect ion:................................................................................ 106
[IP_ADDRESS] PD-L1 expression assessment ......................................................................... 106
8.8.2 Exploratory  biomarkers ................................................................................... 107
[IP_ADDRESS] Microsatellite instabilit y and tum or mutation burden ....................................... 107
[IP_ADDRESS] Tumor biomarkers .......................................................................................... 108
[IP_ADDRESS] Who leblood gene expressio n (PAXgene RNA) .............................................. 108
[IP_ADDRESS] Plasma -ctDNA m utations.............................................................................. 108
8.8.3 Management of bio marker data ....................................................................... 109
8.8.4 Storage, re -use, and destruction of bio marker samples .................................... 109
8.8.5 Labeling and shipment of biological  samples .................................................. 109
8.8.6 Chain o f custody  of biological samples ........................................................... 110
9. STATISTICAL CONSIDER ATIONS ............................................................. 110
9.1 Statistical hypotheses ...................................................................................... 111
9.2 Sample size determinat ion.............................................................................. 111
9.3 Popul ations for analyses .................................................................................. 112
9.3.1 Full analysis set .............................................................................................. 112
9.3.2 Safety analysis set ........................................................................................... 112
9.3.3 PK analysis set ................................................................................................ 113
9.3.4 PD-L1 posit ive analysis set ............................................................................. 113
9.4 Outcom e measures for analyses ...................................................................... 113
9.4.1 Calculation or derivat ion of efficacy variables ................................................ 113
[IP_ADDRESS] RECIST 1.1 -based endpo ints.......................................................................... 113
[IP_ADDRESS] Primary endpo int -progression -free survival ................................................... 114
[IP_ADDRESS] Progression Free Survival (3 y ears) ................................................................. 115
[IP_ADDRESS] Progression free survival in PD -L1 posi tive pati ents....................................... 115
[IP_ADDRESS] Overall survival .............................................................................................. 116
[IP_ADDRESS] Overall survival in PD -L1 postive pat ients...................................................... 116
[IP_ADDRESS] Object ive response rate ................................................................................... 116
[IP_ADDRESS] Com plete response rate ................................................................................... 116
[IP_ADDRESS] Incidence of Local Progression, Distant Disease Progression, Secondary  
Malignancy ................................................................
..................................... 116
[IP_ADDRESS] Durati on of  response for Com plete Responders ............................................... 117
9.4.2 Calculation or derivat ion of safet y variables .................................................... 117
[IP_ADDRESS] Adverse events ................................................................................................ 117
[IP_ADDRESS] Safety assessments .......................................................................................... 118
9.4.3 Calculation or derivat ion of patient -reported outcome variables ...................... 119
[IP_ADDRESS] EORTC -QLQ -C30.......................................................................................... 119

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY [IP_ADDRESS] EORTC QLQ -CX24 ....................................................................................... 120
9.4.4 Patient-reported outcomes versio n of the Commo n Termino logy Criteria for 
Adverse Events ............................................................................................... 120
9.4.5 Patient Gl obal Impressi on of Change and Patient Global Impressio n of 
Severit y.......................................................................................................... 121
9.4.6 EuroQol  five-dimensio nal five-level  questi onnai re (EQ -5D- 5L)..................... 121
9.4.7 Definit ion of compliance and evaluabilit y rates ............................................... 121
9.4.8 Calculation or derivat ion of healt h care resource use ....................................... 122
9.4.9 Calculation or derivat ion of pharmacokinetic variables ................................... 122
[IP_ADDRESS] Popul ation pharmacokinet ics and exposure- response/safet y analysis ............... 122
[IP_ADDRESS] Pharmacokinet ic analysis ................................................................................ 122
[IP_ADDRESS] Immunogenicit y analysis ................................................................................ 123
9.4.10 Calculation or derivat ion of bio marker variables ............................................. 123
9.4.11 Calculation or derivat ion of pharmacogenet ic variables .................................. 123
9.5 Statistical analyses .......................................................................................... 123
9.5.1 Efficacy analyses ............................................................................................ 123
[IP_ADDRESS] Primary endpo int: Progression -free survival .................................................... 126
[IP_ADDRESS] Progression Free Survival (3 y ear).................................................................. 128
[IP_ADDRESS] Progression -free survival in PD -L1 posi tive patients ....................................... 128
[IP_ADDRESS] Overall survival .............................................................................................. 128
[IP_ADDRESS] Overall survival in PD -L1 posi tive pat ients..................................................... 129
[IP_ADDRESS] Object ive response rate ................................................................................... 129
[IP_ADDRESS] Com plete response rate ................................................................................... 129
[IP_ADDRESS] Incidence of Local Progression, Distan t Disease Progressi on, and Secondary  
Malignancy ..................................................................................................... 129
[IP_ADDRESS] Durati on of  com plete response ........................................................................ 130
[IP_ADDRESS] Patient-reported outcomes ............................................................................... 130
[IP_ADDRESS] Health care resource use ................................................................................. 131
9.5.2 Safety analyses ............................................................................................... 132
9.5.3 Pharmacokinet ic data ...................................................................................... 132
9.5.4 Immunogenicit y data ...................................................................................... 132
9.5.5 Pharmacokinet ic/pharmacodynamic relat ionships ........................................... [ADDRESS_768059] OF TABLES
Table 1 Schedule of assessments for durvalumab/placebo ± chemoradiation 
therapy  screening and treatment and retreatment periods (up to total of
24 doses) ................................................................................................. [ADDRESS_768060] ive methods of contraception (<1% failure rate) .................. [ADDRESS_768061] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons....................... 150
Appendix B Adverse Event Definit ions and Addit ional Safet y Inform ation............... 156
Appendix C Handling of hum an bio logical samples .................................................. 161
Appendix D Genet ics................................................................................................. 164
Appendix E Actions Req uired in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s law .......................................................................... [ADDRESS_768062] 1.1 
Criteria (Response Evaluat ion Cri teria in Solid Tumors) ........................ [ADDRESS_768063] of care treatment management ................................................. 216
Appendix K FIGO (2009) guidelines for Cervical C ancer Staging ............................. 224
Appendix L Changes Related to Mitigation of Study  Disrupti ons Due to Cases of 
Civil Crisis, Natural Disaster, or Public Healt h Crisis, including 
COVID -19 Outbreak.............................................................................. 225

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 161. PROTOCOL SUMMARY
1.1 Schedule of activities
The procedures for the screening and treatment periods in this study  are presented in Table 1, 
and the procedures for the fo llow-up peri od are presented in Table 2
. Pati ents who continue on 
the trial bey ond Cycle 24 will cont inue wit h assessments unt il terminat ion of the study  
(Table 2).
Whenever vital signs and blood draws are scheduled for the same no minal time, the 
assessments should occur in the fo llowing order: vital signs and then blood draws. The timing 
of the vi tal signs assessments shoul d be such that i t allows the bl ood dr aw (eg, 
Pharmacokinet ics [PK] blood sample) to occur at the timepoints indicated in the schedule of 
assessments (SoAs). Whenever electrocardiograms (ECGs), vital signs, and blood draws are 
scheduled for the same no minal t ime, the assessments should occur i n the fo llowing order: 
ECG, vi tal signs, and then blood draws. The timing of the first 2 assessments should be such 
that it allows the bl ood draw (eg, PK bl ood sam ple) to occur at the timepo ints indicated in the 
SoAs.
For durvalumab/placebo + standard of c are chemoradiation therapy combination arms
 Patients m ay delay  dosing under certain circumstances.
 Dosing may be delayed per the Dosing Modificat ion and Toxicit y 
Management Guidelines, due to either an immune or a non -immune -
related adverse events (AE).
 Ifdosing must be delayed for reasons other than treatment- related 
toxicity, dosing will resume as soon as feasible.
 Dosing intervals of subsequent cy cles may  be shortened as clinically  
feasible in order to gradually align treatment cy cles wi th the schedule of 
tumor efficacy  (Response Evaluat ion Cri teria in Solid Tum ors versi on 1.1 
[RECIST 1.1]) and patient -reported outcome (PRO) assessments. 
Subsequent time between 2 consecut ive doses cannot be less than 21 
days, based on the half -life of durvalumab (see cur rent Investigator’s 
Brochure [IB] for durvalumab).

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 17Table 1 Schedule of assessments for durvalumab/placebo ± chemoradiation therapy screening and treatment and 
retreatment periods (up to total of 24 doses) 
Screening C1aC2aC3aC4aC5 to 
PD/C24a
For details, see 
SectionWeek -4 to -1 0 q4w ±3 days unless dosing needs to be held for toxicity reasons
Day -28 to -1 1 q28d ±3 days unless dosing needs to be held for toxicity reasons
Informed consent
Informed consent: study proceduresbX 5.1
Consent: genetic sample and analysis 
(optional)X 5.1
Study procedures
Physical exam (full) X 8.2.1
Targeted physical exam c X X X X X 8.2.1
Vital signsdX X X X X X 8.2.2
ECGeXfAs clinically indicated 8.2.3
Concomitant medications <----------------------------------------------------------------------------------------------------------------------- > 6.4
Demography, including baseline 
characteristics and tobacco useX 5.1
Eligibility criteria X 5.1, 5.2
Radiation plan collection X Appendix G
Laboratory assessments
Clinical chemistrygX XhX X X X Table 9
HematologyhX XhX X X X Table 10
TSHi(reflex free T 3or free T 4)jX X X X X X Table 9
Urinalysis X As clinically indicated Table 11
Hepatitis B and C and HIV X 8.2.4
Pregnancy testkX X X X X X 8.2.4
HPV genotype, if available X 8.2.4

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 18Screening C1aC2aC3aC4aC5 to 
PD/C24a
For details, see 
SectionWeek -4 to -1 0 q4w ±3 days unless dosing needs to be held for toxicity reasons
Day -28 to -1 1 q28d ±3 days unless dosing needs to be held for toxicity reasons
Pharmacokinetics 
PK sample (serum) XlXmXm8.5
Monitoring
WHO/ECOG performance statusnX X X X X X 8.2.5
AE/SAE assessmento<------------------------------------------------------------------------------------------------------------ > 8.[ADDRESS_768064]/Patient review for 
safetyDays 14 (±24 hours) of C1, C2, and C3 8.2.6
IP administration
Durvalumab/placebop,qXpX X X X [IP_ADDRESS] , [IP_ADDRESS]
SoC cisplatin chemotherapy Weekly for 5 weeksr (± 1 day 
except cycle 1 )[IP_ADDRESS] , [IP_ADDRESS]
SoC radiation therapy Refer to Appendix G [IP_ADDRESS] , [IP_ADDRESS] , 
Appendix G
Other assessments and assays
Immunogenicity assessment (ADA sampling 
to identify ADA responses in patient 
circulation)XmXmXm8.5.1.1
Whole blood for gene expression (PAXgene 
RNA tubes)X X 8.8.2
ctDNA (plasma) X X s X X (at 6 months 
and PD)8.8.2
EORTC QLQ -C30 and CX24, PGIS, EQ -
5Dt0 (C1D1), 2 (mid -cycle 1), 4 (C2D1), 8 (C3D1), 12 (C4D1), 16 (C5D1), 20 (C6D1) 
weeks from C1D1, then q12 weeks ±1w through 164 weeks (relative to C1D1), and 
then q24w ±2w thereafter (relative to C1D1) through 260 weeks, then q52w ±2w 
(relative to C1D1) up to PD and at IP pre -mature discontinuation and PD; if IP 
discontinuation due to PD, then also at month [ADDRESS_768065] discontinuation; if 
PD but con tinue on treatment, follow treatment period schedule.8.1.3

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 19Screening C1aC2aC3aC4aC5 to 
PD/C24a
For details, see 
SectionWeek -4 to -1 0 q4w ±3 days unless dosing needs to be held for toxicity reasons
Day -28 to -1 1 q28d ±[ADDRESS_768066] IP 
discontinuation (if no PD), or at month [ADDRESS_768067] IP discontinuation (if PD)8.1.3
PGICtSame as PRO -CTCAE but starting 4 weeks (C2D1) from C1D1 8.1.3
Healthcare resource use (HOSPAD)uTo be completed at each hospi[INVESTIGATOR_059] 8.1.3
FFPE tumor sample (mandatory; a newly 
acquired sample is preferred if available per 
site’s routine clinical practice; otherwise, 
archival sample ≤3 months old can be 
provided)vX 8.8
Optional newly acquired tumor biopsy 
collected upon progressionvX (at PD only, strongly encouraged)
Genetics research sample (optional DNA 
element for long -term storage/future use) wX 8.7
Efficacy evaluations 
Tumor radiological assessments 
(RECIST 1.1)y
-AND -
Physical exam including a pelvic 
examination XxOn-study  tumor assessments occur 20w ±1w after randomization and continue q12w 
±1w through 164 weeks (relative to the date of randomization) and then q24w ±2w 
thereafter (re lative to the date of randomization) until RECIST 1.[ADDRESS_768068] be followed regardless of 
any delay s in dosing.
-AND -
Physical examination including a pelvic examination and (if indicated) biopsy for 
histopathological determination of tumor progression will be assessed on the same 
schedul e as the imaging assessments.z,aa8.1
aThese cycles refer to the 28 -day cycles of administration of durvalumab/placebo.
bWritten informed consen t and any locally required privacy act document authorization must be obtained prior to performing any protocol -specific procedures, including 
screening/baseline evaluations. All patients will be required to provide consent to supply a sample of their tumo r (archived or newly acquired biopsy) for entry into this 
study . This consent is included in the main patient ICF. Informed consent of study procedures may be obtained prior to the [ADDRESS_768069] been obtained 
within 28 days of randomization.
cTargeted physical examinations are to be utilized by [CONTACT_584178], 
eyes,ears, nose, and throat and the respi[INVESTIGATOR_696], cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, he matologic/lymphatic, and endocrine 
systems
dBody weight is recorded at each visit along with vital signs.
eAny clinically signif icant abnormalities detected require triplicate ECG results. 
fA single ECG at screening should be done. Any clinically significant abnormalities detected require triplicate ECG results.
gSerum or plasma clinical chemistry (including LFT monitoring) and hematology may be performed more frequently if clinically indicated or based on the local clinical 
practice.
hIf screening clinical chemistry and hematology assessments are performed within 3 days prior to Day 1 (first infusion day), t hey do not need to b e repeated at Day 1. 
iIf TSH is measured within 14 days prior to Day 1 (first infusion day), it does not need to be repeated at Day 1.
jFree T3 or free T4 will only be measured if TSH is abnormal or if there is clinical suspi[INVESTIGATOR_454833].
kFor women of childbearing potential only. A urine or serum pregnancy test is acceptable. Women of childbearing potential are required to have a pregnancy test within 
7days prior to the first dose of study treatment and then q4w. Resul ts must be available and reviewed by [CONTACT_584179]. 
lPost infusion within 1 hour of the end of infusion.
mPre-dose same day as infusion (may not exceed 6 hours prior to start of infusion).
mECO G performance status (PS) of 0 or 1 at enrolment and randomization.
oFor AEs/SAEs reported during screening, additional information such as medical history and concomitant medications may be nee ded
pDuring the combination portion of treatment, durvalum ab or placebo will be administered first. If there is not enough time to administer cisplatin afterward on that day, it 
should be given the following day and must be administered within 1 calendar day of the durvalumab infusion. Treatment should start no m ore than 3 working days after 
being randomized. The day patients begin treatment will be designated C1D1.
qResults for LFTs, electrolytes, full blood count (while on chemotherapy), and creatinine must be available before commencing an infusion (within 3 d ays) and reviewed 
by [CONTACT_539123].
rA 6th week of platinum agent is optional per investigator discretion. 
sSample will be taken at last dose of platinum administration (C2D8 if a 6th week of platinum agent is needed or C2D1 if platinum agent is administered only for 5 weeks)
tWill be administered using a site -based, ePRO device. The PRO questionnaires must be administered and completed at the clinic prior to treatment administration
performed at the site and i deally before any discussions of health status to avoid biasing the participant’s responses to the questions. As feasible, si te staff should also 
ensure PRO questionnaires are completed prior to other study procedures, such as collection of laboratory samp les and before discussion of disease progression to avoid 
biasing the patient’s responses to the questions.PRO -CTCAE will only be administered in those countries where a linguistically validated version exists. It is permitted 
for the baseline ePROs to be completed prior to C1D1 as long as treatment is given within [ADDRESS_768070] pr ogression, the 
HOSPAD form should continue to be administered during the non -study  protocol requ ired hospi[INVESTIGATOR_584142] (except China). Refer to the Laboratory Manual for further details on tissue requirements.
wThe sample for genetic research will be obtained at Day 1 pre -dose (at o r after randomization). If, for any reason, the sample is not drawn at Day 1, it may be taken at any 
visit until the last study visit. Only [ADDRESS_768071] (preferred) or MRI, each preferably with IV contrast o f the chest, abdomen, and pelvis. Additional 
anatomy should be imaged based on the signs and symptoms of individual patients at baseline and follow -up. The follow -up scan collected after a RECIST 1.1- defined 
PD should be performed no less than 4 weeks after and no later than 12 weeks after the prior assessment of PD, and this follow -up scan is evaluated using the criteria 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 21outlined in Appendix F. If an unscheduled assessment is performed (eg, to investigate clinical signs/symptoms of progression) and the patient has not pro gressed, every 
attempt should be made to resume the subsequent assessments following the original imaging visit schedule (relative to the date of randomization). See Section 6.1.3,
Section 8.1and Appendix Ffor additional details relevant to imaging assessments.
zPap smear should be done per investigator discretion. If results are concerning for progression, progression must be confirme d by [CONTACT_584180] [ADDRESS_768072] PD being completed
Note: All assessments on treatment days are to be performed prior to infusion, unless otherwise indicated.
Abbreviations: ADA Antidrug antibody; AE Adverse event; C Cycle; CR Complete response; CRT Chemoradiation therapy; CT Computerized tomography; ctDNA 
Circulating tumor deoxyribonucleic acid; DNA Deoxyribonucleic acid; ECG Electrocardiogram; ECOG Eastern Cooperative Oncology Group; EORTC European Organisation 
for Research and Treatment of Cancer; EQ -5D-5L EuroQol five -dimensional five -level questionnaire; Gy Grey unit; HIV Human immunodeficiency virus; HOSPAD Hospi[INVESTIGATOR_483525]; HPV Human papi[INVESTIGATOR_28597]; ICF Informed consent form; IP Investigational product; IV Intravenous; LFT Liver functio n tests; MRI Magnetic resonance im aging; 
PD Progression of disease; PGIC Patient Global Impression of Change; PGIS Patient Global Impression of Severity; PK Pharmacok inetics; PR Partial response; PRO Patient -
reported outcomes; PRO -CTCAE Patient -reported outcomes version of the Common Termi nology Criteria for Adverse Events; qxw Every x weeks; q28d Every 28 days; 
QLQ -C30 30 item core quality of life questionnaire; QLQ -CX24 Cervical cancer module; RECIST Response Evaluation Criteria in Solid Tumors version 1.1; 
RNA Ribonucleic acid; SAE Serio us adverse event; SD Stable disease; SoC Standard of care; T3 Triiodothyronine; T4 Thyroxine; TSH Thyroid stimulating hormone ; WHO 
World Health Organization.
.

Clinical Study Protocol -4.[ADDRESS_768073] dose of IP
EvaluationDay (±3) Months (±2 week) 21 months and 
every 6 months 
(±2 weeks)For details, see 
Section30 2 3 6 9 12 15
Physical examination (full) X 8.2.1
Vital signs (temperature, respi[INVESTIGATOR_862], blood pressure, and pulse)X 8.2.2
Weight X X X 8.2.2
Pregnancy testaX As clinically indicated 8.2.4
AE/SAE assessment X X X 8.3
Concomitant medications X X X 6.4
WHO/ECOG performance status At timepoints consistent with tumor assessments; at 30, 60, and 90 days; and then at initiation of subsequent 
anticancer therapyb8.2.5
Subsequent anticancer therapyc,d<----------------------------------------------------------------------------------------------------------------------------- -------
>8.1
Survival statuseX X X X X X 8.1
Hematology X X X Table 10
Clinical chemistry X X X Table 9
Urinalysis As clinically indicated Table 11
TSH (reflex free T 3or free T 4f) X X X Table 9
PK assessmentgX 8.5
Immunogenicity assessment (ADA 
sampling) to identify ADA responsesgX Xh8.5.1.1
Whole blood for gene expression 
(PaxGene -RNA tubes)X X8.8.2
ctDNA (plasma) X X X 8.8, 8.8.[ADDRESS_768074] dose of IP
EvaluationDay (±3) Months (±2 week) 21 months and 
every 6 months 
(±2 weeks)For details, see 
Section30 2 3 6 9 12 15
EORTC QLQ -C30 and CX24, PGIS, 
EQ-5Di0 (C1D1), 2 (mid -cycle 1), 4 (C2D1), 8 (C3D1), 12 (C4D1), 16 (C5D1), 20 (C6D1) weeks 
from C1D1, then q12 weeks ±1w through 164 weeks (relative to C1D1), and then q24w 
±2w thereafter (relative to C1D1) through 260 weeks, then q52w ±2w (relative to C1D1) 
up to PD and at IP pre -mature discontinuation and PD; if IP discontinuation due to PD, 
then also at month [ADDRESS_768075] discontinuation; if PD but con tinue on treatment, 
follow treatment period schedule.8.1.[ADDRESS_768076] IP disc ontinuation (if no PD), or at month 
[ADDRESS_768077] IP discontinuation (if PD)8.1.3
PGICiSame as PRO -CTCAE but starting 4 weeks (C2D1) from C1D1 8.1.3
Healthcare resource use (HOSPAD)jTo be completed at each hospi[INVESTIGATOR_059]. 8.1.3
Tumor radiological assessment 
(RECIST 1.1)k 
-AND -
Physical exam including a pelvic 
examinationOn-study  tumor assessments occur 20w ±1w after randomization and continue q12w ±1w through 164 weeks 
(relative to the date of randomization) and then q24w ±2w thereafter (relative to the date of randomization) 
until RECIST 1.[ADDRESS_768078] be followed regardless of any delays in dosing.
-AND -
Physical examination including a pelvic examination and (if indicated) biopsy for histopathological 
determination of tumor progression will be assessed on the same schedule as the imaging assessments.l, m8.[ADDRESS_768079] is acceptable. 
bWHO/ECOG performance status should also be collected at other site visits that the patient attends, if appropriate site staff are available to collect such information. In 
addition, WHO/ECOG performance status should be provided when information on subsequent anticancer therapy is provided, where possible.
cDetails of any treatment for cervical cancer (including surgery) after the last dose of IP must be recorded in the eCRF. At minimum, collect the start date and des cription 
of the subsequent anticancer therapy. 
dFor patients who discontinue their assigned IP following confirmed progression, available readings of CT/MRI from local practice will be collected from patients’ 
medical charts while information on subsequent anticancer treatment is collected.
ePatients may be contact[CONTACT_584181]. D etails of any treatment for cervical cancer (including surgery) after the last dose 
of IP must be recorded in the eCRF.
fFree T3 or free T4 will only be measured if TSH is abnormal or if there is clinical suspi[INVESTIGATOR_584143].
gPK and immunogenicity samples are collected 90 days (3 months) (±7 days) after study treatment ends. In addition, a final imm unogenicity sample is taken 6 months 
(±7days) after study treatment ends.
h Immunogenicity sample and ctDNA sample sho uld be obtained at a scheduled study tumor assessments visit
iWill be administered using a site -based, ePRO device. The PRO questionnaires must be administered and completed at the clinic prior to treatment administration 
performed at the site and ideally before any discussions of health status to avoid biasing the participant’s responses to the questions. As feasible, site staf f should also 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 24ensure PRO questionnaires are completed prior to other study procedures, such as collection of laboratory samples and before discussion of disease progression to avoid 
biasing the patient’s responses to the questions .PRO -CTCAE will only be administered in those countries where a linguistically validated version exists.
jHOSPAD module should be completed by [CONTACT_584182][INVESTIGATOR_307]. A reminder will be provided at each clinic visit. 
Any routine visits for protocol -related requirements do not need to be captured. If the patient discontinues study treatment for reason s other than RECIST progression, the 
HOSPAD form should continue to be administered during the non -study  protocol required hospi[INVESTIGATOR_584144] . 
kOnly for patients yet to progress, RECIST 1.[ADDRESS_768080] (preferred) or MRI, each preferably with IV contrast, of the chest, 
abdomen, and pelvis. Additional anatomy should be imaged based on signs and symptoms of individual patients. The follow -up scan collected after a RECIST 1.1 -
defined PD sh ould be performed no less than 4 weeks after and no later than 12 weeks after the prior assessment of PD, and this follow -up scan is evaluated also using 
the criteria outlined in Appendix F. If an unscheduled assessment was performed (eg, to investigate clinical signs/symptoms of progression) and the patient has not 
progressed, every attempt should be made to resume the subsequent assessments followi ng the original imaging visit schedule (relative to the date of randomization). See 
Section 6.1.3,Section 8.1, and Appendix Ffor additional deta ils relevant to imaging assessments.
lPap smear should be done per investigator discretion. If results are concerning for progression, progression must be confirme d by [CONTACT_584183] 28 d ays of progression confirmed by [CONTACT_584184]: ADA Antidrug antibody; AE Adverse event; CT Computerized tomography; ctDNA Circulating tumor deoxyribonucleic acid; ECOG Eastern Cooperative 
Oncology Group; eCRF Electronic case report form; EORTC European Organization for Research and Treatment of Cancer; EQ -5D-5L EuroQol five -dimensional five -level 
questionnaire; IP Investigational product; IV Intravenous; MRI Magnetic resonance imaging; PD Progression of disease; PFS Pro gression -free surviv al; PGIC Patient Global 
Impression of Change; PGIS Patient Global Impression of Severity; PK Pharmacokinetics; PRO Patient -reported outcome; PRO -CTCAE Patient -reported outcomes version of 
the Common Terminology Criteria for Adverse Events; qxw Every x weeks; QLQ -C30 30 item core quality of life questionnaire; QLQ -CX24 Cervical cancer module; RECIST 
Response Evaluation Criteria in Solid Tumors; RNA Ribonucleic acid; SAE Serious adverse event; T3 Triiodothyronine; T4 Thyrox ine; TSH Thyroid stimulating hormone ; 
WHO World Health Organization.

Clinical Study Protocol - 4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 251.2 Synopsis
International Co-ordinating Investigator
Phoenix, AZ [ZIP_CODE]
Phone: Fax: 
Protocol Title: A Phase III, Randomized, Multi-Cente r, Double-Blind, Global Study to 
Determine the Efficacy and Safety of Durvalumab in Combination With and following 
Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With 
Locally Advanced Cervical Cancer (CALLA)
Rationale:
Cervical cancer is the 4th most common cancer in women worldwide despi[INVESTIGATOR_584145] (Pap smear) for early screening and prevention of cervical cancer in the 1950s, and more recently, human papi[INVESTIGATOR_28597] (HPV) vaccination. Most women globally do not have access to screening and, thus, the global incidence of cervical cancer at all stages continues to rise t hroughout the world as the population rises and ages. The use of 
combination chemoradiotherapy is a mainstay of oncology therapy in multiple tumor types. 
The goal of combination chemotherapy is to utilize agents that affect cancer cells by [CONTACT_129427], thus improving clinical responses and reducing the risk of developi[INVESTIGATOR_584146]. Non-clinical and clinical studies have indicated that blockade of immune checkpoints 
(programmed cell death protein 1 [PD-1]/programmed death-ligand 1 [PD-L1] and cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]) can have a positive effect on anti-tumor 
immunity. Chemotherapy is thought to synergize with PD-1/PD-L1 blockade by [CONTACT_584185] “immunogenic” by [CONTACT_584186], promoting phagocytosis of tumor cells, and 
ultimately leading to reactivation of immune-mediated tumor surveillance. The PACIFIC trial 
evaluated the efficacy of durvalumab after definitive chemoradiotherapy in Stage III non-small cell lung cancer (NSCLC) compared to placebo after chemoradiotherapy and found a significant improvement with durvalumab with a median progression-free survival (PFS) of 16.8 months (95% confidence interval [CI] 13.0 to 18.1) compared to 5.6 months (95%CI, 4.6 to 7.8) in the placebo controlled group. The study’s hypothesis is that durvalumab, when administered concurrently with chemotherapy and radiotherapy (CCRT) and as adjuvant therapy following CCRT will also improve PFS when compared to standard of care concurrent chemoradiation therapy (SoC CCRT) wi th placebo in patients with International 
Federation of Gynaecology and Obstetric s (FIGO 2009) Stage IB2 to IVA cervical cancer.[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 26Objectives and Endpoints
Primary objective: Endpoint/variable:
To assess the efficacy of durvalumab + SoC 
CCRT compared with placebo + SoC CCRT in 
terms of PFSEndpoints based on the investigator assessment 
according to RECIST 1.1 or histopathologic 
confirmation of local tumor progression:
PFS: Time from date of randomization until 
tumor progression or death due to any cause
Secondary objectives: Endpoints/variables:
To further assess the efficacy of durvalumab + 
SoC CCRT compared wi th placebo + SoC 
CCRT in terms of PFS (3 year), PFS in PD -L1 
positive patients, overall survival (OS) (key), OS 
in PD -L1 positive patients, ORR, CR rate, and 
DoR in Patients with a CROS: Time from date of randomization until the 
date of death by [CONTACT_584187] 1.1 or pathologic assessment 
of local disease progression
PFS (3 year): Proportion of patients alive and 
progr ession -free at 3 years
PFS in PD -L1 positive patients: Time from date 
of randomization until tumor progression or 
death due to any cause in patients who are PD -
L1 positive (>=1%) based on either tumor or 
immune cell staining
OS in PD -L1 positive patients: Time from date 
of randomization until the date of death by [CONTACT_584188] p atients who are PD -L1 positive 
(>=1%) based on either tumor or immune cell 
staining
ORR: The percentage of evaluable patients with 
an Investigator -assessed visit response of CR or 
PR 
CR rate: Disappearance of all target and non -
target lesions DoR in Patie nts with a CR: Time 
from date of first detection of CR until the date 
of objective disease progression according to 
RECIST 1.[ADDRESS_768081] of durvalumab + SoC CCRT 
compared with placebo + SoC CCRT on the 
incidence of local progression, distant di sease 
progr ession, and secondary malignancy as the 
first documented progression eventIncidence of Local Progression, Distant Disease 
Progression, and Secondary Malignancy: 
Num ber and percentage of patients who 
develop local progression, distant disease 
recurrence, or secondary malignancy 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 27Objectives and Endpoints
To assess disease -related symptoms and health 
related quality of life (HRQoL) in patients with 
cervical cancer treated with durvalumab + SoC 
CCRT compared with placebo + SoC CCRT 
using the core quality of life questionna ire 
(EORTC QLQ -C30) and core quality of life 
questionnaire cervical cancer module (CX24) Change from baseline in EORTC QLQ -C30 
and EORTC CX24
To assess the PK of durvalumab when in 
combination with CCRT Blood concentration of durvalumab 
To investigate the immunogenicity of 
durvalumab in both arms in combination with 
CCRT Presence of ADAs 
Safety objective: Endpoint/variable:
To assess the safety and tolerability profile of 
durvalumab + SoC CCRT compared to placebo 
+ SoC CCRTAEs, laboratory findings, vital signs, and physical 
examinations,
Exploratory objective: Endpoint/variable:
To collect blood and tissue samples for defining 
biological response to durvalumab +SoC CCRT 
compared to placebo +SoC CCRT for candidate 
markers that may correlat e with likelihood of 
clinical benefit. (All countries except China)Analysis of blood/tissue samples to assess 
exploratory biomarkers, which may include, but 
is not limited to ctDNA, mRNA signatures, 
CD8 by [CONTACT_4658], and Tumor Mutational Burden 
(TMB)
To assess treatment -related symptoms using the 
patient -reported outcomes version of the 
Common Terminology Criteria for Adverse 
Events (PRO -CTCAE)Specific treatment -related PRO -CTCAE 
symptoms 
To assess how a patient perceives her overall 
change in cancer symptoms since the start of 
study treatment using the PGIC and overall 
severity of cancer symptoms using PGIS.PGIC and PGIS
To explore the impact of treatment and disease 
state on health status assessed by [CONTACT_584189] -
dimensional five -level questionnaire (EQ -5D-
5L) to support health economic analysis and 
health technology assessmentEQ-5D-5L
To describe and evaluate resource use associated 
with durvalumab treatment and underlying 
diseaseHealth resource utilizat ion measures 
including hospi[INVESTIGATOR_3094], outpati ent vi sits, 
or em ergency depart ment visits 
Abbreviations: ADA Antidrug antibody; AE Adverse event; BICR Blinded independent central review; CCRT 
Concurrent chemoradiation therapy; CR Complete response; EORTC European Organization for Research and 
Treatment of Cancer; EQ -5D-5L EuroQol five -dimensional five -level questionnaire; HOSPAD Hospi[INVESTIGATOR_584147] -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 28Admission; HRQoL Health -related quality -of-life; IHC Immunohistochemistry; ORR Objective respon se rate; 
OS Overall survival; PFS Progression -free survival; PFS (3yr) Progression -free survival at 3 years; PGIC Patient 
Global Impression of Change; PGIS Patient Global Impression of Severity; PK Pharmacokinetics; PR Partial 
response; PRO -CTCAE Patient -reported oucomes version of the Common Terminology Criteria for Adverse 
Events; QLQ -C30 30item core quality of life questionnaire; QLQ -CX24 Cervical cancer module; RECIST 
Response Evaluation Criteria in Solid tumors; SoC CCRT Standard of care concurrent che moradiatio n therapy .
Overall design:
This is a rando mized, double -blind, placebo controlled, mult i-center, gl obal, Phase III study  to 
determine the efficacy and safety  of durvalumab when co mbined with SoC CCRT and 
administered as adjuvant therapy  following SoC CCRT com pared to pl acebo wi th SoC CCRT 
as systemic treatment in patients with FIGO (2009) Stage IB2 to IVA cervical cancer.
In order to be eligible for this study , patients m ust be ≥18 years of age with FIGO (2009) 
Stage IB2 to IIB N+ and IIIA to IVA with any  N. Pati ents m ust not have previously  received 
any definit ive surgical, radiat ion, or systemic therapy  for cervi cal cancer and m ust be 
immunotherapy -naïve. 
Approximately  714 pati ents fro m mult iple sites will be rando mized 1:1 to receive eit her 
durvalumab 1500 mg or placebo every 4 weeks (q4w) for [ADDRESS_768082] ing of external beam radiotherapy (EBRT) and 
brachyt herapy (See Appendix G) , and concurrent cisplatin 40 mg/m2every  1 week (q1w) × 5 
weeks with an optional 6th week  (See Section 6.1.2 for descri ptions of  the dosing regimen.) 
Randomization will be stratified by [CONTACT_584190] (FIGO (2009) Stage <III and node 
positive, FIGO (2009) Stage ≥III and node negative, or FIGO (2009) Stage ≥III and node 
positive), and region [[LOCATION_002], Canada, European Unio n, South Korea, and Japan] versus 
rest of the world. Patients will receive their assigned treatment unt il completion of planned 
therapy , clinical progression or RECIST 1.1-defined or histopathologic confirmat ion of local 
disease progressi on, unacceptable toxicit y, wi thdrawal  of consent, or another discontinuation 
criteria i s met. (See Section 7.1for addi tional details on discont inuat ion of study  treatm ent.) 
Following com pletion of SoC CCRT, patients will be evaluated by [CONTACT_584191]. During the first 3 years (164 weeks) after randomizat ion, this assessment will 
include an interval history  for new signs or symptoms, physical examinat ion including a 
pelvic examinat ion to evaluate for local cervical cancer progression, and imaging (co mputed 
tomography  [CT] scan or m agnet ic resonance imaging [MRI]) per RECIST 1.1 or 
histopathologic assessment every  12 weeks (q12w). During Years 4, and 5, 
imaging/histopathologic assessments will be performed every  6 months (24 weeks) and then 
annually until a PFS endpoint has been met or closure of the study .

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 29Study Period:
Estimated date of first patient enro lledQ1 [ADDRESS_768083] patient completed Q2 2024
Number of patients:
Approximately  714 patients from mult iple sites will be rando mized 1:1 to receive eit her 
durvalumab + SoC CCRT or placebo + SoC CCRT. In China, recruitment will cont inue unt il 
approximately  [ADDRESS_768084] been randomised, irrespective of whether or not the 
overall study  enro lment has been reached. It is ant icipated that this target may not be met 
before the global recrui tment of approximately  714 is achieved.
Treatments and treatment duration:
Durvalumab 1500 mg via intravenous (IV) infusio n q4w, starting C1D1, until co mpletion of 
planned treatm ent or progression o f disease (PD). (Pl ease note, if a patient’s weight falls to 
30kg or below ( ≤30 kg), then the patient should receive weight -based dosing equivalent to 20 
mg/kg of durvalumab q4w after consultation between Invest igator and Study  Physician, unt il 
the wei ght improves to above 30 kg (>30 kg), at which point the pati ent shoul d start receiving 
the fixed dosing of durvalumab 1500 mg q4w).
Placebo: Sterile so lution of 0.9% (weight/volume [w/v]) sodium chloride for inject ion via IV 
infusio n q4w, starting on C1D1, unt il completion of planned treatment or PD. 
Chem oradi otherapy:
Cisplat in 40 mg/m2IV q1w × [ADDRESS_768085] igator discretion, patients can 
continue wit h an opti onal 6th week of platinum agent. 
See Appendix Gfor details regarding the radiotherapy  regimen.
Duration of treatment
Unless specific treatment discont inuat ion criteria are m et, pati ents will cont inue therapy until 
completion of planned therapy  or clinical progression or RECIST 1.1-defined or 
histopathologic confirmat ion of local disease progressio n. 
Progression during t reatment
During the treatment period, patients who are clinically stable at an init ial RECIST 1.[ADDRESS_768086] 1.1 -defined PD, no later 
than the next scheduled imaging visit, and no less than 4 weeks after the prior assessment of 
PD; this scan is evaluated using the criteria outlined in Appendix F. If the subsequent scan 
does not demonstrate radi ological PD, then patient should continue IP. Scanning should 
continue until the next RECIST 1.1 -defined PD which in turn will require a subsequent scan 
(must b e evaluated using the criteria outlined in Appendix F). 
Alternat ively, pat ients may cont inue treatment until histopathological determinat ion of tu mor 
progression on biopsy . Patients m ay not con tinue on durvalumab/placebo if there is 
histopathological determination o f progression. 
Follow -up of patients post -discontinuation of study treatment
Patients who have discont inued treatment due to toxicit y or symptom atic deterioration, 
clinical progression, or who have co mmenced subsequent ant icancer therapy will be fo llowed 
up with tum or assessments unt il PD (based on RECIST 1.1) plus an addit ional follow-up scan 
or until death (whichever comes first) and fo llowed f or survival. 
Survival
All patients randomized in the study  shoul d be f ollowed for survival.
Independent Data Monitoring Committee:
An independent data monitoring co mmittee (IDMC) composed of independent experts will be 
convened to confirm the safe ty and tol erabili ty of the proposed dose and schedule of 
durvalumab + SoC CCRT. The first safet y review will take place when the first [ADDRESS_768087] ive of this study  is to assess the effic acy of durvalumab + SoC CCRT 
compared wi th placebo + SoC CCRT in terms of PFS as assessed by [CONTACT_584192]. PFS (per RECIST 
1.[ADDRESS_768088] igator tumor assessments or hi stopathol ogic confi rmation of local 
tumor progressi on) will be defined as the time from the date of randomizat ion unt il the date of 
objective disease progression or death (by  [CONTACT_72999]) regardless 
of whether the patient withdr aws fro m therapy  or receives another anticancer therapy  prior to 
progression (ie, date of event or censoring –date of rando mizat ion + 1). A key  secondary  
objective is to assess the efficacy of durvalumab + SoC CCRT compared with placebo + SoC 
CCRT in term s of OS. In order to provide strong control of the ty pe I error rate α=5% (2 -
sided), the testing procedure for the primary  endpoint and key secondary  endpoint is 
hierarchical.
The analysis of the secondary  endpoints of PFS (3 year), PFS and OS in PD -L1 pos itive 
patients, ORR, and CR rate will be based on investigator assessments using RECIST 1.1 or 
histopathologic confirmat ion of local progressio n. In addit ion, the key  secondary  endpoint 
(OS) and other secondary  endpoints (Inci dence of Local Progressi on, Di stant Disease 
Recurrence, and Secondary  Malignancy ) will also be analyzed.
Efficacy data will be summarized and analyzed on an intent -to-treat (ITT) basis, and the
treatm ent arm s will  be com pared on the basis o f rando mized treatment, regardless of the 
treatment actually received. Patients who were randomized but did not subsequent ly go on to 
receive study  treatm ent are included in the full analysis set (FAS) populat ion.
Approximately  714 pati ents will be rando mized 1:1 to durvalumab + SoC CCRT or placebo + 
SoC CCRT to obtain approximately 227 PFS events in the ITT populat ion. The rando mizat ion 
will be stratified according to disease stage status (FIGO (2009) Stage <III and node posit ive, 
FIGO (2009) Stage ≥III and node negat ive, or FIGO (2009) Stage ≥III and node positive) and 
region [Uni ted States, Canada, European Union, South Korea, and Japan] versus rest of world.
The primary  endpoint of PFS will be tested once. The secondary  endpoint of OS will be tested 
at an interim and at a final t imepo int. The alpha level allocated to OS will be controlled at the 
interim and final timepoints using the Lan DeMets ( Lan and DeMets 1983 ) spending funct ion 
separately  for PFS and OS that approximates the O’Brien -Fleming approach, where the alpha 
allocated at the interim depends upon the proportion of informat ion available. 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 32The analysis of PFS and the interim analysis of OS will occur when approximately  227 PFS 
events ha ve occurred across the durvalumab + SoC CCRT and placebo + SoC CCRT 
treatm ent arm s. If the true hazard ratio (HR) for PFS is 0.65 (likely to correspond to an 11% 
increase in the proportion of pat ients event -free at 3 years fro m 65% to 76%), this analysis 
will have 90% power to demonstrate a statist ically si gnificant difference for PFS, assuming a 
2-sided 5% si gnificance level. Given the recruit ment assumpt ions for PFS outlined above, the 
analysis for PFS is ant icipated to occur approximately [ADDRESS_768089] pati ent.It is ant icipated that 86% of the target number of OS events (ie, 
approximately  195 of 227 OS events) will be available for the OS interim analysis.
The final OS analysis will occur at the earlier of [ADDRESS_768090] patient. Assuming the same recruit ment assumpt ions for PFS and a 3 -
year OS rate of 70% for placebo + SoC CCRT ( Rose et al 1999), [ADDRESS_768091] 
ratio (HR) is 0.65 (likely  to correspond to an 9% increase in the proportion of patients alive at 
3years from 70% to 79%), this analysis will have 89% power to demonstrate a statist ically 
significant difference for OS, assuming a 2 -sided 5% significance l evel.
The primary  PFS analysis will be based on the programmat ically derived RECIST 1.[ADDRESS_768092] of durvalumab + SoC CCRT versus placebo + SoC CCRT will be analyzed using a 
log-rank test stratified by  [CONTACT_584190] (FIGO (2009) Stage <III and node posi tive, 
FIGO (2009) Stage ≥III and node negat ive, or FIGO (2009) Stage ≥III and node positive) and 
region [Uni ted States, Canada, European Union, South Korea, and Japan] versus rest of the 
world. The HR together with its 95% CI and p -value will be presented (an HR less than 1 will 
favor durvalumab + SoC CCRT). The HR and CI will be estimated from a stratified Cox 
proporti onal hazards model using the same strata as for the primary  analysis by  [CONTACT_584193] l og 
rank test and using the Efron model for ties. The poi nt estimate of the treatment effect, i.e. HR 
will be obtained by  [CONTACT_584194], which is the product of 
the likelihood of each stratum (an HR less than 1 will favor durvalumab + SoC CCRT). The 
95% CI will be est imated usin g the profile likeliho od approach. The 95% CI and HR from the 
stratified Cox proportional hazards model will be in support of the p -value from the stratified 
log rank test, no p -value will be reported from the stratified Cox proportional hazards model.
Safety is a secondary endpo int in this study . All safety  analyses will be performed on the 
safet y popul ation. Safety  and tolerabilit y data will  be presented by  [CONTACT_584195] y popul ation. Safety  data will be summarized descript ively and will no t be formally 
analyzed.

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 331.3 Schema
The general study  design is summarized in Figure 1. 
Figure 1 Study design
Abbreviations: brachy Brachytherapy; EBRT Exter nal Beam Radiotherapy; FIGO (2009) International 
Federation of Gynaecology and Obstetrics; q4w Every [ADDRESS_768093] imated 528000 new cases diagnosed in 2012 and 266000 deaths ( Ferlay  et 
al 2013 ). North America has the third lowest rate of cervical cancer; however, in the US there 
were [ZIP_CODE] women diagnosed with cervical cancer and 4092 deaths in 2011 ( Bena rd et al  
2014). In contrast, in China [ZIP_CODE] women were diagnosed with cervical cancer and [ZIP_CODE] 
wom en died of the di sease in 2015 ( Chen et al  2016 ). Overall, the 5 -year OS in this pat ient 
popul ation rem ains poor wi th survival  at Stage IIB 58%, IIIA 35%, and IVA 16% ( Ferlay et al  
2013).
Rates of cervical cancer vary greatly between the developi[INVESTIGATOR_584148]. The Pap smear was introduced in 
the 1950s as a screening method to diagnose atypi[INVESTIGATOR_2855], premalignant lesio ns and early stage 
cervical cancer. [LOCATION_002] Preventive Services Task Force (USPSTF) guidelines 
recommend screening for cervical cancer in all women aged 21 to 65 y ears and screening for 
HPV e very 5years in wo men aged 30 to 65 y ears ( USPSTF 2016
). Where implemented, this 
prevent ive care measure has reduced the incidence of advanced stage c ervical cancer 
dram atically. However, most women globally do not have access to screening, and thus the 
global incidence of cervical cancer at all stages cont inues to rise throughout the world as the 
popul ation rises and ages. Addit ionally , there are barri ers to cervical cancer screening. Only  
25% of women in Japan are screened for cervical cancer, and the rates of screening in China 
and India are similarly low with less than 20% of women in China screened and less than 10% 
in India ( De Sanjose 2012). In contrast, the rate of women screened in the US is 88.6% 
(Bena rd et al  2014 ).
2.1.1 Rationale for combining checkpoint inhibitor therapy with 
chemoradiotherapy
Concurrent chemoradiation therapy  (CCRT) have been shown to induce immunogenic cell 
death. Cell death, from radiat ion or CCRT, enhances the abilit y of the immune system to 
recogni ze and respond to the tumor through enhanced antigen release and presentation (tumor 
specific T cell act ivation; Formenti and Demaria 2013 , Weichselbaum et al 2017 ). In addi tion, 
ionizing radiat ion causes upregulat ion of various pro- inflammatory signals and cytokines, 
which play  a key rol e in immune regulatory  pathway , leading to improved ant i-tumor 

Clinical Study Protocol - 4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 35immunity. Victor et al also showed that radiation enhanced the diversity of the T cell receptor 
repertoire of intra-tumoral T cells ( Twyman-Saint Victor et al 2015 ).
Radiotherapy induces double-stranded deoxyribonucleic acid (DNA) breaks that are 
catastrophic for the rapi[INVESTIGATOR_46548], promoting a cascade of cytokine release and mitochondrial disruption and results in apoptosis and activation of both the innate and 
adaptive immune system. This mechanism promotes neoantigen production, resulting in 
antigen presentation to dendritic cells, natural killer (NK) cell activation, and cluster of differentiation 8 (CD8) + T cell recruitment to the area of damage ( Salama et al 2016 ).
The PACIFIC trial evaluated the efficacy of durvalumab after definitive chemoradiotherapy in Stage III NSCLC compared to placebo after chemoradiotherapy and found a significant improvement with durvalumab with a median PFS of 16.8 months (95%CI 13.0 to 18.1) compared to 5.6 months (95%CI, 4.6 to 7.8) in the placebo controlled group (Antonia et al 2017). This improvement in PFS in this patient population was thought to be due to multiple 
variables, with the highly immunogenic tumor microenvironment associated with 
chemoradiotherapy likely an important contributor. 
Concomitant administration of radiotherapy with  anti-PD-L1 monocl onal antibodies (mAb) 
resulted in substantially improved survival benefit in a mouse model. Here, low dose 
fractionated radiotherapy resulted in an increase in interferon gamma (IFN-y) producing 
CD8+ T cells and PD-L1 tumor expression duri ng radiotherapy, peaking at [ADDRESS_768094] dose and significantly declining at 7 days after radiotherapy ( Dovedi et al 2014 ). 
Radiation therapy can additionally induce an absc opal effect, where tumors not directly in the 
field of radiation therapy also become more  immunogenic due to the release of neoantigens 
from the tumor site, when given sequentially ( Postow et al 2012 ) and also concurrently 
(Stamell et al 2013 ).
The use of concurrent durvalumab therapy with chemotherapy and/or radiotherapy is currently being studied in NSCLC  ( ), colorectal cancer 
( ), urothelial bladder cancer , and hepatocellular carcinoma 
([STUDY_ID_REMOVED]). 
The use of combination chemoradiotherapy is a mainstay of oncology therapy in multiple 
tumor types. The goal of combination chemother apy is to utilize agents that affect cancer cells 
by [CONTACT_129427], thus improving clinical responses and reducing the risk of developi[INVESTIGATOR_584146]. Non-clinical and clinical studies have indicated that blockade of immune checkpoints (PD-1/PD-L1 and CTLA- 4) can have a positive effect on anti-tumor 
immunity. Chemotherapy is thought to synergize with PD-1/PD-L1 blockade by [CONTACT_584185] “immunogenic” by [CONTACT_584186], promoting phagocytosis of tumor cells, and ultimately leading to reactivation of imm une-mediated tumor surveillance ( Menderes et al CCI
CCI CCICCI
Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 362016 ). Current studies are now adding immunotherapeutics to chemoradiotherapy  to broaden 
anti-tumor responses through recruit ment of the immune system.
The study ’s hypothesis is that durvalumab, when administered with SoC CCRT and as 
adjuvant therapy  following SoC CCRT, will improve PFS when compared to SoC CCRT 
combined wit h placebo.
2.[ADDRESS_768095] and 
15 potentially oncogenic. About 50% and 20% of cervical cancer has been linked to HPV [ADDRESS_768096] ivation, respectively , 
prom oting carcinogenesis (Lowy  and Schiller 2006 ). Cell cycle deregulat ion mediated by  
[CONTACT_584196] ( Crosbie et al 2013 ). The most commo n screening methods for cervical 
cancer include convent ional Papanico laou (Pap) smear and HPV DNA testing, depending on 
the geographical regio n. The Pa p sm ear can i dentify cellular abnorm alities whereas the HPV 
test can detect suspi[INVESTIGATOR_584149] ( Jin 2014 ). For many years, the Pap smear has been the 
standard m ethod for cervical cancer screening, reducing the incidence by 60% to ( Marth et al 
2017) and has been shown to provide 60% to 70% greater pro tection against invasive cancer 
compared wi th cytology-based screening ( Ronco et al  2014 ).
To prevent a primary  infect ion with HPV, the quadrivalent v accine Gardasil was approved by  
[CONTACT_34033] 2006 for children and adults between the ages of 11 to 25 y ears. Current ly, there 
are 3 vaccines in use: the Cervarix bivalent vaccine, which targets HPV 16 and 18, the 
Gardasil quadrivalet vaccine (HPV 6, 11, 16, and 18) and the Gardasil -9, a 9 valent HPV 
vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58). HPV vaccinat ion is part of the National 
Immunizati on Programs (NIP) or pi[INVESTIGATOR_584150] 83 countries ( Markowitz et 
al 2012 ); however, there are instances where the vaccination program is not being optimally 
utilized. In Japan, for example, the proactive recommendat ions for the HPV vaccine were
suspended 2 months after its inclusio n into the NIP in 2013 after unconfirmed reports of AEs 
following vaccinat ion (Hanley  et al  2015 ). As a result, current low uptake of the HPV vaccine 
in Japan (3.5% in 7th to 11th grades in 2013) may potentially  lead to a hi gh inci dence of 
cervical cancer in the future ( Sekine et al 2016 ). As of October 2014, about 59.[ADDRESS_768097] 1 dose of the vaccine, with the majorit y of wom en from high -
income and upper -middle inco me countries. Wit h increasing vaccine utilizat ion, it is expected 
that by 2080 that approximately 440000 cervical cancer cases will be prevented; y et, because 
many countries have not implemented widespread vaccination or because the cost of vaccine 
precl udes i ts wi despread implementation, an addit ional 510000 women will devel op cervical  
cancer during this interval ( Bruni et al  2016 ).
2.2.2 Staging of cervical cancer
Cervical tum ors are staged using FIGO (2009) classificat ion, which is the most widely used 
classificat ion (Haie-Meder et al  2010) and i s one of the most important prognostic factors 
(Marth et al 2017 ). Cervi cal cancer i s the only gynecological cancer that is clinically staged 
based on tum or size, vaginal  or param etrial involvem ent, bl adder/rectum  extensio n, and
distant m etastases. It requires examinat ion under anaesthesia, radio logical imaging such as 
chest X -ray and IV py elogram, or other di agnost ic tools. CT can detect pathological lymph 
nodes, MRI can determine tumor size, degree of stromal penetrations, para metrial 
involvement, vaginal extensio n, and corpus extension with high accuracy ( Wagenaar et al 
2001).
2.2.3 Lymph node status in cervical cancer
Lymph node status is not part of the FIGO (2009) staging system for cervical cancer, but 
provi des important i nformat ion for prognosis and treatment ( Gien and Covens 2009). As the 
FIGO stage increases, the risk of lymph node metastasis and parametrial invo lvement also 
increases. In patients who have had a surgical resection, the incidence of pelvic lymph node 
metastasis in Stage IB cervical cancer ranges fro m 11.5% to 21.7% ( Lee et al 2006 ). For Stage 
IIA and IIB cervical cancers, the incidence ranges fro m 10% to 26.7% and 28.6% to 43.4%, 
respectively  (Benedetti -Panici  et al  1996 , 
Havrilesky  et al  2004 , Inoue et al 1990, Lai  et al  
1993, Lee et al 2006 , Mori ce et al  1999 , Sakuragi et al 1999 ). In pati ents wi th Stage IB 
cervical cancer, the incidence of para -aortic node invo lvement is low at 2% to 4%. In the more 
advanced stages, the incidence increases to 7% to 17% ( Benedetti -Panici  et al  1996 , Berm an 
et al 1984 , Morice et al 1999 , Sakuragi et al 1999).
Lymph node status is a prognostic predictor of survival ( Macdonald et al 2009 ). The 3 y ear 
OS in FIGO (2009) Stage IB to II node -posit ive patients is lower (55%) compared to 
node- negat ive (94%) ( Morice et al  1999 ). Based on data from over 2200 patients in Stage IA1 
to IIB, higher number of posit ive lymph nodes is associated with adverse survival outcomes 
(Zhou et al 2017), and the extra -pelvic recurrence is higher in pat ients with ≥3involved lymph 
nodes compared to patients with 0 to 2 lymph nodes (data fro m 141 pati ents, Stage IB to IIB) 
(Kasuya et al 2013). Ty pi[INVESTIGATOR_897], the adjacent obturator nodes will be the first site of lymph 
node m etastasi s, and then it will spread in a step- wise fashio n to the i psilateral  commo n iliac 
lymph nodes and para- aortic lymph nodes (PALN). Patients with PALN metastasis have lower 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 38survival rates and need extended field radiat ion (EFRT). In a retrospective study looking at [ADDRESS_768098], wi th a 5-year OS of 62.6% and PFS of 43.9% ( Yoon et al 2015 ).
2.2.4 Treatm ent of cervical cancer
Stage IA1 cervical cancer is ty pi[INVESTIGATOR_584151] y, with 
conization without lymphadenectomy because the risk of nodal metastasis is <1%. Stage IA2 
with no lymphovascular space invo lvement can be treated by [CONTACT_584197] (if fert ility is to be 
preserved) or extrafascial hy sterectomy . In pat ients with surgical  contraindicat ion, 
brachyt herapy may represent an alternat ive option. Stages IB and IIA cervical carcino ma can 
be cured by [CONTACT_584198]  (Haie-Meder 
et al 2010). In wom en wi th locally advanced cervical  cancer (Stages 1B2 to IVA), cisplatin 
with concurrent radiotherapy  has remained the SoC ( Colombo et al 2012) and i s unchanged 
since 1999 ( Rose et al 1999 , 
Koh et al  2013 ).
For wom en who devel op locally  advanced cervical cancer, the SoC has evolved from EBRT 
alone, to EBRT pl us brachy therapy , to combined EBRT p lus brachytherapy wit h concurrent 
chemotherapy ( Green et al  2001 ). Brachy therapy  involves the applicat ion of a radioactive 
source in close proximit y to the tum or, all owing a very  high dose of radi ation being delivered 
to the tum or wi th relative sparing of the surrounding normal structures ( Banerjee and 
Kamrava 2014). Brachy therapy  treatm ents are ei ther interdi gitated wi th EBRT (generally , 
starting no earlier than Week 3 of treatment) or are given after EBRT is completed. Starting 
brachyt herapy later in the treatment course allows for maximal tumor sh rinkage, thus allowing 
for smaller brachy therapy  treatm ent vol umes. Ul timately, the most crit ical part of deciding 
when to start brachy therapy  is the m onitoring of treatment response, through regular pelvic 
examinat ions during the course of EBRT ( Banerjee and Kamrava 2014 ). Brachy therapy  can 
be perform ed using an intracavitary , intersti tial, or combinat ion approach. Intracavitary  
brachyt herapy invo lves placing the radi oactive source using an applicator, through the vaginal 
cavit y, and can treat the upper vagina, cervix, and uterus. In interstit ial brachytherapy, 
catheters (small tubes) are placed in and around residual disease, using a transperineal/vagi nal 
approach. The choice of technique depends primarily on disease extent and anatomy ( Banerjee 
and Kamrava 2014 ).

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 39In the pi[INVESTIGATOR_2397] , Rose et al  1999 randomized 526 women with Stage IIB, III, or IVA 
cervical cancer to receive radiation therapy wit h either cisplat in, cisplat in with 5 -fluorouracil 
(5FU) wi th hydroxyurea or hy droxyurea al one. For the cisplatin mo notherapy  cohort when 
compared to hy droxyur ea m onotherapy , the PFS risk rati o (RR) of 0.57 (95% CI 0.42 to 0.78) 
and OS RR of 0.61 (95%CI 0.44 to 0.85) were observed and was similar to -the cisplat in with 
5FU group (PFS RR=0.55). Toxicit ies included cytopenias -, gastrointest inal (GI) effects, renal
toxicity, and neurotoxi city(Rose et al  1999 ). Additio nally , the durati on for CCRT 
administration is crit ical to patient outcome. Co mpletion of CCRT i n 56 days co mpared to 
more than 56 days was associated with benefits in reduced pelvic failure rate and improved 
OS, com pared to prol onged CCRT administration ( Song et al. 2013, Petereit et al. 1995 ). In 
certain clinical scenarios, carboplat in has been substituted for cisplat in as a radiosensit izer,. 
Thepotenti al difference between carboplat in and cisplat in was retrospectively evaluated in 
247wom en receiving definit ive chemoradiotherapy  for locally advanced cervical cancer. In 
this evaluat ion, cisplat in was superior, with a CR rate of 88.3% compared to 73.9% (p=0.004) 
(Valdivieso et al 2017 ). However, in women that are unable to receive cisplat in due to specific 
pre-exist ing condit ions such as renal insufficiency or peripheral neuropathy , carbopl atin is an 
acceptable alternat ive. Another study  evaluated [ADDRESS_768099] atin with radiotherapy in co mpar ison to a historical control of cisplat in wit h 
radiotherapy , and there was no appreci able difference in OS and PFS between the 2 groups; 
there was an increase in the number of cy cles administered and a reduction in AEs in the 
carbopl atin group ( Nam et al 2013 ). An addi tional retrospective study  of [ADDRESS_768100] atin and concurrent radiotherapy showed that 142 (95.9%) women had a CR and 
only 6 (4.1%) had persi stent disease. The 2- year PFS and OS rates were 75.1% and 81.9%, 
respectively  (Katanyoo et al 2011 ). In pati ents that are able to receive cisplat in, both the 
NCCN guidelines ( NCCN 2020
) and ESMO guidelines ( Marth et al  2017
) for cervi cal cancer recommend cisplatin to be given wit h EBRT.   To ensure appropriate 
balance between patients treated with cisplatin and carboplatin as the radiosensit izer across 
regions in the ongoing study , no further use of carboplat in as the radiosensit izer will be 
allowed in this study . 
Although data are limit ed, available evidence suggests that concurrent chemoradiotherapy  is 
superi or to sequenti al treatm ent. An analysis of the trials evaluat ing systemic chemotherapy 
after chem oradi otherapy  showed that there is limit ed benefit and instead there may be an 
incre ased toxi city in this pat ient populat ion (Tangjitgamo l et al 2014 ). Currently , the 
Gyneco logic Oncol ogic Group (GOG) i s performing a Phase III randomiz ed m ulticenter study  
in 900 wo men with cervical cancer to evaluate the efficacy  of carboplatin wit h paclit axel 
given adjuvant ly following definit ive chemotherapy/radiotherapy wit h a primary  endpoint of 
OS (OUTBACK Trial, [STUDY_ID_REMOVED]). 
Surgery  is not ty pi[INVESTIGATOR_584152]. . In a 
single- center Phase 3 rando mized controlled clinical trial, 633 wom en wi th locally  advanced 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 40cervical cancer were rando mly assigned to receive neoadjuvant chemotherapy fo llowed by  
[CONTACT_584199]; those who received surgery  had 
decreased 5- year disease -free survival (DFS) (69.3% versus 76.7%, p=0.038) ( Gupta et al 
2018) In a retrospective analysis o f 211 pati ents undergoing definit ive chemoradiat ion and 
brachyt herapy, co mpletion hysterectomy  after defini tive chem oradiati on and brachy therapy  
was associated with increased morbidit y with no chan ge in OS or DFS. Cum ulative incidence 
of severe l ate m orbidity was observed in 22.5% of patients in in the group that received a 
hysterectomy co mpared to 6.5% in the non -hysterectomy group (p=0.016) (Mazeron et al 
2016). 
The rel apse rate of cervical cancer ranges between 28 and 64% in FIGO (2009) Stages IIB to 
IVA ( Quinn et al 2006
). Although the m ajority of the recurrences develop in the first 2 to 3 
years after treatment, in so me patients, cervical cancer recurs after 3 years ( Elit et al 2009, 
Fuglsang et al 2015 , Wiebe et al
 2012 ). 
2.2.5 Cervical cancer establishes an immunosuppressive environment
HPV is the primary causative agent for the majorit y of cervical  cancer cases, wi th more than 
90% of squamous cervical cancers containing HPV DNA. In the presence o f a chronic HPV 
infect ion, a natural immune response develops wit h act ivation of the adaptive immune system. 
HPV proteins E6 and E7 also promote neoantigen generat ion, further stimulating the immune 
response ( Qin et al 2017). However, the viral oncoproteins E5, E6, and E7 play a role in 
immune evasio n, wi th E5 inhibit ing expressio n of human leukocy te anti gens-A (HLA -A) and 
HLA -B. This results in evasio n of CTL and NK cell killing ( Menderes et al 2016 ). HPV16 
positive tum ors have a unique immune suppressive environment with increasing numbers of 
tumor-associated macrophages observed, contributing to chronic infect ion (Lepi[INVESTIGATOR_584153] 
2009). From  retrospecti ve tissue evaluat ion of pre -malignant cervical t issue, there is 
increasing PD -1 expressio n seen on cervical T cells with increasing levels seen at higher 
grades of cervical intraepi[INVESTIGATOR_28601] ( Yang et al 2017
). On eval uation of  tumor tissue 
from 115patients wi th cervical  cancer, PD -L1 was expressed in 19% of samples, and 
programmed death -ligand 2 (PD -L2) expressed in 29% of tumors ( Karim et al 2009).
Histologically, cervical cancer is predominant ly squamous cell carcino ma (80% to 90%) with 
a high tum or mutational burden (TMB). Chronic HPV infe ction is thought to contribute to 
continued so matic mutations and therefore the high TMB in cervical cancer. This high 
mutati onal load in cervical  cancer addi tionally  correl ated wi th increased expressio n of PD -L1, 
transforming growth factor beta (TGF -β), and interleukin 10 (IL -10), whi ch supports the rol e 
for immunotherapy  (Qin et al  2017 ). Cervi cal cancer addit ionally evades the immune response 
through mutations in the IFN -γ signaling pathway  and Janus Kinase 2 (JAK2) ( Ojesina et al  
2014). The TMB i s thought to be direct ly correlated to response of i mmune checkpo int 
inhibitor therapy , which appears to be true for cervical cancer as well ( Yarchoan et al 2017 ).

Clinical Study Protocol -4.[ADDRESS_768101] been done in pat ients with cervical cancer that were previously treated. In Study CD-
ON-MEDI4736- 1108 (hereafte r referred to as Study 1108), 10 wom en wi th cervical  cancer 
were treated with durvalumab mo notherapy ; an ORR of 20% (2/10) was observed. This is 
broadly  consistent wi th resul ts seen wi th other checkpoint inhibitors in previously treated 
cervical cancer. Th e KN -158 tri al treated 98 wom en wi th cervical squamous cell cancer with 
pembrolizumab. This study demo nstrated an ORR of 12% (12/98) with 3 patients wi th a CR 
(Schellens et al 2017). The  FDA granted accelerated approval to pembrolizumab for the 
treatm ent of patients with advanced, PD -L1-positive cervical cancer with disease progression 
on or after chemotherapy  in June 2018. CheckMate 358 treated 19 wom en wi th recurrent 
cervical cancer with nivo lumab and found an ORR of 26.3% and median PFS of 5.5 months 
(Hollebecque et al 2017 ). These checkpo int inhibitors were well tol erated and had a 
reasonable toxicit y profile. PD -L1 and PD -1 expressio n posi tively correl ates wi th HPV -
positivity, increase in cervical intraepit helial neoplasia (CIN) grade, and tumor metastasis. In 
fact, l ow expressio n (score 0 or 1) of PD-L1 was found to be a prognostic factor of tumor 
relapse, hi ghlight ing the need for patients with low or negative expressio n of PD -L1 to use 
more aggressive treatm ent other than convent ional CRT ( Yang et al 2017 ).
2.2.7 Immunotherapi[INVESTIGATOR_584154] , and under 
some ci rcumstances, the immune system may  control  or even eliminate tumors 
(Dunn et al 2004).
PD-L1 is part of a complex system of receptors and ligands that are invo lved in controlling 
T-cell act ivation. The PD -1 receptor (CD279) is expressed on the surface of act ivated T cells 
(Keir et al  2008 ). It has 2 known ligands: PD -L1 (B7
-H1; CD274) and PD -L2 (B7- DC; 
CD273) ( Okazaki et al 2007 ). PD -1 and PD -L1/PD -L2 belo ng to a family o f immune 
checkpoint proteins that act as co- inhibitory factors, which can halt or limit the developm ent 
of Tcell response. When PD -L1 binds to PD -1, an inhibitory  signal  is transmi tted into the 
Tcell, which reduces cytokine production and suppresses T cell proliferation. Tumor cells 
explo it this immune checkpo int pathway  as a m echanism to evade detecti on and inhibit 
immune response.

Clinical Study Protocol -4.[ADDRESS_768102] itutively  expressed by  -Bcells-, dendri tic cells, and macrophages ( Qin et al 
2016). Im portantly , PD-L1 is commo nly overexpressed on tum or cells or on nontransformed 
cells in the tumor microenvironment ( Pardoll 2012 ). PD -L1 expressed on the tumor cells 
binds to PD -[ADDRESS_768103] ivated T cells remain inhibited in the tumor microenvironment. The PD -1/PD -L1 
pathway  represents an adapt ive immune resistance mechanism that is exer ted by  [CONTACT_584200] -tumor activi ty.
The inhibitory  mechanism  described above is co -opted by  [CONTACT_178530] -L1 as a way  
of evading immune detection and eliminat ion. The binding of an ant i-PD-L1 agent to the 
PD-L1 recept or inhibit s the interaction of PD -L1 wi th the PD -[ADDRESS_768104] range of cancers. Based on these findings, an ant i-PD-L1 
antibody  coul d be used therapeut ically to enhance ant i-tumor immune responses in pat ients
with cancer. Results of pre -clinical and clinical studies of mAbs targeting the PD- L1/PD -[ADDRESS_768105] ivity and a m anageable safet y profile, supporting 
the hypothesis that an ant i-PD-L1 ant ibody  coul d be used to therapeutic ally enhance ant i-
tumor immune response in cancer patients ( Brahmer et al 2012 , Hirano et a l 2005, Iwai  et al  
2002, Okudaira et al 2009, Topalian et al 2012, Zhang et al 2008) wi th responses that tend to 
be more pronounced in pat ients with tumors that express PD -L1 (Powles et al 2014
, Rizvi et al  
2015, Segal et al 2015). In addi tion, high mutati onal burden (eg, in bladder carcino ma; 
Alexandrov et al 2013 ) may contribute to the responses seen wit h immune therapy.
Pre-clinical data has now been added to a wealth of clinical data showing that blockade of 
negat ive regulatory signals to T cells such as CTLA -[ADDRESS_768106] granted [LOCATION_002] (US) Food and Drug Administra tion 
(FDA) approval for the treatment of metastatic melano ma and is current ly under invest igation 
for several  other m alignancies. Nivol umab and pembrolizumab, [ADDRESS_768107] been granted approvals by [CONTACT_584201] s for the treatm ent 
of a number of malignancies including metastatic melano ma, squamous and non -squam ous 
cell non -small -cell lung cancer, squamous cell carcino ma of the head and neck, and urothelial 
carcino ma. In addit ion there are data fro m agents in the anti-PD-1/PD -L1 cl ass showing 
clinical act ivity in a wide range of tum or types.
2.2.8 Durvalumab
Durvalumab (MEDI4736, Imfinzi™) is a human monoclonal ant ibody  (mAb) of the 
immunogl obulin G 1 kappa subclass that blocks the interaction of PD- L1 (but not PD -L2) 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 43with PD-1 on T cells and CD80 (B7.1) on immune cells. It is being developed by 
[CONTACT_38227]/MedImmune for use in the treatment of cancer. (MedImmune is a wholly owned 
subsidiary  of [COMPANY_008]; [COMPANY_008]/MedImmune will be referred to as [COMPANY_008] 
througho ut this document.) The proposed mechanism of act ion (MOA) for durvalumab is 
interference in the interaction of PD -L1 wi th PD-1 and CD80 (B7.1). Blockade of PD -L1/PD -
1 and PD-L1/CD80 interactions releases the inhibition of immune responses, including those 
that may  resul t in tum or eliminat ion. In vitro studies demonstrate that durvalumab antagonizes 
the inhibitory  effect of PD -L1 on primary human T cells result ing in the restored proliferat ion 
of IFN-γ (Stewart et al 2015 ). In vivo studies have shown that durvalumab inhibit s tum or 
growth in xenograft models via a T cell-dependent mechanism ( Stewart et al 2015 ). Based on 
these data, durvalumab is expected to stimulate the patient’s ant i-tumor immune response by 
[CONTACT_28738] -L1 and shift ing the balance toward an ant i-tumor response. Durvalumab has 
been e ngineered to reduce antibody -dependent cellular cy totoxi city and com plement -
dependent cy totoxi city. 
To date, durvalumab has been given to more than [ADDRESS_768108] ion 4.3.1 and Section 8.3.12 . Refer 
to the current durvalumab IB for a com plete summary  of pre-clinical and clinical informat ion 
including safet y, efficacy , and PK.
2.3 Benefit/risk assessment
More detailed informat ion about the known and expected benefits and risks and reasonably  
expected AEs of durvalumab may be found in the IB.
See Secti on 9.6.1 and Appendix Afor information regarding the IDMC.
2.3.1 Potential benefits
[IP_ADDRESS] Durvalumab as monotherapy in cervical cancer
The m ajority of the safet y and effica cy data currently  available for durval umab are based on 
the first -in-human, single -agent study , Study  1108, in pat ients with advanced so lid tumors, the 
study  of durvalumab m onotherapy  in NSCLC (Study  D4191C00003 [ATLANTIC]), and the 
study  of durvalumab m onotherapy  in NSCLC fo llowing co mpletion o f platinum -based 
chemotherapy concurrent with radiat ion therapy  (the PACIFIC study ). Data from  these studi es 
have demo nstrated clinical activit y of durvalumab therapy  in pat ients with NSCLC. Study  
1108 included a 10 -patient cohort with cervical cancer that showed 14.3% ORR following 
durvalumab monotherapy  (10 mg/kg every 2 weeks [q2w]). Details pertaining to Study  1108 
and ATLANTIC are provided in the durvalumab IB. In a combinat ion study  of durvalumab 
with AXELimogen e (HPV vaccine) in recurrent/persistent or metastatic cervical cancer, the 
durvalumab monotherapy  arm showed 8% ORR, and ORR+ stable disease (SD) was 40%.

Clinical Study Protocol - 4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 44PACIFIC has shown significant improvements in median PFS with durvalumab treatment 
compared with placebo for patients wi th NSCLC (16.8 m onths [95% CI: 13.0, 18.1] versus 
5.6 months [95% CI: 4.6, 7.8]; stratified HR for disease progression or death, 0.52; 95% CI: 0.42, 0.65; p<0.001). Similar findings in favor of durvalumab compared with placebo were found for duration of response (72.8% versus 46.8% of patients had ongoing response at 
18 months, respectively) and median time to death or distant metastasis (23.2 months versus 
14.6 months, respectively; p<0.001). In addition, CCRT followed by [CONTACT_178526] (10 mg/kg q2w) was well tolerated  and had a manageable safety profile relative 
to the SoC.
[IP_ADDRESS] Concurrent immunotherapy and chemoradiotherapy in cervical cancer
Concurrent immunotherapy and chemotherapy
The efficacy of immunotherapy administered conc urrently with chemotherapy agents is 
supported by [CONTACT_584202]021 study (pembrolizumab; PD-1 inhibitor), 
the CheckMate 012 study (nivolumab; PD-1 inhibitor), and preliminary results from 
The anti-tumor activity of pembrolizumab administration concurrent with various 
chemotherapy regimens versus chemotherapy (carboplatin-pemetrexed) alone as first-line treatment for NSCLC (the KEYNOTE-021 study) demonstrated ORRs of 55% (95% CI: 42, 68) versus 29% (95% CI: 18, 41), respectively (p=0.0016), with durations of response of at 
least 6 months in 92% (95% CI: 73, 98) and 81% (95% CI: 51, 93), respectively ( Langer et al 
2016).
The anti-tumor activity of nivolumab administered concurrently with platinum-based doublet 
chemotherapy as firstline treatment for advanced NSCLC (the CheckMate 012 study) demonstrated ORRs for nivolumab 10 mg/kg plus gemcitabine-cisplatin, nivolumab 10 mg/kg plus pemetrexed-cisplatin, nivolumab 10 mg/ kg plus paclitaxel -carboplatin, and nivolumab 
5 mg/kg plus paclitaxel-carboplatin of 33%, 47%, 47%, and 43%, respectively, and 24-week PFS rates of 51%, 71%, 38%, and 51%, respectively ( Rizvi et al 2016 ).
The efficacy of durvalumab ± tremelimumab with standard platinum-based chemotherapy in advanced cancers is being generated from 2 ongoing Phase I studies: internal Study  and a  run by [CONTACT_584203] (CCTG). Study  is evaluating the safety and 
tolerability of durvalumab + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopi[INVESTIGATOR_76351], squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), small cell lung carcinoma (SCLC), and 
gastric/gastro-esophageal junction (GEJ) cancer, pancreatic ductal adenocarcinoma (PDAC) CCI
CCI CCI
CCI
Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 45and esophageal squamous cell carcino ma (ESCC). Results fro m this study  are expected in 
2019. Patients in the CCTG study were treated wi th durvalumab ± tremelimumab at 1 of 4 
dose l evels concomitant ly wit h either pemetrexed + carboplat in/cisplat in followed by  
[CONTACT_584204] -squamous histo logy (45 pati ents) or gemcitabine + 
carbopl atin/cisplat in for squam ous hist ology  (9 patients). Preliminary results from this study  
indicated that a total of 45 patients (44% m ale; m edian age=62 years [range 36 to 78]; 100% 
Eastern Cooperative Oncology  Group [ECOG] PS ≤1) in the pemetrexed -platinum cohort 
received a total of 346 t reatment cy cles whereas 9 patients (78% m ale; m edian age=64 years 
[range 57 to 80]; 100% ECOG PS ≤1) in the gemcitabine -platinum group received a total of 
55treatm ent cy cles. The ORR was 57.1% (95% CI: 39.4, 73.7) in 35 evaluable patients 
receiving pemetr exed-platinum and 37.5% (95% CI: 8.5, 75.5) in 8 evaluable pat ients 
receiving gemcit ibine -platinum ( Juergens et al  2017 ). 
Concurrent immunotherapy and radiation therapy
Current ly, over a dozen clinical studies are evaluating anti -PD-1 and ant i-PD-L1 ant ibodies in 
administration concurrent ly with (as opposed to after com pletion of) radiat ion for cancer 
treatm ent, but robust efficacy  resul ts are not y et available ( Weichselbaum et al 2017 ). Several  
non-clinical studies, as described below, suggest that inhibit ion of the PD -1/PD -L1 checkpo int 
combined with radiotherapy  liberates T cells fro m immunosuppressio n, which in turn 
positively alters the tumor microenvironment owing to killing o f suppressive cells via 
cytokine secret ion. Mouse tum or models have been used to demonstrate the synergist ic effect 
of radiotherapy  and immunotherapy  via checkpoint inhibit ion in so lid tumors ( Weichselbaum 
et al 2017 ). A preliminary  non-clinical report from the Drake la boratory  indicates that 
radiotherapy  combined wit h ant i-PD-[ADDRESS_768109] ( Sharabi etal2014). More recent data from the same group indicate 
that this therapy  combinat ion results in the induct ion of endogenous ant igen-specific immune 
responses, leading to improved local control in single tumor models of melano ma or breast 
carcino ma (Sharabi et al 2015
); however, no experiments on the abscopal effect were 
reported. Dovedi and Illidge ( Dovedi  and Illidge 2015 ) subsequent ly noted that the timing of 
anti-PD-L1 blockade is crucial; concurrent radiation and ant i
-PD-L1 treatm ent, but not 
sequent ial treatm ent, resul ted in l ong-term tumor con trol, suggesting that concurrent 
administration of durvalumab and SoC radiotherapy may  have improved clinical benefit over 
sequent ial therapy.
2.3.[ADDRESS_768110] adverse drug reactions seen wit h the immun e checkpo int inhibitor class of agents are 
thought to be due to the effects of inflammatory  cells on specific t issues. These risks are 
generally events with a potential inflammatory  or immune -mediated mechanism and that may 
requi re more frequent m onitoringand/or unique intervent ions such as immunosuppressants 
and/or endocrine therapy . These immune -mediated effects can occur in nearly any organ 
system , and are m ost comm only seen as GI AEs such as colit is and diarrhea, 
pneumo nitis/interst itial lung disease ( ILD), hepatic AEs such as liver enzyme elevat ions, skin 
events such as rash and dermat itis, and endocrinopathies including hypo -and hyper -
thyroidism . 
[IP_ADDRESS] Durvalumab
Risks wit h durvalumab include, but are not limited to, diarrhea/co litis, pneumo nitis/ILD, 
endocrinopathi es (ie, events of hypophysit is/hypopi[INVESTIGATOR_297], adrenal insufficiency, hyper -
and hypo -thyroidism , type I di abetes m ellitus and di abetes inspi[INVESTIGATOR_27562]), hepat itis/increases in 
transaminases, nephrit is/increases in creatinine, pancreat itis/increases i n amylase and lipase, 
rash/dermat itis (including pemphigoid), myocardit is, myo sitis/polymyo sitis, immune 
thrombocy topenia, infusio n-related reacti ons, hypersensit ivity react ions, pancreatit is, serious 
infect ions, and other rare or less frequent inflammator y events including neuromuscular 
toxicities (eg, Guillain -Barrésyndro me, myasthenia gravis.
For informat ion on all ident ified and potential risks with durvalumab, please always refer to 
the current version of the durvalumab IB.
In monotherapy  clinical  studies, AEs at an incidence of >=20% includes events such as 
fatigue anddecreased appetite. Approximately 10% of pat ients discont inued the drug due to an 
AE. Please see the current version of the IB for a detailed summary o f the monotherapy  data 
including AE s, seri ous adverse events (SAEs), and common termino logy criteria (CTC) 
Grades [ADDRESS_768111] an immune basis, the use of established 
treatment gui delines for immune -mediated toxicit y (see Secti on 8.4.5 ).
A detailed summary  of durvalumab monotherapy  AE data can be found in the current versio n 
of the durvalumab IB.
2.3.3 Overall benefit/risk
The clinical act ivity associated wi th potentiating the proinflammatory  effects of CCRT 
suggests that giving durvalumab in combinat ion with CCRT may have clinical benefit s, 
including increasing the response rate to CCRT, improving the CR rate, and decreasing the 
number of patients who progress on CCRT. 

Clinical Study Protocol -4.[ADDRESS_768112] demonstrated that concurrent administration of CCRT and 
immuno therapy  has generally been well tolerated, with toxicit ies com parable to administration 
of either agent al one. The safet y of concurrent administration of durvalumab and CCRT is 
further supported by  [CONTACT_584205] , which showed that durvalum ab 
administered within 42 days of co mpletion of CCRT had a well tolerated and manageable 
safet y profile that was consistent with the established safet y profile to date.
Therefore, the overall benefit -risk assessment supports the proposed study  to eval uate the 
efficacy  and safety  of concurrent administration of durvalumab + SoC CCRT.
3. OBJECTIVES AND ENDPOINTS
Table 3 Study objectives
Primary objective: Endpoint/Variable:
To assess the efficacy of durvalumab + SoC 
CCRT compared with placebo + SoC CCRT in 
terms of PFSEndpoints based on the investigator assessment 
according to RECIST 1.1 or histopathologic 
confirmation of local tumor progression:
PFS: Time from date of randomization until 
tumor progression or death due to any cause
Secondary objectives: Endpoint/Variables:
To further assess the efficacy of durvalumab + 
SoC CCRT compared with placebo + SoC 
CCRT in terms of PFS (3 year), PFS in PD -L1 
positive patients, overall survival (OS) (key), OS 
in PD -L1 positive patients, ORR CR rate, and 
DoR in Patients with a CROS: Time from date of randomization until 
the date of death by [CONTACT_584206] 1.1 or pathologic 
assessment of local disease progression
PFS (3 year): Prop ortion of patients alive 
and progression -free at 3 years
PFS in PD -L1 positive patients: Time from 
date of randomization until tumor 
progr ession or death due to any cause in 
patients who are PD -L1 positive (>=1%) 
based on either tumor or immune cell 
staining
OS in PD -L1 positive patients: Time from 
date of randomization until date of death by 
[CONTACT_584207] -L1 positive 
(>=1%) based on either tumor or immune 
cell staining

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 48ORR: The percentage of evaluable patients 
with an Investigator -assessed visit response 
of CR or PR 
CR rate: Disappearance of all target and non -
target lesions DoR in Patients with a CR: 
Time from date of first detection of CR until 
the date of objective disease progression 
according to RECIST 1.1
To assess the effec t of durvalumab + SoC CCRT 
compared with placebo + SoC CCRT on the 
incidence of local progression, distant disease 
progr ession, and secondary malignancy as the 
first documented progression eventIncidence of Local Progression, Distant 
Disease Progression, and Secondary 
Malignancy: Number and percentage of 
patients who develop local progression, 
distant disease recurrence, or secondary 
malignancy 
To assess disease -related symptoms and 
health -related quality of life (HRQoL) in 
patients with cervical cancer treated with 
durvalumab + SoC CCRT compared with 
placebo + SoC CCRT using the core quality of 
life questionnaire (EORTC QLQ -C30) and core 
quality of life questionnaire cervical cancer 
module (CX24) Change from baseline in EORTC QLQ -C30 
and EORTC CX24
To assess the PK of durvalumab when in 
combination with CCRT Blood concentration of durvalumab 
To investigate the immunogenicity of 
durvalumab in both arms in combination with 
CCRT Presence of ADAs 
Safety objective: Endpoint/Variable:
To assess the safety and tolerability profile of 
durvalumab + SoC CCRT compared to placebo 
+ SoC CCRTAEs, laboratory findings, vital signs, and 
physical examinations
Exploratory objective: Endpoint/Variable:
To collect blood and tissue samples for defining 
biological response to durvalumab +SoC CCRT 
compared to placebo +SoC CCRT for candidate 
markers that may correlate with likelihood of 
clinical benefit. (All countries except China)Analys is of blood/tissue samples to assess 
exploratory biomarkers, which may include, 
but is not limited to ctDNA, mRNA 
signatures, CD8 by [CONTACT_4658], and tumor 
mutational burden (TMB)
To assess treatment -related symptoms using the 
Patient -reported outcomes version of the 
Common Terminology Criteria for Adverse 
Events (PRO -CTCAE)Specific treatment -related PRO -CTCAE 
symptoms 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 49To assess how a patient perceives her overall 
change in cancer symptoms since the start of 
study treatment using the PGIC and overall 
severity of cancer symptoms using the PGIS.PGIC and PGIS
To explore the impact of treatment and disease 
state on health status assessed by [CONTACT_584189] -
dimensional five -level questionnaire (EQ -5D-
5L) to support health economic analysis and 
health technology asses smentEQ-5D-5L
To describe and evaluate resource use associated 
with durvalumab treatment and underlying 
diseaseHealth resource utilisation measures 
including hospi[INVESTIGATOR_059], outpatient visits, or 
emergency department visits 
Abbreviations: ADA Antidrug antibody; AE Adverse event; CR Complete response; ECG Electrocardiogram; 
EORTC European Organisation for Research and Treatment of Cancer; EQ -5D-5L EuroQol five -dimensional 
five-level questionnaire; HOSPAD Hospi[INVESTIGATOR_91595]; HRQoL Health -related quality -of-life; IHC 
Immuno histochemistry; ORR Objective response rate; OS Overall survival; PFS Progression -free survival; PGIC 
Patient Global Impression of Change; PGIS Patient Global Impression of Severity; PK Pharmacokinetics; PR 
Partial response; PRO -CTCAE Patient -reported outcomes version of the Common Terminology Criteria for 
Adverse Events; QLQ -C30 30 -item core quality -of-life questionnaire; QLQ -CX24 Cervical cancer module; 
RECIST Response Evaluation Criteria in Solid tumors .
4. STUDY DESIGN
4.[ADDRESS_768113] acebo w ith SoC CCRT 
as systemic treatment in patients with FIGO (2009) Stages IB2 to IVA cervical cancer.
In order to be eligible for this study , patients m ust be ≥18 years of age with FIGO (2009) 
Stages IB2 to IIB N+ and IIIA to IVA with any N. Patients must not have previously received 
any definit ive surgical, radiat ion, or systemic therapy  for cervi cal cancer and m ust be 
immunotherapy -naïve. (Addit ional details are provided in Sect ions 5.1and 5.2.)
Approximately  714 patients from mult iple sites will be rando mized 1:[ADDRESS_768114] ing of EBRT + brachyt herapy , and concurrent cisplat in 40 mg/m2
q1w × [ADDRESS_768115] igator discretion (See 
Secti on 6.1.2 for descript ions of the dosing regimens.) Rando mizat ion will be stratified by 

[CONTACT_155871] -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 50disease stage status (FIGO (2009) Stage <III and node posit ive, FIGO (2009) Stage ≥III and 
node negat ive, or FIGO (2009) Stage ≥III and node posit ive), and region [[LOCATION_002], 
Canada, European Unio n, South Korea, and Japan] versus rest of world. Patients will receive 
their assigned treatm ent until co mpletion of planned therapy , clinical  progressi on or 
RECIST 1.1-defined radio logical progressi on or histopathologic progression on biopsy unless 
there is unacceptable toxicit y, withdrawal of consent, or another discont inuat ion criteria is 
met. (See Section 7.1for addi tional details on discontinuat ion of study  treatm ent.) F ollowing 
completion of SoC CCRT, patients will be evaluated by [CONTACT_584208]. 
During the first 3 years (164 weeks) after randomizati on, thi s assessment will include an 
interval  history  for new si gns or symptom s, physical  examinat ion including a pelvic 
examinat ion, and imaging (CT or MRI) per RECIST 1.1 or histopathologic assessment q12w. 
During Years 4, and 5, imaging/histopathologic a ssessments will be performed q24w and then 
annually until a PFS endpoint has been met or closure of the study  (Secti on9.2).
For an overview of the study  design see Figure 1, Secti on 1.3. For details on treatments given 
during the study , see Secti on 6.1Treatments Administered. 
For details on what is included in the efficacy and safet y endpo ints, see Section 3Object ives 
and Endpo ints. 
4.1.1. Study Conduct Mitigation During Stud y Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The gui dance given below supersedes instructions provided elsewhere in this CSP and should 
be implemented only during cases of civil crisis, natural disaster or public he alth crisis 
(eg,during quarant ines and result ing site closures, regional travel restrict ions and 
considerations if site personnel or study  parti cipants beco me infected with severe acute 
respi [INVESTIGATOR_584155] 2 [SARS -CoV-2] or similar pandemic i nfect ion), which 
woul d prevent the conduct of study -related activit ies at study  sites, thereby [CONTACT_584209] f or the parti cipant ’s abilit y to conduct the study . The invest igator or designee 
shoul d contact [CONTACT_584210].
To ensure continuit y of the clinical study  during a civil  crisis, natural  disaster, or public healt h 
crisis, changes m ay be implemented to ensure the safet y of study  parti cipants, maintain 
compliance w ith GCP , and minimise ri sks to study  integri ty. Where allowable by  [CONTACT_584211], ethi cs commi ttees, heal th care provider guidelines (eg, hospi[INVESTIGATOR_13338]) or local 
government, these changes may  include the following options: 
Obtaining [recons ent] f or the mit igation procedures (note, in the case of verbal [reconsent], 
the informed consent form [ICF] should be signed at the participant’s next contact [CONTACT_476688]).

Clinical Study Protocol -4.[ADDRESS_768116] during civil crisis, natural disaste r, or public health crisis, 
refer to Appendix L. 
4.2 Scientific rationale for study design
The primary  aim of this study  is to assess the efficacy  of durvalumab + SoC CCRT compared 
with placebo + SoC CCRT in terms of PFS, with a key  secondary  objective to assess the 
efficacy  of durvalumab + SoC CCRT compared with placebo + SoC CCRT in terms of OS.
4.2.1 Rationale for study endpoints (efficacy)
PFS m ay serve as a surrogate en dpoint for OS when differences between treatment arms are of 
sufficient magnitude and clinically important ( FDA Guidance 2015 , Mauguen et al 2013, 
Pazdur 2008 ). In particular, a close associat ion of PFS and OS has been observed in Stage III 
NSCLC.
ORR can be a useful endpo int because it i s a di rect measure of the drug’s anti -tumor activit y 
(Pazdur 2008 ). The use of ORR in the setting of locally advanced cervical cancer, especially 
when the responses are sustained and durable (a key feature of im munotherapy ), is just ified 
because it is ant icipated that it will serve as an early measure of clinical benefit that may be 
confirmed by [CONTACT_584212] a randomized confirmatory  study . Assessing 
ORR (and CR rate) will help ascertain the benefit of adding durvalumab on top of SoC CCRT 
versus SoC CCRT alone. Addit ionally , for pati ents treated with immunotherapi[INVESTIGATOR_014], including 
durvalumab, responses appear to be durable, reinfo rcing the importance of ORR as a likely 
surrogate for clinical bene fit.
The key  secondary  efficacy  endpoints (i e, those incl uded in the mult iple testing procedure) of 
OS, and other secondary endpoints including rate of CR, will be examined to further evaluate 
the ant i-tumor effect of durvalumab + SoC CCRT versus placebo + SoC CCRT.
The patterns of disease relapse of durvalumab + SoC CCRT compared with placebo + SoC 
CCRT will be described in terms of incidence of local progression, distant disease 
progression, and secondary  malignancy as the first documented progression eve nt.
The secondary  symptom s and overall healt h-related quali ty of life (HRQoL) endpoints will be 
assessed using the European Organisat ion for Research and Treatment of Cancer (EORTC) 
core cancer instrument (EORTC QLQ -C30) and supplemental cervical cancer mo dule 
(EORTC CX24). The EuroQol five -dimensio nal five-level quest ionnaire (EQ -5D- 5L), Patient 
Global Im pressi on of Change (PGIC), Patient Global Impressio n of Severit y (PGIS) and 
Patient-Reported Outcome versio n of the Co mmo n Termino logy Criteria f or Advers e Events 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 52(PRO -CTCAE) questionnaires will be administered as exploratory  endpoints. Health resource 
utilisat ion measures including hospi[INVESTIGATOR_3094], outpati ent visi ts, or emergency  depart ment 
visits will be recorded in eCRF. These will show the overall influ ence of the benefits and 
toxicity of the treatm ent from a pati ent’s perspect ive and will aid in understanding of the 
benefit/risk evaluation. These PRO questionnaires are well established instruments that have 
been previously included in clinical cancer st udies.
Anti-tumor activi ty will be assessed according to RECIST 1.1 guidelines in addit ion to 
progression seen on physical exam and ident ified from histopathology. The analysis o f PFS 
and OS will be based on programmat ically derived PFS and OS based on inv estigator 
assessments; PFS can also be assessed according to histopathologic confirmation o f local 
tumor progressi on. Sensi tivity analyses will also be performed using data from BICR tumor 
assessments based on RECIST 1.1 and histopathologic confirmat ion oflocal tumor 
progression.
Biological samples will be taken from all pat ients to allow for research into PK and 
immunogenicit y of durvalumab, and the relat ionship between durvalumab PK exposure and 
clinical outcomes, efficacy, AEs, and/or safet y param eters.
4.2.2 Rationale for study endpoints (other exploratory endpoints)
Biological samples will be used to explore potential bio markers in tumor, plasma, and/or 
serum , which may  influence the progressi on of  cancer (and associated clinical characterist ics) 
and/or res ponse. 
4.2.[ADDRESS_768117] of care regimen
The study  will randomize approximately  714 patients in a 1:1 ratio to the following treatment 
arms: durvalumab concurrent with and fo llowing chemotherapy  and radi otherapy  and placebo 
concurrent with or following c hemotherapy and radiotherapy . In China, recruit ment will 
continue until approximately  [ADDRESS_768118] ing of EBRT and brachyt herapy. Pelvic and paraaortic radiat ion 
therapy  (RT) can be added based on extent of disease at baseline. This regimen will be 
administered concurrently wit h cisplat in 40 mg/m2q1w for [ADDRESS_768119] atin and cisplatin in cervical 

Clinical Study Protocol - 4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 53cancer are limited and inconsistent in findings. Cisplatin and carboplatin were retrospectively 
evaluated in 247 women receiving definitive CRT for locally advanced cervical cancer. In this evaluation, cisplatin was superior, with a CR rate of 88.3% compared to 73.9% (p=0.004) (Valdivieso et al 2017 ). However, another study evaluated 51 women who received 
concurrent carboplatin with radiotherapy in comparison to a historical control of cisplatin with 
radiotherapy, and there was no appreciable difference in OS and PFS between the 2 groups; 
there was an increase in the number of cycles administered and a reduction in adverse events in the carboplatin group ( Nam et al 2013 ). An additional retrospective study of 148 women 
treated with carboplatin and concurrent radiotherapy showed that 142 (95.9%) women had a CR and only 6 (4.1%) had persistent disease. The 2-year PFS and OS rates were 75.1% and 
81.9%, respectively ( Katanyoo et al 2011 ).  To ensure appropriate balance between patients 
treated with cisplatin and carboplatin as the radiosensitizer across regions in the ongoing study, no further use of carboplatin as the radiosensitizer will be allowed in this study.
4.2.4 Rationale of administering durvalumab concurrent with CCRT
The use of concurrent durvalumab therapy with chemotherapy and/or radiotherapy is currently being studied in NSCLC  colorectal cancer 
, urothelial bladder cancer , and hepatocellular carcinoma 
([STUDY_ID_REMOVED]). As reviewed in Section 2.1.1 , there is a strong scientific rationale for 
combining CCRT with immunotherapy. 
The key aspects of the rationale are as follows: Emerging datasets in other solid tumors, most 
notably NSCLC, suggest that concurrent admin istration of PD1 or PD-L1 antagonists with 
chemotherapy substantively improves OS compared to chemotherapy alone, and this benefit 
extends to patients with low or negative PD-L1 expression. Next, preclinical evidence suggests that concurrent administration of PD-L1 with radiotherapy could have synergistic immunomodulatory effects. Additionally, the PD1 or PD-L1 antibodies have been combined with CCRT in several disease settings with acceptable safety profile. Finally, because brachytherapy is administered after concurrent platinum and EBRT, if a sequential approach was utilized, there could be a long delay b etween completion of platinum + EBRT and 
initiation of PD-L1 which could attenuate the potential therapeutic benefit.
The study’s hypothesis is that durvalumab, when administered with CCRT and as adjuvant 
therapy following CCRT, will improve PFS when compared to CCRT combined with placebo.
4.2.5 Rationale for treatment duration
After completion of SoC CCRT, administration of durvalumab/placebo will continue up to 24 cycles (total) or until RECIST 1.1-defined  PD or histopathologic confirmation of local 
tumor progression, or until another discontinuation criterion is met. The rationale for the duration of durvalumab treatment is approximately 80% of progression events occur within CCI
CCI CCI
Clinical Study Protocol - 4.[ADDRESS_768120] 24 cycles of SoC treatment ( Elit et al 2009 , Fuglsang et al 2015 , Wiebe et al 2012 ). In 
the PACIFIC study, no new safety signals were observed with durvalumab after 6 months of 
treatment. Based on these observations, no new saf ety signals are expected with 24 cycles of 
durvalumab administration. 
4.2.6 Rationale for stratification factors
Stratified randomization prevents imbalance between treatment groups for known factors that influence prognosis or treatment responsiveness. In this study, randomization will be stratified by [CONTACT_584190] (FIGO (2009) Stage <III and node positive, FIGO (2009) Stage ≥III 
and node negative, or FIGO (2009) Stage ≥III and node positive), and region ([LOCATION_002], 
Canada, European Union, South Korea, and Japa n) versus rest of world. Cervical cancer 
disease stage status and nodal status are known prognostic factors in cervical cancer ( Pecorelli 
et al. 2009 and reviewed in sections 2.2.2 and 2.2.3) Region was grouped with the intention to 
accommodate potential differences in initial imaging approach at diagnosis (including PET/CT) and use of radiation therapy. 
4.3 Justification for dose
4.3.1 Durvalumab monotherapy dose rationale
A durvalumab dose of 20 mg/kg q4w is supported by [CONTACT_255702], pre-clinical activity, 
clinical PK/pharmacodynamics, biomarkers, and activity d ata from Study 1108 in patients 
with advanced solid tumors and from a Phase I study performed in Japanese patients with 
advanced solid tumor . There were 10 patients with cervical cancer in Study 
1108, with an ORR of 20% (2/10).
PK/Pharmacodynamic data
Based on available PK/pharmacodynamic data from ongoing Study 1108 with doses ranging 
from 0.1 to 10 mg/kg q2w or 15 mg/kg every 3 weeks (q3w), durvalumab exhibited non-linear (dose-dependent) PK consistent with targe t-mediated drug disposition. The PK approached 
linearity at ≥3 mg/kg q2w, suggesting near complete target saturation (membrane-bound and 
sPD-L1), and further shows that the durvalumab dosing frequency can be adapted to a particular regimen given the linearity seen at doses higher than 3 mg/kg. The expected half-
life with doses ≥3 mg/kg q2w is approximately [ADDRESS_768121] experienced immune-complex disease follo wing exposure to durvalumab. (For further 
information on immunogenicity, please see the current durvalumab IB).
A population PK model was developed using the data from Study 1108 (doses=0.1 to 
10 mg/kg q2w or 15 mg/kg q3w; Fairman et al 2014 ). Multiple simulations indicate that a CCI
Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 55similar overall exposure is expected fo llowing both 10 mg/kg q2w and 20 mg/kg q4w 
regimens, as represented by  [CONTACT_453758](4weeks). Median C max,ss is expected to be higher with 
20mg/kg q4w (~1.5 fold) and media n C trough,ss is expected to be higher with 10 mg/kg q2w 
(~1.25 fold). Clinical act ivity with the 20 mg/kg q4w dosing regimen is ant icipated to be 
consistent with 10 mg/kg q2w with the proposed similar dose of 20 mg/kg q4w expected to 
(a)achieve complete t arget saturation in majorit y of patients; (b) account for anticipated 
variabilit y in PK, pharmacodynamics, and clinical activit y in diverse cancer populations; 
(c)maintain sufficient PK exposure in case o f antidrug antibody (ADA) impact; and 
(d)achieve P K exposure that yielded maximal ant i-tumor activit y in animal models.
Given the similar AUC and modest differences in median peak and trough levels at steady  
state, the observation that both regimens maintain complete sPD- L1 suppressio n at trough, 
and the available clinical data, the 20 mg/kg q4w and 10 mg/kg q2w regimens are expected to 
have similar efficacy and safet y profiles, supporting further development with a dose of 
20mg/kg q4w.
Clinical data
Refer to the current durvalumab IB for a com plete summary of clinical information including 
safet y, efficacy, and PK at the 20 mg/kg q4w regimen.
4.3.2 Rationale for fixed dosing
A population PK model was developed for durvalumab using monotherapy data Study 1108 
(N=292; doses= 0.1 to 10 mg/kg q2w or 15 mg/kg q 3w; so lid tumors). Population PK analysis 
indicated only  minor impact of body  weight (WT) on the PK of durvalumab (coefficient of 
≤0.5). The impact of body  weight (WT) -based (10 mg/kg q2w) and fixed dosing (750 mg 
q2w) of durvalumab was evaluated by [CONTACT_584213] 
(5th, m edian, and 95th percent iles) using the population PK model. A fixed dose of 750 mg 
was selected to approximate 10 mg/kg (based on median body  WT of ~75 kg). A total of 
[ADDRESS_768122] been reported by  [CONTACT_2312] ( Narwal  et al  2013 , Ng et al 2006, Wang 
et al 2009, Zhang et al2012). Wang and co lleagues invest igated 12 monoclonal ant ibodies 
and found that fixed and body  size-based dosing perform similarly, with fixed dosing being 
better for 7 of 12 antibodies ( Wang et al2009
). In addi tion, they  invest igated 18 therapeutic 
proteins and peptides and showed that fixed dosing performed better for 12 of 18 in terms of 
reducing the between -patient variabilit y in PK/pharm acodynamic parameters ( Zhang 
et al 2012).

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 56A fixed dosing approach is preferred by [CONTACT_72959] y due to ease of use and 
reduced dosing error s. Given expectation of similar PK exposure and variabilit y, [COMPANY_008] 
considered it feasible to switch to fixed dosing regimens. Based on average body  WT of 75 
kg, a fixed dose of 1500 mg q4w durvalumab (equivalent to 20 mg/kg q4w) is included in the 
current study .
4.[ADDRESS_768123] expected visit/contact [CONTACT_584214] .
A pat ient is considered to have completed the study  when he/she has co mpleted her last 
scheduled visit or last sch eduled procedure shown in the SoA.
Patients m ay be wi thdrawn from  the study  if the study  itself is stopped. The study  may be 
stopped if, in the judgment of [COMPANY_008], study  patients are placed at undue risk because of 
clinically significant findings.
In the event that a roll -over or safet y extensio n study  is available at the time of the final data 
cutoff (DCO) and database closure, patients currently receiving treatment with durvalumab 
may be transit ioned to such a study , and the current study  woul d reach its end. The roll -over 
or safet y extensio n study  woul d ensure treatm ent continuat ion with visit assessments per i ts 
protocol . Any  patient who would be proposed to move to such a study  woul d be given a new 
Inform ed Consent.
See Appendix A 6for guidelines for the dissemination of study  resul ts.
5. STUDY POPULATION
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known 
as protocol waivers or exemptions, is not permitted.
Each patient should meet all o f the inclusio n criteria and none of the exclusio n criteria for this 
study  in order to assi gned/rando mized to a study  intervent ion. Under no circumstances can 
there be exceptions to this rule. Patients who do not meet the entry  requi rements are screen 
failures; refer to Section 5.4.
In thi s protocol , “enrolled” p atients are defined as those who sign informed consent. 
“Rando mized” pat ients are defined as those who undergo randomizat ion and receive a 
rando mizat ion number.
For procedures for withdrawal o f incorrectly enro lled patients see Section 7.3.

Clinical Study Protocol -4.0 [COMPANY_008]
Durva lumab
CONFIDEN TIAL AND PROPRIETARY 575.1 Inclusion criteria
Patients are eligible to be included in the study  only  if all of the following inclusion criteria 
and none of the exclusio n criteria apply:
Informed consent
1. Capabilit y of giving signed informed consent, which includes co mpliance wit h the 
requi rements and restrict ions listed in the informed consent form (ICF) and in this 
protocol
2. Provisio n of signed and dated, written informed consent form prior t o any  
mandatory  study  specific procedures, sampling, and analyses
3. Provisio n of signed and dated written genet ic informed consent prior to collect ion 
of sample for genetic analysis
The ICF process is described in Appendix A 3.
Age
4. Females age ≥18 y ears at the time of screening. For patients aged <20 y ears and 
enrolled in Japan, a written informed consent should be obtained fro m the pati ent 
and her l egally acceptable representative.
Type of patient and disease characteristics
5. Histologically confirmed cervical adenocarcinoma, cervical squamous carcinoma, 
or cervi cal adenosquamous carcino ma and the fo llowing requirements: 
FIGO (2009) Stages IB2 to IIB, no de posit ive (N ≥1) -OR-FIGO (2009) Stages 
IIIA to IVA with any  N stage (N ≥0) (refer to Appendix K)
Nodal  staging may  be either surgi cal or by  [CONTACT_9661] (CT or MRI) with 
pathol ogical lymph node size defined by a short -axis diameter* of ≥10mm  
(axial plane)
No evi dence of metastatic disease (M0)
*Short -axis diameter is the longest diameter perpendicular to the long -axis diameter
6. World Heal th Organizat ion (WHO)/ECOG performance status (PS) of [ADDRESS_768124] ion as defined below:
Hem oglobin ≥9.0 g/dL
Absolute neutrophil count ≥1.5 × 109/L
Platelet coun t ≥75 × 109/L
Serum  bilirubin ≤1.5 × the upper limit of normal (ULN). This will not apply to 
patients wi th confirmed Gilbert’s syndrome, who will be allowed in 
consultation wit h their physician and [COMPANY_008].
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
≤2.5 ×ULN
Creatine clearance (Cr Cl) ≥60 m L/min calculated by  [CONTACT_72964] t-Gault equation 
(using actual body  weight) or by  [CONTACT_426055] 24 -hour urine collection
Females:
Creatinine CL = Weight (kg) × (140 -Age) × 0.85
(mL/min) 72 × serum creat inine (mg/dL)
10. Life expectancy  of at least 12 weeks
Weight
11. Body  weight >30 kg
Sex
12. Female
5.2 Exclusion criteria 
Medical conditions
1. Diagnosis of small cell (neuroendocrine) histology or mucinous adenocarcinoma 
cervical cancer
2. Intent to administer a fertilit y-sparing treatm ent regimen
3. Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15mm 
(short axis) above the L1 cephalad body , in the inguinal regio n or outside the 
planned radiation field.

Clinical Study Protocol -4.[ADDRESS_768125] a hysterectomy  as part of thei r initial cervical  cancer 
therapy
5. History  of allogeneic organ transplantation
6. Active or prior documented autoimmune or inflammatory disorders (including 
inflammatory  bowel  disease [eg, colit is or Crohn’s dise ase], diverti culitis [wi th the 
exception of diverticulosis], systemic lupus ery thematosus, Sarcoi dosis syndro me, 
or Wegener syndro me [granulo matosis with po lyangiit is, Graves’ disease, 
rheumatoi d arthri tis, hypophysit is, uveit is, etc]). The fo llowing are e xcepti ons to 
this criterion:
Patients wi th vitiligo or al opecia
Patients wi th hypothy roidism  (eg, f ollowing Hashimoto syndrome) stable on 
horm one repl acement 
Patients wi th any chronic skin condit ion that does not require systemic therapy
Patients wi thout active disease in the last 5 years may be included but only after 
consultation wit h the Study  Physician
Patients wi th celiac disease controlled by [CONTACT_33119]
7. Uncontrolled intercurrent illness, including but not limited to, ongoing or active 
infect ion, symp tomatic congest ive heart failure, uncontrolled hypertension, unstable 
angina pectoris, uncontrolled cardiac arrhyt hmia, active ILD, serious chronic GI 
condi tions associ ated wi th diarrhea, or psychiatric illness/social situat ions that 
woul d limi t com pliance with study  requi rement, substantially increase risk of 
incurring AEs or compromise the abilit y of the patient to give written informed 
consent
8. History  of another primary  malignancy  except for
Malignancy  treated wi th curative intent and with no known active disease 
≥5years before the first dose of IP and of low potent ial risk for recurrence
Adequately treated non -melanoma skin cancer or lent igo maligna wit hout 
evidence of disease
Adequately treated carcinoma in situ without evidence o f disease
9. History of active primary immunodeficiency

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 6010. Active infection including tuberculosis (clinical evaluat ion that includes clinical 
history , physical  examinat ion and radiographic findings, and tuberculosis testing in 
line with local practice), hepatitis B (known posit ive HBV HBsAg result), 
hepatitis C (HCV) , or human immunodeficiency virus (posi tive HIV 1/2 
antibodies). Patients with a past or resolved HBV infect ion (defined as the presence 
of hepati tis B core antibody  [anti -HBc] and absence of HBsAg) are eligible. 
Patients posi tive for HCV antibody  are eligible only  if polymerase chain react ion 
(PCR) is negat ive for HCV RNA.
11. Brain metastases or spi[INVESTIGATOR_53894] n. Pati ents wi th suspected brain 
metastases at screening should have an MRI (preferred) or CT each prefe rably  with 
IV contrast of the brain prior to study  entry . Brain metastases will not be recorded 
as RECIST TLs at baseline. 
12. QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms from 
1 ECG.
13. Known allergy  or hy persensi tivity to an y of the study  drugs or any  of the study  drug 
excipi[INVESTIGATOR_840]
14. Prior history  or presence of vesicovaginal, colovaginal, or rectovaginal fistula.
Prior/concomitant therapy
15. Prior chem otherapy  or radi ation therapy  for the m anagement of cervical cancer
16. Exposure to i mmune -mediated therapy  prior to the study  for any  indicat ion 
including, but not limited to, other anti CTLA- 4, ant i-PD-1, anti -PD-L1, and anti -
PD-L2 ant ibodies, or therapeutic ant icancer vaccines
17. Any concurrent chemotherapy, IP, bio logic, or hormo nal thera py for cancer 
treatm ent. Concurrent use of hormonal therapy  for non -cancer -related condit ions 
(eg, hormone replacement therapy ) is acceptable.
18. Receipt of live attenuated vaccine wit hin [ADDRESS_768126] dose of IP. 
Note: Patients, if enro lled, shoul d not receive live vaccine while receiving IP and up 
to [ADDRESS_768127] dose of IP
19. Major surgi cal procedure (as defined by  [CONTACT_24342]) within [ADDRESS_768128] dose of IP. Note: Local surgery  of isolated lesio ns for palliat ive in tent is 
acceptable.
20. Current or prior use of immunosuppressive medication within [ADDRESS_768129] dose of durvalumab. The following are exceptio ns to this criterion:

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 61Intranasal, inhaled, topi[INVESTIGATOR_8826], or local steroid injections (eg, intra 
articular inject ion)
Systemic corti costeroi ds at physio logic doses not to exceed 10 mg/day of 
prednisone or its equivalent
Steroi ds as prem edicati on for hypersensi tivity reacti ons (eg, CT scan 
prem edicat ion)
Prior/concurrent clinical study experience
21. Parti cipation in another clinical study  with an investi gational product (IP) 
administered in the last 28 days
22. Previous IP assignment in the present study
23. Concurrent enrollment in another clinical study , unless i t is an observat ional 
(non-intervent ional) clinical stu dy or during the follow -up peri od of  an 
intervent ional study
24. Prior randomizat ion or treatm ent in a previous durvalumab clinical study  regardl ess 
of treatm ent arm  assignment
Other exclusions
25. Female pat ients who are pregnant or breastfeeding or female pat ients of 
reproducti ve potenti al who are not willing to employ  effect ive birth control fro m 
screening to [ADDRESS_768130] ions, and 
requi rements
27. Genet ics research study  (opti onal): 
Exclusio n criteria for parti cipat ion in the optional (DNA) genet ics research 
component of the study  include:
Previous allogeneic bone marrow transplant
Non-leukocyte -depleted whol e blood transfusio n in [ADDRESS_768131] ion

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 625.3 Lifestyle restrictions
The fo llowing restri ctions apply while the patient is receiving IP and for the specified times 
before and after:
1. Female pat ient of child -bearing potenti al
Female pat ients of childbearing potential who are not abst inent and intend to be 
sexually  active wit h a nonsterilized male partner must use at least [ADDRESS_768132] ive method of contraception ( Table 4) from the time o f screening 
throughout the total duration o f the drug treatment and the drug washout period 
([ADDRESS_768133] dose of study  treatm ent). Non -sterilized m ale partners of 
a femal e pati ent of  childbearing potential must use a male condo m plus 
spermicide throughout this period. Cessat ion of birth con trol after this point 
shoul d be discussed wit h a responsible physician. Periodic abst inence, the 
rhythm method, and the withdrawal meth od are not acceptable methods of 
contraception. Female pat ients should refrain from breast feeding throughout 
this peri od. 
Please note, females of childbearing potential are defined as those who are not surgically 
sterile (ie, bilateral  salpi[INVESTIGATOR_1656], bila teral oophorectomy, or complete hysterectomy) or 
post-menopausal. 
Women will  be considered post -menopausal if they have been amenorrheic for 12 months 
without an al ternat ive medical cause. The following age -specific requirements apply: 
Women <[ADDRESS_768134] itution.
Women ≥[ADDRESS_768135] menses >[ADDRESS_768136] menses >1 y ear ago.
Women who are surgically sterile (ie, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy) are 
eligible. 
Highly effect ive methods of contraception, defined as one that results in a low failure rate 
(ie,less than 1% per year) when used consistent ly and correctly are described in Table 4
. Note 
that som e contracepti on m ethods are not considered highly effective (eg, m ale or female 
condom  with or wi thout spermici de; female cap, diaphragm, or sponge with or without 
spermicide; non -copper containing intrauterine device; progestogen -only oral horm onal 
contraceptive pi[INVESTIGATOR_285944] [excluding 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 63Cerazette/desogestrel which is considered highly effective]; and triphasic co mbined oral 
contraceptive pi[INVESTIGATOR_3353]).
Patients shoul d follow the l ocal prescribing information for their SoC CCRT relat ing to the 
contraception, the tim e limi ts for such precautions, and any addit ional restrict ions for agents.
Table 4 Highly effective methods of contraception (<1% failure rate)
Barrier/intrauterine methods Horm onal methods
Copper T intrauterine device
Levonorgestrel -releasing intrauterine system 
(eg, Mirena®)aImplants: Etonogestrel -releasing 
implants (eg, Implanon®or Norplant®)
Intravaginal Devices: 
Ethinylestradiol/etonogestrel -releasing 
intravaginal devices (eg, NuvaRing®) 
Injection: Medroxyproges terone 
injection (eg, Depo- Provera®)
Combined Pi[INVESTIGATOR_4382]: Normal and low dose 
combined oral contraceptive pi[INVESTIGATOR_4382]
Patch: Norelgestromin/ethinylestradiol -
releasing transdermal system (eg, Ortho 
Evra®)
Minipi[INVESTIGATOR_4382]: Progesterone based oral 
contraceptive pi[INVESTIGATOR_584156]: 
Cerazette®is currently the only highly 
effective progesterone based pi[INVESTIGATOR_584157] a hormonal method.
2. All patients: Patients should not donate blood or blood components while 
participat ing in this study  and through [ADDRESS_768137] the reason for study  withdrawal  recorded 
as “eligibilit y criteria not fulfilled” (i e, pati ent does not m eet the requi red inclusi on/exclusi on 
criteria). Thi s reason for study  withdrawal is on ly valid for screen failures (ie, not randomized 
patients). Pati ents m ay be rescreened a single t ime, but they may not be re -randomized. 
A minimal set of screen failure informat ion is required to ensure transparent reporting o f 
screen failure patients to meet the Consolidated Standards o f Reporting Trials (CONSORT) 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDEN TIAL AND PROPRIETARY 64publishing requirements and to respond to queries fro m regulatory  authori ties. Minimal 
inform ation includes demography, screen failure details, eligibilit y criteria, and any  SAE.
6. STUDY TREATMENTS
Study  treatm ent is defined as any IP(s) (including marketed product comparator and placebo) 
or medical device(s) intended to be administered to a study  parti cipant according to the study  
protocol . Study  treatm ent in this study refers to durvalum ab + SoC CCRT or placebo + SoC 
CCRT.
6.1 Treatments administered
6.1.1 Investigational products
[COMPANY_008] will supply  durvalumab (MEDI4736). Further details about the study  treatments 
are in Table 5. EBRT + brachyt herapy, cisplatin, and the saline so lution for the pl acebo will  
be supplied locally . Under certain circumstances when local sourcing is not feasible, an SoC 
treatm ent m ay be supplied centrally through [COMPANY_008]. 

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 65 (228 ) Form Doc Number: AZDoc0070547 Parent Doc Number: 
AZDoc0017426Table 5 Study treatments
Durvalumab PlaceboChemoradiotherapy (Standard of care)
EBRT + 
brachytherapy Chemotherapyf
Study treatment 
name:[CONTACT_73030] 
(MEDI4736)aSaline solution External beam 
radiotherapy and 
brachytherapyCisplatin
Dosage formulation: 500-mg vial solution 
for infusion after 
dilution, 50 mg/mLSterile solution of 
0.9% (w/v) sodium 
chloride for 
injectionAs sourced locally As sourced locally
Route of 
administration IV IV Whole pelvic or 
pelvic and para -
aortic radiation and 
brachytherapybIV
Dosing instructions: 1500 mg IV q4w Dosing to match 
durvalumabSee Appendix Gfor 
treatment details40 mg/m2q1w × [ADDRESS_768138] -
hydration with 1 -2L 
of IV fluid is 
recommended with 
IV supplementation 
of Mg. Anti -emetics 
are recommendedc, d

Clinical Study Protocol -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 66 (228 ) Form Doc Number: AZDoc0070547 Parent Doc Number: 
AZDoc0017426Table 5 Study treatments
Durvalumab PlaceboChemoradiotherapy (Standard of care)
EBRT + 
brachytherapy Chemotherapyf
Packaging and 
labelingStudy treatment will 
be provided in 
500-mg vials. Each 
vial will be labeled 
in accordance with 
Good 
Manufacturing 
Practice (GMP) 
Annex 13 and per 
country regulatory 
requirement.aSourced locally by 
[CONTACT_584215]/a Sourced locally by 
[CONTACT_584216] (MEDI4736) will show the product name [INVESTIGATOR_17174] “MEDI4736” or “durvalumab (MEDI4736)” depending u pon the agreed 
product name [CONTACT_73031]. All naming conventions are correct during this transi tional period. 
bPelvic and paraaortic radiotherapy is added based on extent of disease at baseline.
cStandard antiemetic regimens consist of a steroid and 5HT -antago nist, with or without a substance P antagonist such as aprepi[INVESTIGATOR_053].
dAn additional 6th w eek of platinum agent will be administered per investigator discretion
eUnder certain circumstances when local sourcing is not feasible, an SoC treatment may be supplied centrally through AstraZene ca.
Abbreviations: EBRT External beam radiotherapy; Gy Gre y unit; IV Intravenous; n/a Not applicable; qxw Every x weeks; SoC Standard of care; w/v 
Weight/volume.
fFor patients who were treated with carboplatin prior to Protocol Version 3, please see Section [IP_ADDRESS].2

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY [IP_ADDRESS] Durvalumab (MEDI4736)
Durvalumab (MEDI4736) will be supplied by [CONTACT_62653] a 500 -mg vial so lution for 
infusio n after dilut ion. The so lution contains 50 mg /mL durvalumab (MEDI4736), 26 mM 
histidine/hist idine hydrochloride, 275 mM trehalose dihydrate, and 0.02% w/v polysorbate 80; 
it has a pH of 6.0. The nominal fill volume is 10.0 mL. IP vials are stored at 2°C to 8°C (36°F 
to 46°F) and must not be frozen. D rug product should be kept in secondary  packaging unt il 
use to prevent excessive light exposure.
Preparation of durvalumab (MEDI4736) doses for administration with an IV bag
The dose of durvalumab (MEDI4736) for administration must be prepared by [CONTACT_24338]’s or site’s designated IP manager using aseptic technique. Total time fro m needle 
puncture of the durvalumab (MEDI4736) vial to the start of administration should not exceed:
 24 hours at 2°C to 8°C (36°F to 46°F)
 4hours at room temperature
A dose of 1500 mg (for patients >30 kg in weight) will be administered using an IV bag 
containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab (MEDI4736) 
concentration ranging fro m 1 to 15 m g/mL, and delivered through an IV administration set 
with a 0.2 -or 0.22 -μm in-line filter. Add 30.0 mL of durvalumab (MEDI4736) (ie, 1500 mg 
of durvalumab [MEDI4736]) to the IV bag. The IV bag size should be selected such that the 
final concentration is within 1 to 15 mg/mL. Mix the bag by [CONTACT_584217] y of the dose in the bag. The IV bag should be covered with an opaque or 
transparent coloured sleeve (e.g. amber) after preparation by [CONTACT_584218] m aintain double -blind co nditions.
If weight falls to ≤30 kg, weight -based dosing at 20 mg/kg will be administered using an IV 
bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab (MEDI4736) 
concentration ranging fro m 1to 15 m g/mL, and delivered through an IV administration set 
with a 0.[ADDRESS_768139] infusio n time is 1 hour (± 5min). In the event that there are interruptions during 
infusio n, the total allowed infusion t ime should not exceed [ADDRESS_768140] be 
prepared fro m new vials. Durvalumab (MEDI4736) does not contain preservatives, and any  
unused porti on m ust be discarded. 
Order of administration
After rando misat ion to receive durvalumab/placebo + SoC CCRT, patients will receive 
durvalumab/placebo via IV infusio n over 1 hour (± 5min) . It is recommended that a [ADDRESS_768141] ace after durvalumab/placebo is administered, at least for Cy cle 1. 
If no issues are observed fo llowing durvalumab/placebo administration during the first cy cle, 
reducti on of  the observat ion peri od to [ADDRESS_768142] igator’s 
discreti on.
Durvalumab/Placebo administration will be fo llowed by  [CONTACT_584219] [IP_ADDRESS] , with radiat ion therapy given on the same day. If there is not 
enough time to administer cisplat in it must be administered wi thin 1 calendar day  of the 
durvalumab infusio n. This will allow for flexibilit y in t imely administration of the treatment 
regim en, as radi ation therapy  and durvalumab/placebo can be given on C1D1, and cisplat in 
given on C1D2 and similarly for subsequent cy cles
Cisplat in  should only be given on a day that external -beam radiat ion is scheduled. Radiat ion 
therapy  can occur before or after durvalumab and the plat inum agent are administered and 
shoul d be given on the same day  if possible. Treatment should preferably  be given on a 
Monday , Tuesday  or Wednesday . Cisplat in should not be given on a day o f brachyt herapy 
treatm ent. 
All pati ents shoul d be planned to receive [ADDRESS_768143] atinum chemotherapy can be 
administered per investigator discret ion.
[IP_ADDRESS] Standard of care
The SoC chemotherapy  agent for CCRT will either be locally sourced or centrally supplied by 
[CONTACT_584220]. Under certain circumstances when local 
sourcing is no t feasible, [COMPANY_008] will centrally supply  the drug, and i t will be labeled with 
local language translated text in accordance with regulatory  guidelines.
[IP_ADDRESS].1 Cisplatin
If a patient develops a toxicit y related to cisplatin, the SOC TMGs (Appendix J) shoul d be 
followed. Pati ents are not permitted to switch between cisplat in and carboplatin. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY [IP_ADDRESS].[ADDRESS_768144] atin AUC2 was given for init ial treatment or if 
cisplatin was intolerable. Subjects recruited t o the study  under thi s regimen may cont inue 
unchanged, as clinically  indicated. Carboplatin is to be given A UC 2 q1w × [ADDRESS_768145] such as aprepi[INVESTIGATOR_053]. 
[IP_ADDRESS] Placebo 
Placebo will  be sourced l ocally . The placebo should be prepared such that the volume matches 
that expected for a durvalumab infusio n, thi s requires the addit ion of 30ml o f a sterile so lution 
of 0.9%(w/v) sodi um chloride for inject ion to the IV bag containi ng 0.9% (w/v) saline or 5% 
(w/v) dextrose The vo lume of saline so lution added will be 30.0 mL or same vo lume as 
durvalumab if weight falls to ≤30 kg. The IV bag should be covered with an opaque or 
transparent coloured sleeve (e.g. amber) after preparation by [CONTACT_584218] m aintain double -blind condit ions. Infusio n time is 1 
hour (± 5min) and shoul d be delivered through an IV administration set with a 0.2- or 0.22 -μm 
in-line filt er.
6.1.2 Dose and treatmen t regimens
Table 6shows the dosing regimen for the study . 
Table 6 Treatment regimen
WeekBaseline
C1aC2aC3aC4aC5 to PDa,b
0 q4w ±3 days unless dosing needs to be held for toxicity reasons
Day 1 q28d ±3 days unless dosing needs to be held for toxicity reasons
Durvalumab/placebobX X X X X
SoC cisplatin 40 mg/m2q1w × 5 weeksc(± 1 
day except cycle 1)
SoC EBRTd,eAppendix G
SoC brachytherapy Appendix G
aThese cycles refer to the 28 -day cycles of administration of durvalumab/placebo.
bDuring the combination portion of treatment, durvalumab will be administered first. If there is not enough time to 
administer cisplatin afterward on that day, it must be administered within 1 calendar day of the durvalumab infusion.
cAn additional 6th week of platinum agent will be administered per investigator discretion
dChemotherapy, radiotherapy an d brachytherapy should ideally be completed within 56 days and up to 59 days. 
eRadiotherapy should start on C1D1 following Durvalumab/placebo infusion on the same day. Refer to footnote b of this 
table. .
Abbreviations: C Cycle; CR Complete response; EBR T External Beam Radiotherapy; Gy Gray unit; PD Progression of 
disease; PR Partial response; qxw Every x weeks; q28d Every 28 days; SD Stable disease; SoC Standard of care.

Clinical Study Proto col -4.[ADDRESS_768146] 1.1 -defined PD. This fo llow-up scan is evaluated using the criteria outlined 
in Appendix F. Pati ents will not be permitted to cont inue rando mized therapy if progressio n 
occurs after response (CR or PR as defined by  [CONTACT_393] 1.1) in the target lesio ns (regardless o f 
the appearance of new lesio ns) (ie, the response and progression events both occurred in the 
target lesio ns while receiving randomized therapy  during the sam e treatm ent peri od). Pati ents 
may not continue on durvalumab/placebo if there is histopathological determination o f 
progression. 
Patients wi th rapid tum or progressi on or wi th symptom atic progression that requires urgent 
medical intervention (eg, central nervous system metastasis, respi[INVESTIGATOR_584158], or spi[INVESTIGATOR_53894] n) will not be eligible for continuing IP.
For all patients who are treated through progression, the Invest igator should ensur e pat ients do 
not have any significant, unacceptable, or irreversible toxicit ies that indicate continuing.
Crossover within the study  will not be permi tted.
For all patients who are treated through progression, the Invest igator should ensure that:
 The pati ent does not have any significant, unacceptable, or irreversible toxicit ies 
that indicate continuing treatment will not further benefit the patient. The patient 
may not have experienced a toxicit y that required permanent discont inuat ion of 
study  treatm ent.
 There i s absence of clinical symptoms or signs indicat ing clinically significant 
disease progressi on acco mpanied by a decline in WHO/ECOG PS to >1.
 There i s absence of rapid disease progression or threat to vital organs or crit ical 
anatomical sites (eg, c entral nervous system metastasis, respi[INVESTIGATOR_584159], or spi[INVESTIGATOR_53894] n) requi ring urgent alternat ive 
medical intervention.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 72 The patient still fulfills the eligibilit y criteria for this study  (see Sect ion 5.1and 
5.2), with the exception o f inclusio n criteria [ADDRESS_768147] 1.1 -defined PD 
plus an addi tional follow-up scan or until death (whichever comes first) and followed for 
survival. Alternat ively, PD may be determined by [CONTACT_584221] o f tumor 
progression on biopsy .
Post final data cut off 
Patients who con tinue to receive benefit fro m their assi gned treatm ent at the final DCO and 
database closure may  cont inue to receive their assign ed treatment for as long as they  and thei r 
physician considers they  are gaining clinical benefit (total of 24 cycles). For patients 
continuing to receive durvalumab treatment fo llowing the final DCO and database closure, it 
is reco mmended that the patients conti nue the schedul ed site visi ts and Investi gators m onitor 
the pati ents’ safet y laboratory  resul ts pri or to and peri odically  during treatm ent wi th 
durvalumab in order to manage AEs in accordance with the durvalumab Dosing Modificat ion 
and Toxicit y Manag ement Gui delines (see Section 8.4.5). 
In the event that a roll -over or safet y extensio n study  is available at the time of the final DCO 
and databa se closure, pati ents currently receiving treatment with durvalumab may be 
transi tioned to such a study , and the current study  woul d reach i ts end. The roll -
over or safet y 
extensio n study  woul d ensure treatm ent continuat ion with visit assessments per its pr otocol . 
Any pat ient who would be proposed to move to such a study  woul d be given a new Informed 
Consent.
6.1.4 Storage
The Investigator, or an approved representative (eg, pharmacist), will ensure that all IP is 
stored in a secured area, in refrigerated temperat ures (2°C to 8°C) and in accordance wit h 
applicable regulatory  requi rements. A tem perature l og will be used to record the temperature 
of the storage area. Temperature excursions outside the permissible range listed in the clinical 
supply packaging are to b e reported to the study  monitor upon detecti on. A calibrated 
temperature m onitoring device will  be used to record the temperature condit ions in the drug 
storage facilit y. Storage condi tions stated i n the IB may  be superseded by [CONTACT_4671]. 
The IP l abel on the pack/bottle/carton for SoC specifies the appropriate storage for these 
agents.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 736.2 Measures to minimize bias: randomization and blinding
6.2.[ADDRESS_768148] enroll ment and randomization
Patients will  be randomized in a 1:1 ratio to durvalumab + SoC CCRT or plac ebo + SoC 
CCRT. Rando mizat ion will be stratified by  [CONTACT_584190] (FIGO (2009) Stage <III and 
node posit ive, FIGO (2009) Stage ≥III and node negative, or FIGO (2009) Stage ≥III and node 
positive), and region [[LOCATION_002], Canada, European Unio n, South Korea, and Japan] versus 
rest of the world.
All patients will be centrally assigned to randomized study  treatm ent using an interactive web 
response system (/IWRS). Before the study  is init iated, the telephone number and/or the log -in 
inform ation and d irections for the IWRS will be provided to each site. 
If a patient withdraws fro m the study , then her enrollment/randomization code cannot be 
reused. Withdrawn pat ients will not be replaced.
Invest igators should keep a record (ie, the patient screening lo g) of  patients who entered 
screening. 
At screening/baseline (Days -28 to -1), the Invest igators or suitably trained delegate will:
 Obtain signed informed consent before any study  specific procedures are 
perform ed. If laboratory  or imaging procedures were performed for alternate 
reasons prior to signing consent, these can be used for screening purposes with 
consent of the patient. However, all screening laboratory  and imaging results must 
have been obtained within 28 days of rando mizat ion. For patients with a single TL, 
if biopsy ≤3months old is co llected (in place of an archived sample) prior to 
screening imaging for baseline tumor assessment, allow approximately 2 weeks 
before imaging scans are acquired.
 Obtain a unique 7 -digit enrollment number (E -code),through the IWRS in the 
following form at (ECCNNXXX: CC being the country  code, NN being the center 
number, and XXX being the patient enro llment code at the center). This number is 
the pati ent’s unique ident ifier and is used to identify the patient on the electroni c 
case report forms (eCRFs).
 Determine patient eligibilit y (see Sect ions 5.1and 5.2)
 Obtain signed informed consent for genetic research study  (opti onal)
At randomizat ion, once the patient is confirmed to be eligible, the Invest igator or suitably 
trained delegate will:

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 74 Obtain a unique randomizat ion number via the IWRS. Numbers will start at 001 and 
will be assigned strictly sequent ially by [CONTACT_584222]. The system  will randomize the eligible patient to 1 of the 2 treatment 
arms.
 Obtain tumor sa mple and send for centralized PD -L1 testing.
If the patient is ineligible and not randomized, the IWRS should be contact[CONTACT_584223].
Treatment should start no more than [ADDRESS_768149] ensure all decisio ns are appropriately 
docum ented and that the poten tial benefi t:risk profile rem ains posi tive for the patient.
6.2.3 Methods for assigning treatm ent arm s
The actual  treatm ent given to patients will be determined by [CONTACT_584224]/IWRS. The rando mizat ion scheme will be produced by  a com puter softw are program 
that incorporates a standard procedure for generating rando mizat ion numbers. 
One randomizat ion list will be produced for each of the randomization strata. A blocked 
rando mizat ion will be generated, and all centers will use the same list in orde r to minimize 
any imba lance in the number of patients assigned to each treatment arm.
Patients will  be ident ified to the IWRS per country regulat ions. Rando mizat ion codes will be 
assigned strict ly sequent ially, within each stratum , as pati ents become eligi ble for 
rando mizat ion. The IWRS will provide the kit identification number to be allocated to the 
patient at the randomization visit and subsequent treatment visits.

Clinical Study Proto col -4.[ADDRESS_768150] igators will remain blinded to each patient’s 
assigned study  treatm ent throughout the cours e of the study . To m aintain this blind, an 
otherwi se uninvo lved 3rd party  will be unblinded and responsible for the reconstitution and 
dispensat ion of all study  treatm ent and will endeavour to ensure that there are no differences 
in time taken to dispense following rando mizat ion.
In the event that the treatment allocat ion for a pati ent becom es known to the Investigator or 
other study  staff invo lved in the management of study  patients, or needs to be known to treat 
an individual pat ient for an AE, the Sponso r must be notified prompt ly by [CONTACT_584225], before unblinding.
The IWRS will be programmed with blind -breaking instructions. The blind may be broken if, 
in the opi[INVESTIGATOR_3078] n of the Invest igator, it is in the pat ient’s best interest for the I nvest igator to know 
the study  treatm ent assignment. The Sponsor must be notified before the blind is broken 
unless identificat ion of the study  treatm ent is required for a medical emergency  in which the 
knowl edge of the specific blinded study  treatm ent will affect the immediate management of 
the pati ent’s condit ion (eg, antidote available). In this case, the Sponsor must be notified 
within [ADDRESS_768151] 
be recorded in the source document ation and CRF (el ectroni c or paper), as applicable. Study  
unblinding should not occur until database lock and all decisio ns on the evaluabilit y of the 
data from  each individual pat ient have been made and documented.
6.3 Treatment compliance
The administration of all IPs shoul d be recorded in the appropriate sections of the eCRF.
Any change fro m the dosing schedule, dose delays/interruptions, and dose discontinuations 
shoul d be recorded in eCRF. Dose reductions are not allowed.
The IP Storage Manager is responsi ble for managing the IP from  receipt by  [CONTACT_584226].
6.[ADDRESS_768152] dose of study  treatm ent. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 76Any medicat ion or vaccine including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements that the patient is r eceiving at the time o f enrollment or receives 
during the study  must be recorded along wit h:
 Reason for use
 Dates of administration including start and end dates
 Dosage information including dose, unit, and frequency
Patients m ust be instructed not to take any medicatio ns, including over -the-counter products, 
without fi rst consul ting wi th the Invest igator.
Restricted, prohibited, and permitted concomitant medicat ions are described in the fo llowing 
tables. Refer also to the Dosing Modificat ion and Toxicit y Management Guidelines (see 
Secti on8.4.5 ). For SoC agents, please refer to the local prescribing informat ion with regards 
to warnings, precautions, and contraindicat ions.
General Concomitant Medication and Supportive Care Guidelines for Radiotherapy
Patients shoul d receive full supportive care, including transfusio ns of blood and blood 
products, supplemental iron, ant ibiotics, ant i-emet ics, etc., when appropri ate at the discret ion 
of the treati ng physician. Because it has been observed that hemoglobin levels below 10 -12 
g/dL during radiotherapy  are associ ated wi th decreased local control, blood transfusio ns 
shoul d be offered to and used to treat patien ts at the di scret ion of treating physicians prior to 
or during radiotherapy . There shoul d be no radi otherapy  treatm ent del ays due to a l ow 
hemoglo bin levels. Tri als evaluat ing epoeit in alpha (Procrit, Epogen) and radio -chemotherapy 
in cervical cancer have indicated that epoeit in alpha may be associated with an increased risk 
for thromboembo lism, and thus, may not be used in this study . 
In parti cular, pati ents shoul d be tol d of the ty pi[INVESTIGATOR_584160]. At the first sign that 
their stools becom e softer than usual or they  have any increase in stool frequency  over what is 
norm al for them , they  shoul d begin taking over -the-counter loperamide as directed by [CONTACT_153155](s). Patients should understand that if they do not start taking loperamide at t he start 
of diarrhea, the diarrhea may  becom e severe and last several days. Persistent diarrhea or any  
evidence of hematochezia should prompt a stool evaluat ion for fecal leukocy tes and/or 
Clostridium  difficile toxin & ova/parasite evaluat ion. Diphenoxylat e/ atropi[INVESTIGATOR_584161]. Loperamide will be recommended during the study  in order to prevent diarrhea 
that may  ultimately  lead to intravenous infusio n of fluids or hospi[INVESTIGATOR_602]. Diarrhea that is 
suspected to be associated with durvaluma b shoul d be treated according to the Toxicit y 
Management Guidelines .

Clinical Study Proto col -4.[ADDRESS_768153] any questi ons about taking l operamide, if they 
believe they  are not achieving adequate control of diarrhea, or if they  are f eeling extrem ely 
weak, lightheaded, or dizzy (symptoms of dehydration). Side effects of loperamide include 
tiredness, drowsiness, or dizziness. If they  experience these side effects, they  shoul d avoi d 
driving a motorized vehicle or operating machinery. Before using any l axative, patients should 
consult their physician. Patients should make an extra effort to drink lots of fluids (several 
glasses of water, fruit juices, soda, soup, etc.) every  day while they  parti cipate in thi s study
Table 7 Prohibi ted concomitant medications
Prohibited medication/class of drug: Usage:
Any investigational anticancer therapy other 
than those under investigation in this studyShould not be given concomitantly while the patient 
is on study treatment
mAbs against CTLA -4, PD -1, or PD -L1 
other than those under investigation in this 
studyShould not be given concomitantly while the patient 
is on study treatment
Any concurrent chemotherapy, radiotherapy, 
immunotherapy, or biologic or hormonal 
therapy for cancer treatm ent other than those 
under investigation in this studyShould not be given concomitantly while the patient 
is on study treatment. (Concurrent use of hormones 
for non -cancer -related conditions [eg, insulin for 
diabetes and hormone replacement therapy] is 
acceptable. Local treatment of isolated lesions, 
excluding TLs, for palliative intent is acceptable 
[eg,by [CONTACT_72971]])
Live attenuated vaccines Should not be given through [ADDRESS_768154] 
immune -modulating effectsShould not be given concomitantly unless agreed by 
[CONTACT_584227] -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 78Prohibited medication/class of drug: Usage:
Immunosuppressive medications including, 
but not limited to, systemic corticosteroids at 
doses exceeding 10 mg/day of prednisone or 
equivalent, methotr exate, azathioprine, and 
tumor necrosis factor -α blockersShould not be given concomitantly or used for 
premedication prior to the I -O infusions. The 
following are allowed exceptions:
Use of immunosuppressive medications for 
the management of IP -related AE s, 
short -term premedication for patients 
receiving cisplatin is permitted 
Use in patients with contrast allergies. 
In addition, use of inhaled, topi[INVESTIGATOR_2855], and 
intranasal corticosteroids is permitted.
A temporary period of steroids will be allowed if 
clinically indicated and considered to be essential 
for the management of non -immunotherapy related 
events experienced by [CONTACT_102] (eg, chronic 
obstructive pulmonary disease, radiation, nausea, 
etc).
EGFR TKIs Should not be given concomitantly. 
Shoul d be used with caution in the [ADDRESS_768155] 
dose of durvalumab. 
Increased incidences of pneumonitis (with third 
generation EGFR TKIs) and increased incidence of 
transaminase increases (with 1stgeneration EGFR 
TKIs) has been reported when durvalumab h as been 
given concomitantly.
Abbreviations: CTLA -4 Cy totoxic T lymphocyte associated protein 4; IP Investigational product; PD -1 Programmed 
cell death protein 1; PD-L1 Programmed death ligand 1 .
Table 8 Supportive medications
Supportive medication/class of drug: Usage:
Concomitant medications or treatments 
(eg,acetaminophen or diphenhydramine) 
deemed necessary to provide adequate 
prophylactic or supportive care, except for 
those medications identified as “prohibited,” 
as listed above To be administered as prescribed by [CONTACT_72973] (including antibiotics, 
nutritional support, correction of metabolic 
disor ders, optimal symptom control, and pain 
management [including palliative 
radiotherapy to non -target lesions, etc])Should be used, when necess ary, for all patients

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 79Inactivated viruses, such as those in the 
influenza vaccinePermitted
6.4.1 Other concomitant treatment
Other medication other than that described above, which is considered necessary  for the 
patient’s safet y and wellbeing, may be given a t the discret ion of the Invest igator and recorded 
in the appropriate sections of the eCRF.
6.4.[ADDRESS_768156] s. As a resul t, there are no 
expected pharmacokinet ic drug -drug interactions. The mechanism o f action of durvalumab 
involves binding to PD -L1 and, therefore, significant pharmacodynamic drug interactions wit h 
the commo nly admin istered concomitant medications are not expected. Despi[INVESTIGATOR_6831],
appropriate clinical mo nitoring in all o f the planned clinical studies will be conducted to 
evaluate any potential drug -drug interactions.
6.4.3 Rescue medication
As a result of immune -mediated adverse events (imAEs) that could potentially be experienced 
by [CONTACT_584228], steroids and other immunosuppressant rescue medicat ion has to be 
made available to this pat ient populat ion. The 2 products that fall into the category  of 
immunosuppress ants are infliximab (eg, for colit is) and mycopheno late (eg, for hepatit is). 
[COMPANY_008] supply chain will be responsible for sourcing these [ADDRESS_768157]. If required for use as a result of 
an imAE, then the IWRS will provide to the unblinded pharmacists the kit ident ification 
number to be allocated to the patient at the time. Blinde d and unblinded access and 
notifications will be controlled using the IWRS.
6.5 Dose modification
Dose delays are permitted for immuno -oncol ogy (IO) therapy  (see Dosing Modificat ion and 
Toxicit y Management Guidelines). However, dose reduction is not permitted .For Standard 
of care, pl ease refer to secti on [IP_ADDRESS]

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 806.6 Treatment after the end of the study
After the final analysis, [COMPANY_008] will cont inue to supply  open -label study  medicat ion to 
patients who had not completed 24 doses of study  therapy up to the time that they  discont inue 
the treatment for whatever reason (see Section 6.1.2).
7. DISCONTINUATION OF T REATMENT AND SUBJECT
WITHDRAWAL 
7.1 Discontinuation of study treatment 
An individual pat ient will not receive any further IP (durvalumab + SoC CCRT or placebo + 
SoC CCRT) if any  of the fo llowing occur in the patient in quest ion:
Withdrawal o f consent fro m further treatment with IP. The patient is, at any  time, free to 
discontinue treatm ent, wi thout prej udice to further treatment. A patient who discont inues 
treatm ent is norm ally expected to continu e to participate in the study  (eg, for safet y and 
survival fo llow-up) unless they  specifically wit hdraw their consent to all further participat ion 
in any study  procedures and assessments (see Section 7.3). 
 An AE that, in the opi[INVESTIGATOR_1649] o f the Invest igator or [COMPANY_008], contraindicates 
further dosing
 Any AE that meets criteria for discontinuation as defined in the Dosing 
Modificat ion and Toxi city Mana gement Gui delines (see Section 8.4.5 ) or as defined 
in the local prescribing informat ion for the SoC agent 
 Pregnancy or intent to beco me pregnant
 Non-compliance wi th the study  protocol  that, in the opi[INVESTIGATOR_72910], warrants withdrawal fro m treatm ent wi th IP (eg, refusal to adhere to 
scheduled visits)
 Initiation of  alternative anticancer therapy  including another invest igational agent
 Clinical progression or RECIST 1.1 -defined radio logical progressi on (refer to 
Appendix F) and Investi gator determinat ion that the patien t is no l onger benefi ting 
from treatment wi th IP
 Histopathol ogical determinat ion of tumor progressio n on biopsy
 Com pletion of planned therapy  (24 cy cles)

Clinical Study Proto col -4.[ADDRESS_768158] the patient’s participation 
in the study . A pat ient who decides to discont inue IP will always be asked about the reason(s) 
for discont inuat ion and the presence of any AE. The patient should continue attending 
subsequent study  visits, and da ta collect ion should continue according to the study  protocol . If 
the pati ent does not agree to continue in -person study  visits, a m odified fo llow-up m ust be 
arranged to ensure the collection o f endpo ints and safet y informat ion. This fo llow-up coul d be 
a telephone contact [CONTACT_10970], a contact [CONTACT_4490] a relat ive or treating physician, or 
inform ation from medical records. The approach taken should be recorded in the medical 
records. A patient that agrees to modified fo llow-up is not considered to have wit hdrawn 
consent or to have withdrawn fro m the study .
Patients who are perm anent ly discont inued from further receipt of IP, regardless of the reason, 
will be ident ified as having permanent ly discontinued treatment. Patients who are permanent ly 
discontinued w ill enter fo llow-up (see the SoAs).
Patients who perm anent ly discont inue drug for reasons other than progression (per RECIST 
1.[ADDRESS_768159] igator tumor assessments or histopathologic confirmat ion of local 
tumor progressi on) shoul d continue to ha ve RECIST scans and physical exam including 
pelvic examinat ion performed q20w ±1w after randomizat ion and continue q12w±1w through 
164weeks and then q24w±2w thereafter until progressio n (per RECIST 1.[ADDRESS_768160] opathol ogic confirmat ion of local tumor progression) 
plus an addi tional follow-up scan or death (whichever comes first) as defined in the SoAs.
If a patient is discont inued for progression, then the patient should have 1 additional fo llow-up 
scan performed preferably at the next (and no later than the next) scheduled imaging visit, and 
no less than [ADDRESS_768161] has been established by [CONTACT_72977] (see Section 4.4), such that there is insufficient informati on to 
determine the patient’s status at that time. Patients who refuse to continue participat ion in the 
study , including tel ephone contact, should be documented as “wit hdrawal o f consent” rather 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 82than “lost to follow -up”. Invest igators should document attem pts to re -establish contact [CONTACT_570435]. If  contact [CONTACT_29881] a missing pat ient is 
re-established, the patient should not be considered lost to follow -up and evaluat ions should 
resum e according to the protocol.
In order to support key end points of PFS and OS analyses, the survival status of all pat ients in 
the full analysis and the safet y analysis sets should be re -checked, this includes those patients 
who wi thdrew consent or are classified as “lo st to follow -up.”
Lost to f ollow -up - site personnel shoul d check hospi[INVESTIGATOR_1097], the patient’s current 
physician, and a publicly  available death regi stry (if available) to obtain a current survival 
status. (The applicable eCRF modules will be updated.)
In the event that the patie nt has actively wit hdrawn consent to the processing o f their personal  
data, the survival status of the patient can be obtained by  [CONTACT_584229] (if available) where it is possible to do so under applicable local la ws 
to obtain a current survival status. (The applicable eCRF modules will be updated.)
7.3 Withdrawal from the study
Patients are free to withdraw from the study  at any time (IP and assessments) without 
prejudice to further treatment.
Patients who wi thdraw con sent f or further parti cipati on in the study  will not receive any  
further IP or further study  observat ion, wi th the excepti on of  follow-up for survival, which 
will cont inue unt il the end of the study unless the patient has expressly wit hdrawn their 
consent to survival fo llow-up. Note that the patient may  be offered addit ional tests or tapering 
of treatm ent to wi thdraw safely.
A pat ient who wi thdraws consent will always be asked about the reason(s) for withdrawal and 
the presence o f any AE. The Invest igator w ill follow-up AEs outside of the clinical study . 
If a patient withdraws consent, they  will be specifically asked if they are withdrawing consent 
to:
All further parti cipat ion in the study including any further fo llow-up (eg, survival contact 
[CONTACT_21646])
Withdrawal to the use of any samples (see Sect ion Appendix C 2)
8. STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing are summarized in the SoA. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 83The Investigator will ensure that data are recorded on the eCRFs. The Web Based Data 
Capture (WBDC) system will be used for data collection and query handling.
The Investigator ensures the accur acy, com pleteness, l egibili ty, and timeliness of the data 
recorded and of the provisio n of answers to data queries according to the Clinical Study  
Agreement. The Investigator will sign the completed eCRFs. A copy  of the com pleted eCRFs 
will be archived at the study  site.
Immediate safet y concerns should be discussed wit h the Sponsor immediately upon 
occurrence or awareness to determine if the patient should continue or discontinue study 
treatm ent.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential pat ients 
meet all eligibilit y criteria. The Invest igator will maintain a screening log to record details o f 
all patients screened and to confirm eligibilit y or record reasons for screening failure, as 
applicable. 
Procedures conducted as part of the patient’s routine clinical management (eg, blood coun t 
and imaging assessments) and obtained before signing of t he ICF may be utilized for 
screening or baseline purposes, provided the procedures met the protocol -specified criteria 
and were performed within the t ime frame defined in the SoA.
The m aximum  amount of  blood collected from  each patient over the duration of the study , 
including any  extra assessments that may be required, will be described in the Laboratory  
Manual. Repeat or unscheduled samples may be taken for safet y reasons or for technical 
issues wit h the samples.
8.[ADDRESS_768162] 1.1 as assessed by 
[CONTACT_584230]. 
Efficacy assessments of ORR, CR rate will be derived (by [CONTACT_38227]) using RECIST 1.[ADDRESS_768163] 164 weeks (about 3 years) after randomization, 
q12w (starting at W20) assessments will include interval hi story  for new signs or symptoms, a 

Clinical Study Proto col -4.[ADDRESS_768164] (preferred) or MRI, each preferably with IV 
contrast, of the chest, abdomen, and pelvis co llected during screening/baseline and at regular 
(follow-up) intervals during study  treatm ent. Any other areas of disease involvement should 
be addit ionally imaged based on the signs and symptoms of individual pat ients. It i s important 
to fo llow the tum or assessment schedule as closely as possible (refer to the SoAs). If an 
unscheduled assessment is performed (eg, to investigate clinical signs/symptoms of 
progression) and the patient has not progressed, every  attem pt shoul d be m ade to resum e the 
subsequent assessments fo llowing the ori ginal  imaging visi t schedule (rel ative to the date of 
rando mizat ion). Treatment continues unt il completion of planned therapy , clinical progression 
or RECIST 1.1-defined radio logical progressi on (refer to Appendix F) or histopathol ogic 
progression on biopsy  unless there i s unacceptable toxicit y, withdrawal  of consent, or another 
discontinuat ion criterion is m et. Scanning cont inues throughout treatment until RECIST 1.[ADDRESS_768165] ive cervical 
cancer on histopath ology , the pati ent will not be reported as a PD and will continue with all 
study  procedures according to the Schedule of Assessments ( Table 1).
8.1.[ADDRESS_768166] with the pati ent or the pati ent’s 
family, or by  [CONTACT_584231]’s current physician. The details of first and subsequent 
therapi [INVESTIGATOR_72911], after discontinuation o f study  treatm ent, will  be collected.
In addit ion, pati ents on treatm ent or in survival fo llow-up will be contact[CONTACT_584232]. These contacts should generally occur within 7 days o f the DCO.
8.1.3 Patient -reported Outcomes (PROs)
PROs allow for an understanding o f treatm ent effect from  the pati ents’ perspect ive. In this 
study , PROs will be used to capture the patient experience of symptoms, funct ioning and 
HRQoL and will aid in understanding of the benefit/risk evaluation. The fo llowing PRO 
instrum ents will  be administered in this study : EORTC core qualit y of life quest ionnaire 
(EORTC QLQ -C30 v3) and supplemental cervical cancer module (EORTC QLQ -CX24, 
Patient-Reported Outcomes -Commo n Termino logy Criteria for Adverse Events 
(PRO -CTCAE ), Pati ent Gl obal Impressi on of Change (PGIC), Patient Global Impressio n of 
Severit y (PGIS) and EuroQol five -dimensio nal five -level quest ionnaire (EQ -5D- 5L) (see 
Appendix H). PROs will be administered according to the SoAs.
[IP_ADDRESS] EORTC QLQ -C30 and QLQ -CX24
The EORTC QLQ -C30 was developed by [CONTACT_584233] y of Life Group in 1993. It 
consists of 30 items and measures symptoms, functioning, and global healt hstatus/qualit y of 
life (QoL) ( Aaronson et al 1993 ) for all cancer ty pes. Items are grouped into 5 functional 
scales (physical, role, cognit ive, emoti onal, and soci al), 3 symptom  scales (fat igue, pain, and 
nausea and vo miting), 5 individual items (dyspnea, inso mnia, appetite loss, const ipation, and 
diarrhea), and a 2 -item global measure of healt h status/QoL (see Appendix H). 
The EORTC QLQ -CX24 i s a 24 -item com plementary  module to the QLQ -C30, desi gned 
specifically for use in cervical cancer. Items are grouped into three mult i-item scales 
(symptom experi ence, body  image, and sexual/vaginal funct ioning) and six single -item scales 
(lymphedema, peripheral neuropathy , menopausal  symptoms, sexual act ivity, sexual  worry , 
and sexual enjo yment) ( Greimel et al 2006 ). 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY [IP_ADDRESS] PRO -CTCAE
The PRO -CTCAE is included to address tolerabilit y from the pati ents’ perspect ive. It was 
developed by [CONTACT_584234]. The PRO -CTCAE will only  be administered in 
those countries where a linguist ically validated version exists. It was developed in recognit ion 
that collect ing treatment -related symptom data directly fro m patients using PRO tool s can 
improve the accuracy  and efficiency of symptomatic AE data collect ion. Th is was based on 
findings fro m mult iple studies demo nstrating that physicians and nurses underest imate 
treatm ent-related symptom onset, frequency, and severit y in co mpar ison with pat ient ratings 
(Basch et al 2009 , Litwin et al  1998 , Sprangers and A aronson 1992). These treatm ent-related 
symptoms have been converted to patient -friendly  term s (e.g., the Commo n Termino logy 
Criteria for Adverse Event [CTCAE] term “myalgia” has been converted to “aching 
muscles”). Items capture the presence, frequency, severit y and/o r interference with usual 
activit ies, depending upon the AE. The items included in the PRO- CTCAE have undergone 
extensive qualitat ive review among experts and patients. Not all items are administered in any 
clinical study . In this study , only i tems that ar e considered relevant for the study, site of 
cancer, and cancer treatment are selected (see Appendix H). 
[IP_ADDRESS] PGIC
The Pati ent Gl obal Impressi on of Chan ge (PGIC) is a single item included to assess how a 
patient perceives her overall change in healt h status since the start of study  treatm ent. Pati ents 
choose from amo ng seven response options ranging fro m “much better” to “much worse” (see 
Appendix H).
[IP_ADDRESS] PGIS
The Pati ent Gl obal Impressi on of Severi ty (PGIS) is a single item to assess how a patient 
perceives her overall severit y of symptom s at the time o f assessment. Pati ents choose from 
among five response options ranging from “no symptoms” to “very  severe” (see Appendix H).
[IP_ADDRESS] EuroQol five -dimensiona l five -level questionnaire (EQ -5D- 5L) and visual 
analogue scale (VAS)
The EQ -5D- 5L (Appendix H) is a standardized measure of healt h status developed by [CONTACT_584235] a simple, generic measure of healt h for clinical and economic 
apprai sal (EuroQol  Group 1990 ). Applicable to a wide ra nge of health condit ions and 
treatm ents, i t provi des a simple, descriptive profile and a single index value for health status 
that can be used in the clinical and econo mic evaluation of healt h care as well as in populat ion 
healt h surveys. The quest ionnaire assesses 5 dimensions: mobilit y, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depressi on. Each dimensio n has 5 response options (no 
probl ems, slight problems, moderate problems, severe problems, and extreme problems) that 
reflect increasing l evels o f difficult y (EuroQol  Group 2013 ).

Clinical Study Proto col -4.[ADDRESS_768167] imaginable health state ( Appendix H).
[IP_ADDRESS] Administration of patient reported outcome questionnaires
Patients will  perform the PRO assessments using an electronic tablet (ePRO) during clinic 
visits.
Each site must allocate the responsibilit y for the administrati on of  the PRO instruments to a 
specific individual (eg, a research nurse or study  coordinator) and, if possible, assign a back 
up person to cover if that individual is absent. The PRO questionnaires must be administe red 
and co mpleted at the clinic as per the SoAs. If technical or other issues prohibit co mpletion on 
the device, an appropriate back -up opti on may  be consi dered wi th prior approval  from 
[COMPANY_008].
It is important that the site staff explains the value and relevance of hearing direct ly from 
patients how they  feel. The fo llowing best practice guidelines should be fo llowed:
The PRO questionnaires must be administered and completed at the clinic prior to treatment 
administration performed at the site and idea lly before any  discussi ons of  heal th status to 
avoid biasing the participant’s responses to the questions. As feasible, site staff should also 
ensure PRO questionnaires are co mpleted prior to other study  procedures, such as co llection 
of laboratory  samples and before discussio n of disease progression to avoid biasing the 
patient’s responses to the questions. 
 It is permitted for the baseline ePROs to be completed prior to C1D1 as long as first 
of dose of Durvalumab and CCRT is given wit hin 3 day s of ePRO c ompletion
 PRO questionnaires must be completed in private by [CONTACT_102].
 Patients shoul d be given sufficient time to complete the PRO questionnaires at their 
own speed.
 The research nurse or appointed site staff should stress that the information is 
confident ial and will  not be shared wi th the si te staff. Therefore, if the part icipant 
has any medical problems, he/she should discuss them with the doctor or research 
nurse separately fro m the ePRO assessment.
 The research nurse or appointed site staff mu st train the patient on how to use the 
ePRO device using the materials and training provided in the ePRO device.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 88 The research nurse or appointed site staff must remind patients that there are no 
right or wrong answers, and the research nurse or appointed s ite staff should avo id 
clarifying i tems to avoi d introducing bias. 
 Patients m ust not receive help from relat ives, friends, or clinic staff deciding on 
answers to the PRO questionnaires. The responses are the participant’s alo ne.  Site 
staff must not read or com plete the PRO questi onnai res on behalf of the patient. If 
the pati ent is unable to read the questionnaire (eg, is blind, illiterate or unable to 
read in the available language), that patient should be exempted fro m completing 
PRO questionnaires but m ay st ill participate in the study. Patients exempted in this 
regard should be flagged appropriately  by [CONTACT_584236].
A key  aspect of study  success i s to have high PRO compliance. Therefore, it is essent ial to 
follow the S oAs, and that sites make sure the device is charged and fully functional at all 
times in order to minimize missing data.
8.1.4 Health care resource use
Health care resource use will be captured including inpatient admissio ns, ICU, and length of 
stay in hospi[INVESTIGATOR_584162]. The module is for all non -study  protocol -related 
hospi [INVESTIGATOR_140754]; any  routi ne hospi [INVESTIGATOR_584163] -related requi rements do not 
need to be captured.
The assessment of healt h care resource use will increase the unders tanding regarding the 
relationship between treatment and tumour related cancer symptoms on resource use, such as 
the need for palliat ive procedures to address obstruction and bleeding. This will be captured 
and analysed to inform submissio ns to pay ers. 
[IP_ADDRESS] Administration of health care resource assessment
The site should co mplete the HOSPAD eCRF every t ime a patient is hospi[INVESTIGATOR_584164]. If the patient discont inues 
study  treatm ent for reas ons other than RECIST progressio n, the “HOSPAD” eCRF should 
continue to be captured until progressio n has been confirmed. Study  mandated visits should 
not be included as a hospi[INVESTIGATOR_4073] n.
8.2 Safety assessments 
Planned timepo ints for all  safety  assessments are provided in the SoA.
8.2.1 Physical examinations
Physical examinat ions will be performed according to the assessment schedules (see the 
SoAs). Full physical examinat ions will include assessments of the head, ey es, ears, nose, and 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 89throat and the r espi[INVESTIGATOR_696] , cardi ovascular, GI, urogenital, musculoskeletal, neurological, 
derm atological, hematol ogic/lymphat ic, and endocrine systems. Height will be measured at 
screening only. Targeted phy sical examinat ions are to be utilized by [CONTACT_584237]. Situations in which physical examinat ion 
resul ts shoul d be reported as AEs are described in Section 8.3.7 . 
8.2.2 Vital signs
Vital signs (blood pressure [BP], pulse, temperature, and respi[INVESTIGATOR_41351]) will be evaluated 
according to the SoAs. Body  weight is also recorded at each visit along with vital signs. 
First infusion
On the first infusio n day , pati ents will  be monitored and vital signs co llected/recorded in 
eCRF pri or to, during, and after infusio n of IP as presented in the bulleted list below. 
BP and pulse will be collected from pat ients before, during, and after eac h infusio n at the 
following t imes (based on a 60 -minute infusio n):
 Prior to the beginning of the infusion (measured once from approximately 
30minutes before up to 0 minutes [ie, the beginning of the infusio n])
 Approximately  30minutes during the infusio n (halfway  through infusio n) 
 At the end of the infusio n (approximately 1 hour ±5 minutes)
If the infusio n takes l onger than [ADDRESS_768168] infusio n of study  treatm ent. 
Subsequent infusions
BP, pul se, and other vital signs should be measured, collected/recorded in eCRF prior to the 
start of the infusio n. Pati ents shoul d be care fully moni tored and BP and other vital signs 
shoul d be measured during and post infusio n as per inst itution standard and as clinically 
indicated. Any clinically significant changes in vit al signs shoul d be entered onto an 
unscheduled vital signs eCRF page.
Patients receiving SoC will be mo nitored pre -dose and as clinically indicated with every 
infusio n or administration.
Situations in which vital signs results should be reported as AEs are described in 
Secti on8.3.[ADDRESS_768169] ing 12 -lead ECG will be recorded at screening and as clinically indica ted throughout the 
study  (see the SoAs). ECGs should be obtained after the patient has been in a supi[INVESTIGATOR_158147] 5minutes and recorded while the patient remains in that posit ion.
At screening Mean QT interval corrected for heart rate using Fridericia' s formula (QTcF) 
shoul d be recorded. For subsequent visit s in case of clinically significant ECG abnormalit ies, 
including a QTcF value >470 ms, 2 addit ional 12 -lead ECGs should be obtained over a brief 
period (eg, 30 minutes) to confirm the finding. 
Situations in which ECG results should be reported as AEs are described in Sect ion8.3.7 .
8.2.4 Clinical safety laboratory assessments
Blood and urine samples for determinat ion of clinical chemistry , hematol ogy, and urinalysis 
will be taken at the times indicated in the assessment schedules and as clinically indicated (see 
the SoAs). 
Clinical laboratory  safet y tests, including serum pregnancy  tests, will  be performed in a 
licensed clinical laboratory  according to l ocal standard procedures. Sample tubes and sample 
sizes may  vary depending on the laboratory  method used and routine practice at the site. 
Pregnancy tests may be performed at the site using a licensed test (urine or serum pregnancy 
test). Abnormal clinically significant laboratory  resul ts shoul d be repeated as soon as possible 
(preferably within 24 to 48 hours).
Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the
Invest igator. The date, time of co llection, and results (values, units, and reference ranges) will 
be recorded on the appropriate eCRF.
The l aboratory  variables to be measured are presented in Table 9(clinical chemistry ), Table 
10(hematology ), and Table 11(urinalysis).

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 91Other safet y tests to be performed at screening include assessment for HBV surface ant igen, 
HCV ant ibodies, and HIV ant ibodies.
HPV status will be recorded at screen ing, if available.
The fo llowing laboratory  variables will be measured:
Table 9 Clinical chemistry
Albumin Lipaseb
Alkaline phosphataseaMagnesiumc
ALTaPotassium
AmylasebSodium
ASTaTotal bilirubina
BicarbonatecTotal protein
Calcium TSHe
ChloridecT3freef (reflex)
CreatininedT4freef (reflex)
Gamma glutamyltransferasecUrea or blood urea nitrogen, depending on local practice
Glucose
Lactate dehydrogenase
aTests for ALT, AST, alkaline phosphatase, and total bilirubin must be conducted and assessed concurrently. 
If total bilirubin is ≥2 × upper limit of normal (and no evidence of Gilbert’s syndrome), then fractionate into 
direct and indirect bilirubin.
bIt is preferable that both amylase and lipase parameters are assessed. For sites where only 1 of these 
parameters is routinely measured, either lipase or amylase is acceptable.
cBicarbonate (w here available), chloride, creatinine clearance, gamma glutamyltransferase, magnesium, 
testing are to be performed at s creening, on Day 1 (unless all screening laboratory clinical chemistry 
assessments are performed within 3 days prior to Day 1), and if clinically indicated.
dCreatinine clearance will be calculated using Cockcroft -Gault (using actual body weight). 
eIf TSH is measured within 14 days prior to Day 1 (first infusion day), it does not need to be repeated at Day 
1.
fFree T 3or free T 4will only be measured if TSH is abnormal or if there is a clinical suspi[INVESTIGATOR_72912].
Abbrevi ations: AE Adverse event; ALT Alanine aminotransferase; AST Aspartate aminotransferase; T 3
Triiodothyronine; T 4Thyroxine; TSH Thyroid -stimulating hormone.
Table 10 Hematology
Absolute neutrophil countaAbsolute lymphocyte counta
Hemoglobin Platelet count
Total white cell count
Note: For coagulation parameters, activated partial thromboplastin time and international normalized ratio are to 
be assessed at baseline on Day 1 (unless all screening laborator y hematology assessments are performed 
within 3 days prior to Day 1), and as clinically indicated.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 92aCan be recorded as absolute counts or as percentages. Absolute counts will be calculated by [CONTACT_72987]. Total white cell count therefore has to be pro vided.
Table 11 Urinalysis
Bilirubin Ketones
Blood pH
Color and appearance Protein
Glucose Specific gravity
Note: Urinalysis should be done at baseline (screening) and then as clinically indicated.
Note: Microscopy should be used as appropriate to investigate white blood cells and use the high power field for 
red and white blood cells. 
If a patient shows an AST or ALT ≥3×ULN together with total bilirubin ≥2×ULN, refer to 
Appendix Efor further instructi ons on cases of increases in liver biochemistry  and evaluat ion 
of Hy’s Law. Cases where a participant shows elevations in liver biochemistry may require 
further evaluat ion and occurrences of AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN 
may need to be reported as SAEs. Please refer to Appendix E for further instruction on cases 
of increases in liver biochemistry  and evaluat ion of Hy’s Law
All patients should have further chemistry  profiles performed at 30 days (±3 days), 2 m onths 
(±1week), and 3 months (±1 week) after permanent discont inuat ion of study  treatm ent (see 
the SoAs).
Any clinically  significant abnormal laboratory  values shoul d be repeated as clinically  
indicated and recorded on the eCRF. Situations in which laboratory  safet y resul ts shoul d be 
reported as AEs are described in Sect ion 8.3.[ADDRESS_768170] returned to Grade 1 
or 2, unless these values are not likely to impro ve because of the underlying disease.
8.2.5 WHO/ECOG performance status
WHO/ECOG PS will be assessed at the times specified in the assessment schedules (see the 
SoAs) based on the following:
0. Fully  active; able to carry  out all  usual  activities wit hout restrict ions
1. Restricted in strenuous activit y, but ambulatory  and able to carry  out light work or 
work of a sedentary  nature (eg, light housework or office work)
2. Ambulatory  and capable o f self-care, but unable to carry  out any  work activit ies; up 
and about more than 50% of waking hours.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 933. Capable of only limited self -care; confined to bed or chair more than 50% of 
waking hours
4. Com pletely disabled; unable to carry  out any  self-care and totally  confined to bed or 
chair
5. Dead 
Any significant change from baseline or screen ing must be reported as an AE.
8.2.[ADDRESS_768171] 3 cy cles of 
durvalumab (Cy cle 1 Day  14 [±24 hours], Cycle 2 Day  14 [±24 hours], and Cy cle 3 Day  14 
[±24 hours]) t o ensure early  identificat ion and management of toxicit ies. 
8.2.7 Other safety assessments
If new or worsening pulmo nary symptom s (eg, dyspnea) or radio logical abnorm ality 
suggest ive of pneumo nitis/ILD are observed, toxicit y management as described in detail in the 
Dosing Modificat ion and Toxi city Management Gui delines (see Sect ion 8.4.5 ) will be applied. 
The results of the full diagnostic workup (includin g high-resolution computed tomography 
[HRCT], bl ood and sputum culture, hematological parameters, etc) will be captured in the 
eCRF. It i s strongly reco mmended to perform a full diagnost ic workup, to exclude alternat ive 
causes such as lymphangit ic carcino matosi s, infectio n, allergy , cardi ogenic edema, or 
pulmo nary hemorrhage. In the presence of confirmatory  HRCT scans where other causes of 
respi [INVESTIGATOR_584165], a diagnosis of pneumonit is (ILD) shoul d be 
considered and the Dosing Modificat ion and Toxi city Management Gui delines shoul d be 
followed.
Pneumonitis investigation
The fo llowing assessments, and addit ional assessments if required, will be performed to 
enhance the invest igation and di agnosis of potenti al cases of pneum onitis. The resul ts of the 
assessment will be co llected.
Physical examinat ion
Signs and symptom s (cough, shortness of breath, and py rexia, etc) including 
auscultat ion for lung field will be assessed.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 94Saturati on of  peripheral  oxygen 
Other items
When pneumo nitis (ILD) is suspected during study treatment, the fo llowing 
markers should be measured where possible:
(i) ILD Markers (KL -6, SP -D) and β -D-glucan
(ii) Tumor markers: Particular tumor markers, which are related to 
disease progressi on. 
(iii) Addit ional Clinical chemistry : C-react ive protein (CRP), lactate 
dehydrogenase (LDH)
8.[ADDRESS_768172] ion
The definit ions of an AE or SAE can b e found in Appendix B.
AE will be reported by  [CONTACT_25034] (or, when appropri ate, by  a caregiver, surrogate, or the 
patient's l egally authori zed rep resentative).
The Investigator and any designees are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE or SAE. For informat ion on how to fo llow up AEs, 
seeSecti on 8.3.3 .
8.3.1 Method of detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the patient is the preferred method to inquire about 
AEoccurrences.
8.3.2 Time period and frequency for collecting adverse event and serious 
adverse event information 
AEs and SAEs will be co llected fro m the time of the pat ient signing the informed consent 
form until the fo llow-up peri od is com pleted ([ADDRESS_768173] dose of study  treatm ent). If 
an event that starts post the defined safet y follow-up peri od noted above i s consi dered to be 
due to a l ate onset toxicit y to study  treatm ent, then it should be repor ted as an AE or SAE as 
applicable.

Clinical Study Proto col -4.[ADDRESS_768174] igator learns of any SAE, including a death, at any time after a patient’s last visit 
and he/she considers the event to be reasonably related to the Study treatment or study  
participat ion, the Invest igator should notify the Sponsor.
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the 
procedures for complet ing and transmitting SAE reports are provided in Appendix B.
8.3.3 Follow- up of adverse events and serious adverse even ts
After the init ial AE/SAE report, the Invest igator is required to proactively fo llow each pat ient 
at subsequent visits/contacts. All AEs and SAEs will be followed unt il resolut ion, 
stabilization, the event is otherwise explained, or the pat ient is lost to foll ow-up.
Any AEs that are unresolved at the patient’s last AE assessment or other assessment in the 
study  are f ollowed up by [CONTACT_24342] f or as l ong as m edically  indicated (this m ay be 
beyo nd the [ADDRESS_768175] dose of study  treatm ent), but without further recording in the 
eCRF. [COMPANY_008] retains the right to request addit ional inform ation for any  patient with 
ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
8.3.4 Adverse event data collection
The fo llowing variables will be collected for each AE:
 AE (verbat im)
 The date when the AE started and stopped
 The m aximum  comm on terminol ogy criteria for adverse events (CTCAE) grade 
reported
 Changes in CTCAE grade (report only the maximum CTCAE grade for a calendar 
day)
 Whether the AE is serious or not
 Invest igator causalit y rating against the IPs (yes or no)
 Action taken with regard to IPs
 Administrati on of  treatm ent for the AE

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 96 Outcom e
 In addit ion, the fo llowing vari ables will be collected for SAEs:
 Date the AE met criteria for SAE
 Date the Invest igator became aware of the SAE
 Seriousness criteria 
 Date of hospi[INVESTIGATOR_059]
 Date of discharge
 Probable cause of death
 Date of death
 Whether an autopsy  was perform ed
 Causalit y assessment in relat ion to study  procedure(s)
 Causalit y assessment in relat ion to other medicat ion, as explained in Section 8.3.5
 Descript ion of the SAE
The grading scales found in the revised National Cancer Inst itute (NCI) CTCAE version 5 
will be ut ilized for all events with an assigned CTCAE grading. For those events without 
assigned CTCAE grades, the recom mendat ion in the CTCAE criteria that converts mild, 
moderate, and severe events into CTCAE grades should be used. A copy  of the CTCAE 
versio n 5 can be downloaded fro m the Cancer Therapy  Evaluat ion Program websi te 
(http://ctep.cancer.gov). 
8.3.5 Causality collection
The Investigator will assess causal relat ionship between IP and each AE, and answer “yes” or 
“no” to the question “Do y ou consider that there is a reasonable possibilit y that the event m ay 
have been caused by [CONTACT_33249]?”
For SAEs, causal relat ionship will also be assessed for other medicat ion and study  procedures. 
Note that for SAEs that could be associated with any  study  procedure the causal relationship is 
implied as “yes.”
A guide to the interpretation of the causalit y quest ion is found in Appendix Bto the Clinical 
Study  Protocol .

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 978.3.6 Adverse events based on signs and symptoms
All AEs spontaneously reported by  [CONTACT_72992]: “Have y ou had any  health probl ems since the previous visit/y ou were 
last asked?” or revealed by  [CONTACT_584238]. When 
collect ing AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the dia gnosis and each sign or symptom will be 
recorded separately.
8.3.7 Adverse events based on examinations and tests
The results from the Clinical Study  Protocol  (CSP) mandated l aboratory  tests and vi tal signs 
will be summarized in the clinical study  report (CSR) . Deteri oration as com pared to baseline 
in protocol -mandated laboratory  values and vi tal signs shoul d therefore only  be reported as 
AEs if they  fulfill any  of the SAE cri teria or are th e reason for discont inuat ion of study  
treatm ent.
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE, and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting Invest igator 
uses the clinical, rather than the laboratory  term  (eg, anemia versus low hemoglobin value). In 
the absence of clinical signs or symptoms, clinically relevant deteriorations in non -mandated 
param eters shoul d be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless unequivocally 
related to the disease under study , see Secti ons 8.3.9 and 8.3.10 .
8.3.8 Hy’s law
Cases where a patient shows elevat ions in liver bio chemistry  may require further evaluat ion 
and occurrences o f AST or ALT ≥3×ULN together with total bilirubin ≥2×ULN may  need 
to be report ed as SAEs. Please refer to Appendix Efor further instructi on on cases of 
increases in liver biochemistry  and evaluat ion of Hy’s Law.
8.3.9 Disease progr ession
Disease progressi on can be considered as a worsening of a patient’s condit ion attributable to 
the disease for which the IP is being studied. It may be an increase in the severit y of the 
disease under study  and/or increases in the symptoms of the dis ease. The development of new 

Clinical Study Proto col -4.[ADDRESS_768176] been ident ified 
after the pati ent’s inclusio n in this study .
8.3.[ADDRESS_768177] be reported as 
follows:
 Death cl early  resul ting fro m disease progression should be reported to the Study  
Moni tor/Phy sician at the next monitoring visit and should be documented in the 
eCRF in the Statement of Death page. It should not be reported as an SAE.
 Where death is not due (or not clearly  due) to progressio n of the disease unde r 
study , the AE causing the death must be reported to the Study  Moni tor/Phy sician as 
an SAE wi thin 24 hours. It should also be documented in the Statement of Death 
page in the eCRF. The report should contain a comment regarding the co 
involvement of PD, if appropri ate, and shoul d assign main and contributory  causes 
of death.
 Deaths with an unknown cause should always be reported as an SAE. It should also 
be docum ented in the Statement of Death page in the eCRF. A postmortem may be 
helpful in the assessment of the cause of death, and if performed, a copy  of the 
post-mortem results should be forwarded to [COMPANY_008] Pat ient Safet y or its 
representative wit hin the usual time frames.
Deaths occurring after the protocol defined safet y follow -up peri od after the a dministrati on of  
the last dose of study  treatm ent shoul d be documented in the Statement of Death page. If the 
death occurred as a result of an event that started post the defined safet y follow-up peri od and 
theevent is considered to be due to a late onset toxicit y to study drug then i t shoul d also be 
reported as an SAE.
8.3.[ADDRESS_768178] specific to the further understanding of 
durvalumab safet y profile and require close mo nitoring and rapid co mmunicat ion by [CONTACT_584239]. An AESI can be serious or non -serious. All AES Is will be 
recorded in the eCRF. Serious AESIs will be recorded and reported as per Section 8.4.1

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 99AESIs for durvalumab include but are not limited to events with a potential inflammatory  or 
immune -mediated mechanism and which may require more frequent monitoring and/or 
intervent ions such as steroids, immunosuppressants, and/or hormone replacement thera py. 
These AESIs are being clo sely monitored in clinical  studi es wi th durvalumab monotherapy  
and co mbinat ion therapy . An imAE is defined as an AESI that is associated with drug 
exposure and is consistent with an immune -mediated m echanism of act ion and where there is 
no cl ear al ternate eti ology. 
If the Investigator has any quest ions in regards to an event being an imAE, the Invest igator 
shoul d prom ptly contact [CONTACT_33139].
AESI/imAEs observed wit h ant i PD-L/PD -1 agents such as durvalumab include:
 Diarrhea/coli tis and intestinal perforation
 Pneumo nitis/ILD
 Endocrinopathies (ie, events of hypophysit is/hypopi[INVESTIGATOR_297], adrenal insufficiency, 
hyper -and hypo -thyroidism  and type I di abetes m ellitus)
 Hepati tis/transaminase increases
 Nephrit is/blood creatin ine increases
 Pancreat itis/serum  lipase and amylase increases
 Rash/dermat itis(including pemphigo id)
 Myocardi tis
 Myositis/polymyosit is
 Immune thrombocy topeni a 
 Rare/l ess frequent imAEs including neuromuscular toxicit ies such as myasthenia 
gravis and Guillai n-Barré syndrome 
 Other inflammatory  responses that are rare or less frequent with a potential 
immune -mediated etio logy include, but are not limited to, pericardit is, sarco idosis, 
uveit is, and other events invo lving the eye, skin, hematological, and 
rheuma tological events.
In addit ion, infusio n-related reacti ons and hypersensit ivity/anaphylact ic react ions wit h a 
different underlying pharmaco logical etiology are also considered AESIs.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 100Further informat ion on these risks (eg, present ing symptoms) can be found in the current 
versio n of the durvalumab IB. More specific guidelines for their evaluat ion and treatment are 
described in detail in the Dose Modificat ion and Toxi city Management Gui delines (see 
Secti on 8.4.5 ). These guidelines have been prepared by  [CONTACT_584240]. These guidelines 
apply to AEs consi dered causally related to the study  drug/study  regimen by [CONTACT_584241].
8.3.13 Safety data to be collected following the final Data Cutoff of the study
For pati ents continuing to receive durvalumab treatment after final DCO and database closure, 
it is recommended that the patients continue the scheduled site visits and Investigators monitor 
the pati ent’s safet y laboratory  resul ts pri or to and peri odically  during treatm ent wi th 
durvalumab in order to manage AEs in accordance with the durvalumab Dose M odificat ion 
and Toxicit y Management Guidelines (see Section 8.4.5). All data post the final DCO and 
database closure will be recorded in the patien t notes but, with the exception of SAEs, will not 
otherwi se be reported for the purposes of this study .
All SAEs that occur in patients still receiving durvalumab treatment (or within the [ADDRESS_768179] dose of durvalumab treatment) post the fi nal DCO and database closure 
must be reported as detailed in Sect ion 8.4.[ADDRESS_768180] to be reported, whether or not considered causally related to the IP, or to the 
study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , then Invest igators or other site personnel inform 
the appropriate [COMPANY_008] representatives within 1 day  (ie, immediately but no later than 
24hours of when he or she beco mes aware of it).
The designated [COMPANY_008] representative works with the Invest igator to ensure that all the 
necessary  informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site 
within 
1calendar day of initial receipt for fatal and life -threatening events and within [ADDRESS_768181] igators or other site personnel inform [COMPANY_008] 
representatives of any  follow-up inform ation on a previously reported SAE within 1 calendar 
day (ie, immediately but no later than 24 hours of when he or she beco mes aware of it).

Clinical Study Proto col -4.[ADDRESS_768182] igators or other site personnel indicate an AE is serious in the electronic data 
capture system, an automated email alert is sent to the designated [COMPANY_008] representative.
If the electronic data capture sy stem  is not available, then the Investigator or other study  site 
staff reports an SAE to the appropriate AstraZ eneca representative by  [CONTACT_756].
The [COMPANY_008] representative will advise the Investigator/study  site staff how to proceed. 
For further guidance on the definit ion of an SAE, see Appendix Bof the Clinical Study  
Protocol .
8.4.[ADDRESS_768183] igator should inform the Sponsor within 24 hours of 
learning of the pregnancy.
Abnorm al pregnancy outcom es (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
[IP_ADDRESS] Maternal exposure
If a patient becomes pregnant during the course of the study , IP shoul d be discont inued 
immediately .
Pregnancy itself is not regarded as an AE unless there is a suspi[INVESTIGATOR_24510] n that the IP under study  
may have interfered with the effect iveness of a contraceptive medicat ion. Congenital 
abnorm alities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout complicat ions should not be handled as AEs. The outcome 
of all pregnancies (spontaneous m iscarri age, elect ive terminat ion, ectopic pregnancy, normal 
birth, or congenital abnormalit y) shoul d be f ollowed up and docum ented even if the pat ient 
was discont inued from the study.
If any pregnancy  occurs in the course of the study , then the Invest igato r or other site personnel 
informs the appropriate [COMPANY_008] representatives within 1 day (ie, immediately but no 
later than 24 hours of when he or she becom es aware of i t).
The designated [COMPANY_008] representative works with the Invest igator to ensure t hat all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site wi thin 1 or 5 
calendar day s for SAEs (see Secti on 8.4.1 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 102Patients who are perm anent ly discont inued from further receipt of IP, regardless of the reason, 
will be ident ified as having permanent ly discontin ued treatment and will enter fo llow-up (see 
the SoAs).
8.4.3 Overdose
[IP_ADDRESS] Durvalumab 
Use of durvalumab in doses in excess o f that specified in the protocol is considered to be an 
overdose. There is current ly no specific treatment in the event of overdose of durvalumab, and 
possible symptoms of overdose are not established. 
 An overdose wit h associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
 An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an [COMPANY_008] study  drug occurs in the course of the study , then the 
Invest igator or other site personnel will inform appropriate [COMPANY_008] representatives 
immediately , or no later than [ADDRESS_768184] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site.
 For overdoses associated with an SAE, the standard reporting timelines apply, see 
Section 8.3.[ADDRESS_768185] occur within 30 days.
[IP_ADDRESS] Standard of Care
Please refer to the local prescribing informat ion for treat ment of cases of overdose if any 
overdose is associated with an AE or SAE please record the AE/SAE diagnosis or symptoms 
in the relevant AE modules only o f the eCRF.
8.4.[ADDRESS_768186] igator or other si te 
personnel informs the appropriate [COMPANY_008] representatives within 1 day (ie, immediately 
but no l ater than 24 hours of when he or she becomes aware of it).
The designated [COMPANY_008] representative works with the Invest igator to ensure that all 
relevant informat ion is completed wi thin 1 (init ial fatal/life-threatening or fo llow-up fatal/life-
threatening) or 5 (other serious init ial and fo llow-up) calendar days if there is an SAE 
associ ated wi th the m edicat ion error (see Section 8.3.2 ) and within 30 days for all other 
medicat ion errors.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 103The definit ion of a medicat ion error can be found in Appendix B.
8.4.5 Management of durvalumab -related toxicities 
The fo llowing general guidance should be fo llowed for m anagement of toxi cities.
 Treat each of the toxicit ies with maximum supportiv e care (including ho lding the 
agent suspected of causing the toxicit y if required).
 If the symptoms promptly resolve with supportive care, considerat ion should be 
given to continuing the same dose of the assigned IP along wit h appropriate 
continuing suppor tive care. If medically  appropri ate, dose m odificat ions are 
permitted 
 All dose modificat ions should be documented with clear reasoning and 
docum entati on of  the approach taken.
All toxicit ies will be graded according to NCI CTCAE, versio n 5. 
[IP_ADDRESS] Specific toxicity management and dose modification information -durvalumab 
Com prehensive toxi city management guidelines (TMG) have been developed to assist 
investigators with the recognit ion and management of toxicit ies associ ated wi th the use of the 
immune -check point inhibitor durvalumab. These guidelines are applicable when durvalumab 
is used alo ne or in combinat ion and is administered concurrently or sequentially wit h other 
anti-cancer drugs (i .e. antineoplast ic chemotherapy, targeted agents), as part of a prot ocol 
specific treatment regimen. Guidelines for the management of immune -mediated reactions, 
infusio n-related reacti ons, and non -immune -mediated reactions for durvalumab are provided 
in the Dosing Modificat ion and Toxi city Management Gui delines. The most c urrent version of 
these guidelines is also maintained wit hin the Site Master File. 
Patients shoul d be thoroughly  eval uated and appropri ate efforts should be made to rule out 
neopl astic, infecti ous, m etabo lic, toxin, or other etiologic causes of the imAE. Serologic, 
immuno logic, and histologic (biopsy) data, as appropriate, should be used to support an imAE 
diagnosis. In the absence of a clear alternative etio logy, events shoul d be considered 
potenti ally immune related.
In addit ion, there are certain circum stances in which durvalumab should be permanent ly 
discontinued (see Sect ion 7.1of this protocol  and the Dosing Modificat ion and Toxicit y 
Managemen t Gui delines).
Following the first dose of IP, subsequent administration of durvalumab can be modified 
based on toxicit ies observed as described in the Dosing Modificat ion and Toxicit y 
Management Guidelines. These guidelines have been prepared by [CONTACT_584242] -4.[ADDRESS_768187] igator should consult with the 
Study  Physician.
[IP_ADDRESS] Specific toxicity management and dose modification information -
chemoradiotherapy
Invest igators should fo llow toxici ty management gui delines for chemotherapy  and radi ation 
therapy (Appendix J). All effort should be taken to fo llow the gui delines to ensure optimal and 
timely  medical  care for the pati ents. If the gui delines are not able to be followed, just ification 
shoul d be clearly docum ented in the el ectroni c database. For specifi c informat ion regarding 
the individual agents used in this study , please refer to the local prescribing informat ion for 
the relevant agent.
Every  effort shoul d be made to continue a patient on CCRT definit ive SoC therapy . In the 
case of clinically  signifi cant toxici ty possibly  due to SoC or durval umab, durvalumab dosing 
can be delayed one cycle. For further informat ion on durvalumab toxicit y management and 
dose m odificat ion see sect ion [IP_ADDRESS] and the Sponsor study  physician may  also be contact[INVESTIGATOR_530] . 
8.[ADDRESS_768188] pa rty on behalf o f [COMPANY_008]. Samples will be collected, labeled, stored, 
and shipped as detailed in the Laboratory  Manual. Full details o f the analy tical method used 
will be described in a separate Bioanalyt ical Validation Report.
[IP_ADDRESS] Collection of samples to measure for the presence of antidrug antibodies
The presence of ADA will be assessed in serum samples taken according to the SoAs. 
Samples will  be measured for the presence of ADAs and ADA -neutralizing ant ibodies for 
durvalumab using validated assays. Ti ered analysis will be performed to include screening, 

Clinical Study Protocol - 4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 105confirmatory, and titer assay components, and positive negative cut points previously 
statistically determined from drug-naïve v alidation samples will be employed
8.5.2 Storage and destruction of pharmacokinetic/antidrug antibody samples
Durvalumab PK and ADA samples will be destroyed within [ADDRESS_768189] samples. The results from the evaluation will not be reported in the CSR but 
separately in a Bioanalytical Validation Report.
Any residual back-up PK samples may be used fo r future exploratory biomarker research (in 
this case, residual back-up PK samples will be shipped to [COMPANY_008]-assigned Biobank; see 
details in the Laboratory Manual).For China: PK and ADA samples collected in China will be stored and disposed according to 
local laws and regulations. PK and ADA samples collected in China will be destroyed after 
finalization of bioanalytical report or completion of CSR
8.[ADDRESS_768190] pati ent’s l ast visi t (LPLV), after 
which they  will be destroyed. DNA is a finite resource that m ay be used up during analyses. 
The results of any  further analyses will be reported either in the CSR itself or as an addendum, 
or separately  in a scient ific report or publicat ion.
No personal details identifying the individual will be available to AstraZe neca or designated 
organi zations working wit h the DNA.
8.8 Biomarkers
By [CONTACT_584243]. 
8.8.1 Tumour samples:
[IP_ADDRESS] Tumor sample collection:
Several tum our bi opsy  samples are requested for this study  as described below:
MANDATORY: A newly acquired sample is preferred if available per site’s routine clinical 
practi ce; otherwise, archival sample ≤3 m onths ol d prior to screening can be provided. 
Samples shou ld be collected via a core needle (18 gauge or larger) or be collected as an 
excisio nal or incisio nal tumor biopsy  sample. 
Please refer to the Laboratory  Manual for specific instructions and guidelines regarding tumor 
sample collect ion.
OPTIONAL: The co llection of an addit ional biopsy  sample upon progressi on is opti onal but 
strongly  encouraged.
All optional tumour sample will not be collected in China.
Details for collect ion, storage, and shipment of bio logic samples are presented in a separate 
Laboratory  Manual. 
[IP_ADDRESS] PD-L1 expression assessment
PD-L1 is a potential bio marker for checkpo int inhibitor therapy  in metastatic previously 
treated cervical cancer. However, it is unknown whether this is true in locally  advanced 
cervical cancer. Previous studies demo nstrate about 88% of cases in this populat ion are ≥ 1 % 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 107positive for PD -L1 (Emeka et al  2017 ). Addi tionally , the addi tion of  concurrent 
chemoradiotherapy  can resul t in a shift towards an increase in PD -L1 expressio n. Therefore, 
to further evaluate the PD -L1 as a potential bio marker, pretreatment tumor P D-L1 expressio n 
will be evaluated in all rando mized patients. Data will be co mpared between arms to 
determine if baseline PD -L1 status i s prognostic and/or predict ive of outcomes associated with 
durvalumab + SoC CCRT versus placebo + SoC CCRT. 
8.8.[ADDRESS_768191] oratory  biomarker analyses will be obtained according to the schedules 
presented in the SoAs. Details for collection, vo lumes, storage, and shipment of bio logic 
samples are presented in a separate Laboratory  Manual. 
Basel ine (preferred to be collected prior to dosing at C1D1) and/or on -treatm ent m easures will  
be correlated with outcomes. Note that samples will be obtained fro m patients randomized to 
each treatment arm. Comparisons will be made between baseline measures to determine if 
biomarkers (or combinat ion of markers) are prognostic or predict ive of outcomes associated 
with durvalumab + SoC CCRT versus placebo + SoC CCRT therapi[INVESTIGATOR_014], subgrouped by  
[CONTACT_96726]. 
Addit ional sample co llections and analyses may be completed at select study sites by 
[CONTACT_3725]-specific amendment. All samples collected for such exploratory  analyses will be stored at 
site, a reference laboratory , or [COMPANY_008] facilit ies and may be used for subsequent research 
relevant to eval uating response to therapy .
The exploratory  biomarker pl an is described by  [CONTACT_570443].
[IP_ADDRESS] Microsatellite instability and tumor mutation burden
Tumor tissue remaining after PD -L1 testing will be analyzed retrospectively for microsatellite 
instabilit y (MSI) and tum or mutation burden (TMB) using a Next Generat ion Sequencing 
(NGS) -based method such as who le exo me sequencing (WES) or a targeted NGS assay. The 
MSI-H/MSS status and TMB will be determined based on the MSI events or somatic variants 
detected in the tumor sequence data and correlated with efficacy as an exploratory  objective. 
Blood-based MSI testing may also be performed in cases of insufficient tissue material, 
unsuccessful t issue-based MSI/TMB testing or for evaluat ion of blood -based MSI/TMB with 
clinical outcomes and other bio markers.
Note: This sample will not be collected in China.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 1088.8.2.2 Tumor biomarkers
Based on availabilit y of tissue (described in sect ion [IP_ADDRESS] ), additional exploratory 
biomarkers might be analysed by  [CONTACT_9064]  (IHC). A primary  goal  is to m easure 
CD8 and/or CD4/FoxP3 protein expression in an effort to enumerate cy totoxi c versus 
regul atory  T cells. Based on availabilit y of tissue, a pan el of addi tional, immune -relevant 
markers expressed on tumor -infiltrating lymphocytes or on tumor cells may be assessed. 
Markers of special interest include, but are not limited to, CXCL9 and LAG3.
Other tissue -based approaches may  be pursued including me ssenger ribonucleic acid (mRNA) 
profiling and in situ hybridizat ion (eg, detection of IFNg signaling genes), mo lecular profiling, 
and/or som atic variant detection methodologies.
Note: Above tumor bio marker sample will not be collected in China.
[IP_ADDRESS] Whole blood gene expression (PAXgene RNA)
Who le blood sam ples will be obtained for RNA analysis. Total RNA will be prepared for 
quant ificat ion of mRNA and/or micro -RNA expression using quant itative reverse 
transcri ption PCR, microarray , sequencing, or similar techno logy. Focus is likely  to be given 
to the expressio n of immuno modulatory  genes. Baseline and/or on -treatm ent correl ations wit h 
outcom e data will be completed on select candidates, predictive markers with the aim o f 
ident ifying useful expressio n thresho lds for identifying patients likely to receive benefit.
Note: This sample will not be collected in China.
[IP_ADDRESS] Plasma -ctDNA mutations
Blood sam ples will be collected for analysis of circulat ing tumor deoxy ribonucleic acid 
(ctDNA) in plasma. ctDNA samples will be collected at baseline, during treatment, at disease 
progression, and during fo llow-up after di scont inuation of study  treatm ent, as specified in the 
Schedule of Assessments ( Table 1& Table 2). Analyses will include, but not be limited to 
evaluat ing baseline sensit izing mutations to treatment and cor relations wit h clinical outcomes, 
changes in levels and variant frequencies of ctDNA and potentially minimal residual disease. 
Plasma may  also be evaluated for relevant cy tokines, chemokines and other immune -related 
biomarkers.
Details for collect ion, vo lumes, storage, and shipment of bio logic samples are presented in a 
separate Laboratory  Manual .
Note: This sample will not be collected in China. 

Clinical Study Proto col -4.[ADDRESS_768192] party , unless 
requi red to do so by  [CONTACT_2371]. The pati ent’s samples will not be used for any  purpose other than 
those described in the study  protocol .
Indiv idual  patients will not be ident ified in any report or publicat ion result ing from this work. 
The data and results of this research may  be reviewed wi th collaborators and published, but 
neither the patient’s name [CONTACT_584271].
8.8.4 Storage, re -use, and destruction of biomarker samples
All samples co llected for bio marker analyses will be stored at the study  site, a reference 
laboratory , or at [COMPANY_008] facilit ies and may  be used for subsequent resear ch relevant to 
evaluat ing biological  and/or clinical  response to therapy  as described in the exploratory  
analyses section.
Samples will  be stored for a m aximum  of [ADDRESS_768193] ed in future research.
For China: The stained tissue slides (PD -L1 and H&E slides) will be retained at Covance as 
raw data for a minimum of [ADDRESS_768194] igator will ensure that samples are labeled and shipp ed in accordance with 
the Laboratory  Manual and the Bio logical Substance, Category  B, Regul ations (materials 
containing or suspected to contain infect ious substances that do not meet Category  A cri teria); 
see Appendix C“IATA 6.2 Guidance Document.”

Clinical Study Proto col -4.[ADDRESS_768195] igator at each center will keep full traceabilit y of collected bi ological 
samples fro m the pati ents while in storage at the center until shipment or disposal (where 
appropriate) and will keep documentation of receipt of sample shipments.
The sample receiver w ill keep full traceabilit y of the samples while in storage and during use 
until used or disposed of or until further shipment and will keep documentation of receipt of 
arrival.
[COMPANY_008] will keep oversight of the entire life cycle through internal proce dures, 
monitoring of study  sites, audi ting or process checks, and contractual requirements of external 
laboratory  provi ders.
Samples retained for further use will be stored in the [COMPANY_008]- assigned bi obanks and will 
be registered with the [COMPANY_008] Bi obank Team  during the ent ire life cycle.
9. STATISTICAL CONSIDER ATIONS 
The primary  aim of the study  is to com pare the efficacy  and safet y of durval umab + SoC 
CCRT to placebo + SoC CCRT in terms of PFS in patients with FIGO (2009) Stage IB2 to 
IVA cervical ca ncer.
 Analyses will be performed by [CONTACT_244979]. 
 Refer to SAP for details.
 The SAP will be signed off before review o f any potenti al treatm ent-revealing data 
is undertaken (this includes blinded delivery reviews and data monitoring 
committee reviews). For all situat ions, a full draft of SAP should be available to 
ensure sufficient time to prepare for any  blinded or unblinded data review. A first 
draft of the SAP will be available before the first patient is enrolled.
Depending on the extent of any impact, summaries of data relat ing to patients diagnosed with 
COVID -19, and impact of COVID -[ADDRESS_768196] (in particular missed visit s, del ayed or 
discontinued IP, and other protocol deviations) may  be generated. More detail will be 
provided in the SAP.

Clinical Study Proto col -4.[ADDRESS_768197] the main hypotheses: 
 H0: No difference between durvalumab + SoC CCRT and placebo + SoC CCRT
 H1: Difference between durvalumab + SoC CCRT and placebo + SoC CCRT
The primary  object ive of this study  is to assess the efficacy  of durvalumab + SoC CCRT 
compared wi th placebo + SoC CCRT in terms of PFS as assessed by [CONTACT_584192]. A key s econdary  
objective is to assess the efficacy in terms of OS.
9.2 Sample size determination 
Approximately  714 pati ents will be rando mized 1:1 to durvalumab + SoC CCRT or placebo + 
SoC CCRT to obtain approximately 227 PFS events in the ITT populat ion. The rando mizat ion 
will be stratified according to disease stage status (FIGO (2009) Stage <III and node posit ive, 
FIGO (2009) Stage ≥III and node negat ive, or FIGO (2009) Stage ≥III and node positive), and 
region [Uni ted States, Canada, European Union, South Korea, and Japan] versus rest of the 
world.
The PFS analysis will occur when approximately [ADDRESS_768198] occurred across the 
durvalumab + SoC CCRT and placebo + SoC CCRT treatment arms. If the true HR is 0.65 
(likely to correspond to a 11% increase in the proporti on of  patients progressi on-free at 
3years fro m 65% to 76%) ( Rose et al 1999 ), this analysis will have 90% power to 
demonstrate a stati stically significant difference for PFS, assuming a 2 -sided 5% si gnificance 
level. Assuming non -uniform recrui tment, a 3 -year PFS rate of 65% for placebo + SoC CCRT 
and an exponential distribut ion, recruit ment of [ADDRESS_768199] pati ent. In 
addition, the sam ple size has been derived on the assumpt ion that 5% of patients will drop out 
at an exponential rate within [ADDRESS_768200] patient.
If the true OS HR is 0.65, the study  is also si zed to provi de 89%  power for the OS endpoint in 
the com parison of durvalumab + Soc CCRT versus placebo + SoC CCRT, assuming a 2 -sided 
5% significance level allowing for 1 interim analyses co nducted at approximately 86% of the 
target events. The final OS analysis will occur at the earlier of [ADDRESS_768201] pati ent. Assuming the same recruit ment assumpt ions for PFS 
and a 3 -year OS rate of 70% fo r placebo + SoC CCRT ( Rose et al 1999), [ADDRESS_768202] patient. The boundaries of 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 112the treatment comparison will be derived based upon the actual number of OS events observed 
at that time. 
9.3 Populations for analyses
Definit ions of the analysis sets for each outcome variable are provided in Table 12.
Table 12 Summary of outcome variables and analysis populations
Outcome variable Populations
Efficacy data
PFS Full analysis set (ITT population)
PFS (3 year), OS, ORR, CR rate, DoR in Patients with a CR, Incidence 
of Local Progression, Distant Disease Progression, and Secondary 
Malignancy,)Full analysis set (ITT population)
PFS, OS PD-L1 positive analysis set
Demography Full analysis set (ITT population)
PK data PK analysis set
PROs Full analysis set (ITT population)
Safety data
Exposure Safety analysis set
AEs Safety analysis set
Laborato ry measurements Safety analysis set
Vital Signs Safety analysis set
Abbreviations: AE Adverse event; CR rate Complete response rate; ITT Intent -to-treat; ORR Objective response 
rate; OS Overall survival; PFS Progression -free survival; PK Pharmacokinetics; PRO Patient -reported outcomes;.
9.3.1 Full analysis set
The full analysis set (FAS) will include all rando mized patients (ITT population). The FAS 
will be used for all efficacy analyses (including PROs). Treatment arms will be co mpared on 
the basis o f rando mized study treatment, regardless of the treatment actually received. Patients 
who were randomized but did not subsequent ly go on to receive study treatment are included 
in the analysis in the treatment arm to which they  were randomized. The responders analysis 
set will include the subset of patients the FAS, who achieve an objective response.
9.3.2 Safety analysis set
The safet y analysis set (SAS) will consist of all patients who received at least 1 dose of study 
treatm ent (durval umab orplacebo). Safet y data will not be formally  analyzed but summarized 
using the SAS according to the treatment received; that is, erroneou sly treated patients (eg, 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 113those randomized to treatment A but actually given treatment B) will be summarized 
according to the treatment they  actually  received.
9.3.[ADDRESS_768203], and Stati stician pri or 
to any  analyses being performed.
9.3.4 PD-L1 positive analysis set 
The PD -L1 posit ive analysis set will include the subset of patients in the FAS whose PD -L1 
status is PD- L1 posit ive as defined ≥1% based on either tumor or immune cell s taining.
9.4 Outcome measures for analyses
9.4.1 Calculation or derivation of efficacy variables
[IP_ADDRESS] RECIST 1.[ADDRESS_768204] 1.1 or pathologic assessment of local disease progressi on. In 
addition, the key  secondary  endpoint (OS) and other secondary  endpoints (Inci dence of Local 
Progression, Distant Disease Recurrence, and Secondary Malignancy) will also be analyzed.
Investigator RECIST 1.1- based assessments
All RECIST 1.[ADDRESS_768205] 1.1 visit response of CR, 
PR, SD, or PD depending on the status of their disease co mpared with baseline and previous 
assessments. Baseline will be assessed within the 28 day s prior to enrolm ent. If  a pati ent has 
had a tumor asses sment that cannot be evaluated, then the patient will be assigned a visit 
response of NE (unless there is evidence of progressio n, in which case the response will be 
assigned as PD).
Blinded independent central review
The BICR of all radio logical  imaging data will be carried out using RECIST version 1.1. All 
images will be collected centrally. The imaging scans will be reviewed by [ADDRESS_768206] 1.1 and will be adjudicated, if required. For each patient, the BICR 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 114will define the overall visit response data (CR, PR, SD, PD, or NE) and the relevant scan dates 
for each t imepo int (ie, for visits where response or progression is/is not ident ified). If a patient 
has had a tumor assessment that cannot be evaluated, then the patient will b e assigned a visit 
response of not evaluable (NE; unless there is evidence of progression, in which case the 
response will be assigned as PD). Endpoints (of PFS) will be derived from the overall visit 
response date and the scan dates.
Further details of t he BICR will be documented in the Imaging Charter.
Pathological confirmation of local progression
At response assessment physical exams, patients will be evaluated for local progression. Any 
lesion detected on physical exam that is not evaluable through RE CIST 1.1 and is wit hin the 
radiation field and suspected to be progressive disease will be biopsied. Lesio ns wit h 
histopathologic confirmat ion of disease will be reported as a response of PD. If there is no 
evidence of active cervical cancer on biopsy , the patient will not be reported as PD, and will 
continue wit h all study  procedures according to the Schedule of Assessments ( Table 1). If  
there is evide nce of act ive cervical cancer on biopsy, the date of progression will be the date 
of the physical exam that triggered the biopsy . 
Please refer to Appendix Ffor the definit ions of CR, PR, SD, and PD.
[IP_ADDRESS] Primary endpoint - progression -free survival
PFS (per RECIST 1.1 as assessed by  [CONTACT_584244]) will  be defined as the time from the date of 
rando mizat ion unt il the date of object ive disease progression or death (by  [CONTACT_255749]) regardless of whether the patient withdraws from therapy or receives 
another anticancer therapy  prior to progressi on (ie, date of event or censoring –date of 
rando mizat ion + 1). Progression free survival events will be classified as either local 
progression, distant recurrence, secondary  malignancy, or death. Patients who hav e not 
progressed or died at the time of analysis will be censored at the time of the latest date of 
assessment at which the RECIST 1.[ADDRESS_768207] vis it assessment i s 
not performed. 
The PFS time will always be derived based on scan/physical exam dates and not visit dates.
PFS assessments/scans contribut ing toward a particular visit may be performed on different 
dates within a 4 week window for the specific timepoint assessment. The fo llowing rul es will  
be applied:
 For progression by  [CONTACT_584245], date of progression will be 
determined based on the date of the physical exam which showed suggested 
progression.
 For on -study  tumorassessments, the date of progressio n will be determined based 
on the earliest date of the scan for RECIST 1.1 defined radio logical progressi on or 
progression seen on physical exam. 
 For BICR sensit ivity analysis, date of progression will be determined bas ed on the 
earliest of the dates of the component that triggered the progression on the first set 
of scans that indicates progression for the adjudicated reviewer select ing PD, or of 
either reviewer where both reviewers select PD as a timepoint response, an d there i s 
no adj udicat ion for central review (BICR) data. 
 When censoring a patient for PFS, the patient will be censored at the latest of the 
dates contribut ing to a particular overall visit assessment where both the RECIST 
1.1 assessment and response ev aluat ion physical exam were evaluable within a 4 
week time frame. 
[IP_ADDRESS] Progression Free Survival (3 years)
Progression Free Survival (3 y ears) will be defined as the Kaplan -Meier est imate of PFS at 3 
years . 
[IP_ADDRESS] Progression free survival in PD -L1 positive patients
PFS (per RECIST 1.1 as assessed by  [CONTACT_584246]) in PD- L1 posit ive patients ( ≥1% based on either 
tumor or immune cell staining ) will be defined as for the primary  endpoint as the time fro m 
the date of rando mizat ion until the date of objective disease progression or death (by  [CONTACT_38250]) regardless o f whether the patient withdraws fro m therapy  
or receives another ant icancer therapy  prior to progressio n (ie, date of event or censoring –
date of rando mizat ion + 1). 

Clinical Study Proto col -4.[ADDRESS_768208] 
recorded date on which the patient was known to be alive. 
Note: Survival calls will be made fo llowing the date of DCO for the analysis (these contacts 
shoul d generally  occur wi thin 7 days of the DCO). If patients are confirmed to be alive or if 
the death date is after the DCO date, these patients will be censored at the date of DCO. Death 
dates m ay be found by  [CONTACT_584247]
[IP_ADDRESS] Overall survival in PD- L1 postive patients
OS in PD- L1 posi tive pati ents ( ≥1% based on either tum or or immune cell staining) will be 
defined as the time fro m the date of rando mization until death due to any cause. Any pat ient 
not known to have died at the time of analysis will be censored based on the last recorded date 
on which the patient was known to be alive.
[IP_ADDRESS] Objective response rate
ORR (per RECIST 1.[ADDRESS_768209] igator assessments or pathologic assessment of local 
disease progressi on) is defined as the number (%) of patients with at least [ADDRESS_768210] evaluable assessment in the absence 
of progressi on, will be included in the assessment of ORR. Patients who go off treatment 
without progressi on, receive a subsequent therapy , and then respond will not be included as 
responders in the ORR. 
[IP_ADDRESS] Complete response rate
CR rate (per RECIST 1.1 using investigator assessments or pathologic assessment of local 
disease progressi on) is defined as the disappearance of all TLs and non -target l esions and no 
evidence of new lesions, which enco mpasses R ECIST 1.1 staging in addit ion to a physical 
exam to evaluate for recurrence. 
[IP_ADDRESS] Incidence of Local Progression, Distant Disease Progression, Secondary 
Malignancy 
The incidence of local progression, distant disease progression, secondary malignancy, and 
death will each be considered separately and defined as the number and percentage of patients 
with documented evidence of local progression, distant disease recurrence, secondary  
malignancies, and death. The time from rando mization to the date of first documen ted local 
progression, distant disease recurrence/secondary  malignancy or death fro m any cause will 
also be summarized. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 117For the summaries, if two recurrence events (local progression and distant disease 
progression) occur within [ADDRESS_768211] case will be taken as the 
event ‘ty pe’, but the date of recurrence will be the earliest of the two events. For example, if 
local progressi onand di stant recurrence are reported within a [ADDRESS_768212] date of the two events.
Distant di sease progressi on, secondary  malignancy, and deaths are considered to be compet ing 
risks for l ocal progressi on. Local  progressi on and death are considered to be competing risks 
for distant disease recurrence/secondary  malignancy . From  the time to event endpoint, distant 
disease recurrences and secondary malignancies will be summarized together. 
Local progressi ons will be determined by  [CONTACT_393] 1.[ADDRESS_768213] ion [IP_ADDRESS] . Distant disease recurrence should be 
diagnosed by [CONTACT_393] 1.[ADDRESS_768214] be confirmed by [CONTACT_9256] . If a biopsy is not abl e to perform ed 
then the sus pected secondary  malignancy will be counted as a distant disease recurrence for 
the summary .
[IP_ADDRESS] Duration of response for Complete Responders 
Durati on of  response in co mplete responders (per RECIST 1.[ADDRESS_768215] igator assessments, 
physical examinat ion, and histopathological confirmat ion of local disease progression) will be 
defined as the time fro m the date of the first documented CR  to the first date of documented 
progression or death in the absence of disease progressio n. The end of response should 
coincide wit h the date of progression or death from any  cause used for the PFS endpoint. 
The time of the init ial response will be defined as t he latest of the dates contribut ing towards 
the assessment visit. If a patient does not progress fo llowing a CR, then their DoR will be 
censored at the PFS censoring time. Duration of response for complete responders will not be 
defined for those patients who do not have a documented response of CR.
9.4.2 Calculation or derivation of safety variables
[IP_ADDRESS] Adverse events
Safety and tol erabilit y will  be assessed in term s of AEs (including SAEs), physical 
examinat ions, laboratory  findings, vital signs, and exposure. Thes e will be collected for all 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 118patients. Data from  all cycles o f treatm ent will be combined in the presentation of safet y data. 
“On treatm ent” will be defined as assessments between date of start dose and 90 day s 
following discont inuat ion of study treatment ( ie, the last dose of study treatment). For AEs, on 
treatm ent (or treatm ent-emergent AEs) will be defined as any AEs that started after dosing or 
prior to dosing and which worsens fo llowing exposure to the treatment.
AEs observed up unt il [ADDRESS_768216] subsequent therapy fo llowing di scontinuat ion of study  treatm ent 
(whichever occurs first) will be used for the reporting of the AE summary  tables. Thi s will  
more accurately  depi[INVESTIGATOR_584166] a ttributable to study  treatm ent only  as the number of AEs up to 
90days following discont inuat ion of durvalumab + SoC CCRT or placebo + SoC CCRT are 
likely  to be attributable to subsequent therapy . However, to assess the l onger -term toxicity 
profile, AE sum maries will also be produced containing AEs observed up unt il 90 days 
following discont inuat ion of durvalumab + SoC CCRT or placebo + SoC CCRT. Any  events 
in this period that occur after a patient has received further therapy  for cancer (fo llowing 
disconti nuation of study  treatm ent) will be flagged in the data list ings.
The SAS will be used for reporting of safet y data.
A separate data list ing of AEs occurring more than 90 days after discontinuation o f study  
treatm ent will be produced. These events will not be included in AE summaries.
[IP_ADDRESS] Safety assessments
For the change fro m baseline summaries for vital signs, laboratory  data, hem atology, ECGs, 
and physical examinat ions, the baseline value will be the latest result obtained prior to the 
start of study  treatm ent. 
QTcF will be derived during creation o f the reporting database using the reported ECG values 
(RR and QT) using the fo llowing form ula:
QTcF = QT/RR^ (1/3), where RR is in seconds
Corrected calcium product will be derived during creation of the reportin g database using the 
following form ula:
Corrected calcium (mmo l/L) = Total calcium (mmol/L) + ([40 – albumin (G/L)] × 0.02)
The deno minator used in laboratory summaries will only include evaluable patients, ie, those 
who had sufficient data to have the pos sibilit y of an abnormalit y.
For example:

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 119 If a CTCAE criterion invo lves a change from baseline, evaluable patients would 
have both a pre -dose and at least [ADDRESS_768217] -dose value recorded.
 If a CTCAE criterion does not consider changes from baseline to be evaluable, the 
patient need only have [ADDRESS_768218] -dose value recorded.
The deno minator in vital signs data should include only those patients with recorded data.
9.4.3 Calculation or derivation of patient -reported outcome variables
All items/quest ionnaires will be sc ored according to published scoring guidelines.
[IP_ADDRESS] EORTC -QLQ -C30
The EORTC QLQ -C30 consists of [ADDRESS_768219] ional 
scales (physical, role, cognit ive, emotional, and social), 3 symptom scales (fat igue, pain, and 
nausea/vo miting), 5 individual items (dyspnea, insomnia, appetite loss, constipat ion, and 
diarrhea), and global healt h status/QoL scale. The EORTC QLQ -C30 will be scored according 
to the EORTC QLQ- C30 Scoring Manual ( Fayers et al  2001 ). Bri efly, outcome scores are 
computed by  [CONTACT_584248] (i.e., a raw score) making up the scale. 
Outcom e scores are com puted using a linear transformation o f the raw score such that scores 
range fro m 0 to 100.
Higher scores on the global measure of healt h status/QoL and funct ional scales indicate better 
healt h status/funct ion, but higher scores on symptom scales represent greater symptom 
severit y. For each su bscale, if <50% of the subscale items are missing, then the subscale score 
will be divided by [CONTACT_154562]- missing items and mult iplied by  [CONTACT_584249] ( Fayers et al 2001). If  at least 50% of the i tems are missing, then that 
subscale will be treated as missing. Missing single items are treated as missing. The reason for 
any missing quest ionnaire will be identified and r ecorded. If there is evidence that the missing 
data are sy stem atic, missing values will be handled to ensure that any possible bias is 
minimized.
At each post- baseline assessment, the change fro m baseline in symptom, funct ional, and 
global measure of healt h status/QoL scale scores will be calculated.
Definition of clinically meaningful changes
Changes in score compared with baseline will be evaluated. Change in symptoms, funct ioning 
and glo bal health status from  baseline will be categorised as improved, sta ble or worsened as 
shown in Table 13. A minimum clinically relevant change is defined using the cut off value of 
10 points ( Osoba et al 1998 ). Specifically , a clinically  meaningful improvement in a symptom 
is defined as a decrease in the score fro m baseline of ≥10, while a clinically  meaningful  

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 120deterioration in a symptom is defined as an increase in the score from baseline of ≥10. In 
contrast, a clinically meaningful improvement in a funct ional scale or gl obal heath status is 
defined as an increase in the score fro m baseline of ≥10, while a clinically meaningful 
deteri oration in a a funct ional scale or global heath status is defined as a decrease in the score 
from baseline o f ≥10.
Table 13 Visit responses for EORTC QLQ- C30
Score Change from baseline Visit response
Symptom scales/items ≥+10 Worsened
≤-10 Improved
Otherwise Stable
Functional scales and global health 
status/QoL≥+10 Improved
≤-10 Worsened
Otherwise Stable
[IP_ADDRESS] EORTC QLQ -CX24
The QLQ- CX24 consists of 24 questions that can be combined to produce three multi-item 
scales (symptom experience, body  image, and sexual/vaginal funct ioning) and six single -item 
scales (lymphedema, peripheral neuropathy , menopausal  symptoms, sexual  activity, sexual  
worry , and sexual  enjoyment). The scales and single item measures are al so scored from  [ADDRESS_768220] -baseline assessment, change in symptoms/functioning 
from baseline will be categorized as improved, stable, or worsened using the pre -specified 
clinically meaningful cut -off defined in the SAP.
9.4.4 Patient -reported outcomes version of the Common Terminology Criteria 
for Adverse Events
The PRO -CTCAE items are not currently  scored. The data will be descript ively summarized. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 1219.4.5 Patient Global Impression of Change and Patient Global Impression of 
Severity
The response options of the PGIC are scored as fo llows: Much Better (+3), Moderately  Better 
(+2), A Little Better (+1), No Change (0), A Little Worse ( -1), Moderately Worse ( -2) and 
Much Worse ( -3).
The response options of the PGIS are scored using a 6- point scale: 1 = None; 2 = Very  Mild; 3 
= Mild; 4 = Moderate; 5 = Severe; 6 = Very  Severe.
9.4.6 EuroQol five -dimensional five-level questionnaire (EQ -5D-5L)
The EQ -5D- 5L index co mprises 5 dimensio ns of health (mobilit y, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depressi on). For each dimensio n, respondents select which 
statement best describes their healt h on that day  from a possible 5 opti ons of increasing levels 
of severi ty (no probl ems, slight problems, moderate problems, severe problems, and extreme 
probl ems). A unique EQ -5D healt h state i s referred to by  a 5-digit code all owing f or a total  of 
3,125 health states. For example, state [ZIP_CODE] indicates no problems on any  of the 5 
dimensio ns. These data will be converted into a weighted healt h state index by [CONTACT_584250] m EQ-5D value sets elicited fro m general  popul ation samples (the base case will be 
the United Kingdo m valuat ion set, with other country  value sets appli ed in scenario analyses). 
Where EQ -5D- 5L values sets are not available, the EQ -5D- 5L to EQ-5D- 3L crosswalk will be 
applied ( Oemar and Oppe 2013 ).
9.4.7 Defin ition of compliance and evaluability rates
Com pliance rates for the PRO questionnaires should be 85%; this rate will be monitored as the 
trial goes on. Com pliance wi th the EORTC QLQ -C30 and EORTC QLQ -CX24 will be 
calculated separately  for each questi onnai re:
Compliance rate= number of evaluable forms
number of expected forms× 100
Evaluabilit y rates for the EORTC QLQ -C30 and EORTC QLQ -CX24 will also be calculated 
separately  for each questi onnai re:
Evaluability rate =number ofevaluable forms
number ofreceive dforms×100
An expected form = a questionnaire that is expected to be completed at a scheduled 
assessment time, that is, a questionnaire fro m a patient who has not withdrawn fro m the study  
at the scheduled assessment time but excluding patients in countr ies with no available 
transl ation. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 122An evaluable form = a questionnaire with a co mpletion date and at least 1 subscale that is non -
missing. 
A received form = a questionnaire that has been received and has a co mpletion date and at 
least [ADDRESS_768221] of treatment and disease on healt h care resource use the fo llowing 
variables will be captured:
 Planned and unplanned hospi[INVESTIGATOR_584167] 
(including physician visit s, em ergency  room  visits, day  cases and admissio ns) 
 Primary sign or symptom the patient presents with
 Length of hospi[INVESTIGATOR_4408]
 Length of any t ime spent in an intensive care unit (ICU)
Where admitted overnight, the length of hospi[INVESTIGATOR_584168] (or death date) and the start date of hospi[INVESTIGATOR_584169] i s after start date of hospi[INVESTIGATOR_72913] (length of 
hospi [INVESTIGATOR_231999] = end date of hospi[INVESTIGATOR_72913] –start date of hospi[INVESTIGATOR_72913] + 1). Patients with 
missing discharge dates will be calculated as the difference between the last day  with 
available data and the start date of hospi[INVESTIGATOR_72913]. The length of ICU stay  will be calculated 
using the same method.
9.4.9 Calculation or derivation of pharmacokinetic variables
[IP_ADDRESS] Population pharmacokinetics and exposure -response/safety analysis
A population PK model may be developed using a non -linear mixed -effects m odeling
approach. The impact of physio logically -relevant pati ent characteri stics (covariates) and
disease on PK may  be evaluated. The relationship between the PK exposure and the effect on
safet y and efficacy endpo ints may be eval uated (as data allow). The results of such an
analysis will be reported in a separate report. The PK, pharmacodynamics, demographic,
safet y, and efficacy  data collected in this study  may also be combined wit h similar data from
other studi es and explored using population PK and/or PK -pharmacodynamic meth ods.
[IP_ADDRESS] Pharmacokinetic analysis
PK concentration data and summary  statistics will be tabulated. PK parameters will be
determined fro m the raw data. The fo llowing PK param eters will  be determined after the first

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 123and steady -state doses: peak and trough conce ntration (as data allow).
[IP_ADDRESS] Immunogenicity analysis
Immunogenicit y resul ts will  be analyzed descript ively by [CONTACT_584251]. 
The immunogenicit y titer and pr esence of neutralizing ADAs will be reported for samples 
confirmed posit ive for the presence of ADAs. The effect of immunogenicit y on PK, 
pharmacodynamics, efficacy , and safet y will be evaluated, if the data allow.
9.4.[ADDRESS_768222] consent to participat ion in the 
genet ic research and the date the blood sample was taken from the patient will be recorded in 
the eCRF and database. The genet ic data generated fro m the study  will be stored in the 
[COMPANY_008] Laboratory  Informati on Management System  database or other appropriate 
system . This database is a secure database, which is separate from the database used for the 
main study . Som e or all of the dataset from the main study may be duplicated within the 
[COMPANY_008] Laboratory  Informati on Management System  database for exploratory  genet ic 
analysis. Data will be reported outside the CSR (please see Appendix C).
9.[ADDRESS_768223] ical analyses of the primary  and 
secondary  endpoints. Any deviat ionsfrom thisplan willbereported intheCSR.
9.5.1 Efficacy analyses
The study  has been sized to characterize the PFS benefit of durvalumab + SoC CCRT versus 
placebo + SoC CCRT. The analysis will be performed when approximately [ADDRESS_768224] occurred across the durvalumab + SoC CCRT and placebo + SoC CCRT treatment arms 
(32% m aturity).

Clinical Study Proto col -4.[ADDRESS_768225] ical analysis will be presented using a 95% CI and [ADDRESS_768226] ical analysis, together 
with pre-planned sensit ivity analyses, making it clear which analysis is regarded as primary  
for that endpoint. Note that all endpo ints com pare durvalumab + SoC CCRT versus placebo + 
SoC CCRT in all rando mized patients (FAS; ITT populat ion), unless otherwise indicated.
Table 14 Pre-planned statistical and sensitivity analyses to be conducted
Endpoints analyzed Notes
Progression -free survival Stratified log -rank analysis for:
Primary analysis using Investigator RECIST 1.1 assessments or 
histopathologic confirmation of local tumor progression
Sensitivity analyses using BICR assessments (RECIST 1.1) or 
histopathologic confirmation of local tumor progression
PFS (3 year) Kaplan Meier estimate of PFS at 3 years

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 125Endpoints analyzed Notes
PFS in PD -L1 positive 
patients
Overall survival
OS in PD -L1 positive patientsStratified log -rank analysis for:
PFS in PD -L1 positive patients
Stratified log -rank analysis for:
Overall survival
Stratified log -rank analysis for:
OS in PD -L1 positive patients
Objective response rate Secondary analysis for the ITT population 
Logistic regression for:
Secondary analysis for the ITT population using Investigator 
RECIST 1.1 assessments or histopathologic confirmation of local 
tumor progression
Complete response rate Logistic regression for:
Secondary analysis for the ITT population using Investigator 
RECIST 1.1 assessments or his topathologic confirmation of local 
tumor progression 
Duration of Response in 
Patients with a Complete 
ResponseSummary statistics and KM plot by [CONTACT_106866]:
Secondary analysis for the ITT population using Investigator 
RECIST 1.[ADDRESS_768227] objective 
response of complete response 
Incidence of local 
progr ession, distant disease 
progr ession, and secondary 
malignancySummary statistics and KM plot and cumulative incidence plot by 
[CONTACT_106866]:
Secondary analysis for the ITT population
Change from baseline 
(EORTC QLQ -C30 and 
EORTC QLQ -CX24) Average change from baseline using a Mixed Model Repeated 
Measurements (MMRM) analysis
EQ-5D-5L (health state utility 
values and Visual Analog 
Scale)Summary statistics for health state utilities and visual analogue 
scale, including change from baseline.
healthcare resource use Descriptive statistics (as appropriate, including means, median, 
ranges or frequ encies and percentages)
Abbreviations: BICR Blinded independent central review; EORTC European Organisation for Research and 
Treatment of Cancer; FAS Full analysis set; ITT Intent -to-treat; KM Kaplan -Meier; PK Pharmacokinetic; 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 126QLQ -C30 30 item core quality of life questionnaire; QLQ -CX24 Cervical cancer module; RECIST Response 
Evaluatio n Criteria in Solid Tumors.
[IP_ADDRESS] Primary endpoint: Progression -free survival
The primary  PFS analysis will be based on the programmat ically derived RECIST 1.[ADDRESS_768228] of durvalumab + SoC CCRT versus placebo + SoC CCRT will be 
analyzed using a log -rank test stratified by  [CONTACT_584190] (FIGO (2009) Stage <III and 
node posit ive, FIGO (2009) Stage ≥III and node negative, or FIGO (2009) Stage ≥III and node 
positive) and region [[LOCATION_002], Canada, European Unio n, South Korea, and Japan] versus 
rest of worl d. In addi tion, PFS will be analysed using a stratified Cox proportiona l hazards 
model using the same strata as for the primary  analysis by [CONTACT_584252]. The point estimate of the treatment effect, i.e. HR will be obtained by 
[CONTACT_584253], whic h is the product of the likelihood of each 
stratum . (an HR l ess than 1 will favor durvalumab + SoC CCRT). The 95% CI will be 
estimated using the profile likelihood approach. The 95% CI and HR from the stratified Cox 
proporti onal hazards model will be in su pport of the p -value from the stratified log rank test, 
no p-value will be reported from the stratified Cox proportional hazards model. 
Stratificat ion vari ables will be defined according to data from the IWRS. If there are any  
patients who are mis- stratif ied, a sensit ivity analysis may  be carri ed out using the baseline 
data collected in the eCRF.
Kaplan -Meier pl ots of  PFS will be presented by  [CONTACT_584254] (FIGO (2009) Stage <III and node posit ive, FIGO (2009) Stage ≥III and 
node negat ive, or FIGO (2009) Stage ≥III and node posit ive) and regio n [[LOCATION_002], 
Canada, European Unio n, South Korea, and Japan] versus rest of world subgroups, where 
appropriate. Summaries of the number and percentage of patients expe riencing a PFS event 
and the ty pe of event (l ocal progressi on, distant progressi on, or death) will be provided along 
with median PFS for each treatment.
Sensit ivity analyses will be performed to assess possible evaluat ion-time bias that may be 
introduced i f scans and physical examinat ions are not performed at the protocol -scheduled 
timepo ints. The midpo int between the time of progressio n and the previous evaluable 
assessment will be analyzed using a log -rank test. For patients whose death was treated as a 
PFS event, the date of death will be used to derive the PFS time used in the analysis. This 
approach has been shown to be robust even in highly asymmetric assessment schedules ( Sun 
and Chen 2010).
Attrition bias will be assessed by  [CONTACT_584255], except that the actual PFS event 
times, rather than the censored times, of patients who progressed or died in the absence o f 

Clinical Study Proto col -4.[ADDRESS_768229] ots of  complementary  
log-log (event times) versus log (time) and, if these raise concerns, by [CONTACT_584256] a time -dependent 
covari ate to assess the extent to which this represents random variat ion. If a lack o f 
proporti onali ty is evident, the variat ion in treatment eff ect will be described by  [CONTACT_584257][INVESTIGATOR_584170] -periods. In such circumstances, the HR can st ill be 
meaningfully  interpreted as an average HR over time unless there is extensive crossing of the 
survival curves. If lack of pro portionali ty is found, this m ay be a resul t of treatm ent-by
-
covariate interacti ons, which will be invest igated. In addit ion, the Kaplan- Meier curve along 
with landmark analyses (eg, 1 -year PFS rate) will also help in understanding the treatment 
benefit.
Subgroup analyses will be conducted comparing PFS (per RECIST 1.[ADDRESS_768230] igator 
tumor assessments or histopathologic confirmat ion of local tumor progression) between 
durvalumab + SoC CCRT and placebo + SoC CCRT in the fo llowing (but not limited to) 
subgroups of the FAS:
 Age at randomizat ion (<65 versus ≥65 y ears of age) 
 PD-L1 status ( ≥1% vs < 1%)
 Disease stage status (FIGO (2009) Stage <III and node posit ive, FIGO (2009) Stage 
≥III and node negative, or FIGO (2009) Stage ≥III and node positive) 
 Intent to administer cisplatin or carboplat in
 Race (Asian versus non -Asian)
 Region [Uni ted States, Canada, European Union, South Korea, and Japan] versus 
rest of the world
 HPV status (HPV 16, HPV 18 versus other)

Clinical Study Proto col -4.[ADDRESS_768231] across expected prognostic and/or predict ive factors. F orest 
plot will be performe d.
No adj ustment to the si gnificance level for testing of the subgroup and sensit ivity analyses 
will be made, since all these analyses will be considered supportive of the analysis o f PFS.
Interacti ons between treatment and stratificat ion factors will also be tested to rule out any  
qualitat ive interacti on using the approach of Gail an d Sim on 1985 .
Addit ionally , for each subgroup, the HR (durvalumab + SoC CCRT:placebo + SoC CCRT) 
and 95% CI will be calculated fro m a Cox proportional hazards model, wit h treatment as the 
only covari ate. These will be presented on a Forest plot including the H R and 95% CI from 
the overall populat ion. 
If there are too few events available for a meaningful analysis o f a particular subgroup (it is 
not consi dered appropri ate to present analyses where there are less than 20 events in a 
subgroup), the relat ionship b etween that subgroup and PFS will not be formally analyzed. In 
this case, only  descri ptive summaries will be provided. 
[IP_ADDRESS] Progression Free Survival (3 year)
PFS (3 y ear) will  be summarized (using the Kaplan -Meier curve) and presented by  [CONTACT_584258].
[IP_ADDRESS] Progre ssion -free survival in PD -L1 positive patients
PFS in PD -L1 posit ive pat ients will be analyzed using a stratified log -rank test, using the same 
methodol ogy as for the primary PFS endpoint. The effect of durvalumab + SoC CCRT versus 
placebo + SoC CCRT will be est imated by [CONTACT_584259] p -
value using the same methodology  as described for PFS in the subset of patients with PD -L1 
status of ≥1%. Kaplan -Meier pl ots will be presented by  [CONTACT_3219] . Summari es of  the 
number and per centage of pati ents experiencing a PFS event and ty pe of  event (l ocal 
progression, distant progression, or death) will be provided along wit h median PFS for each 
treatm ent.
[IP_ADDRESS] Overall survival
OS in the ITT population will be analyzed using a stratified log -rank tests, using the same 
methodol ogy as described for the primary PFS endpoint. The effect of durvalumab + SoC 
CCRT versus placebo + SoC CCRT will be est imated by  [CONTACT_584260] p- value using the same methodology  as describe d for PFS. Kapl an-
Meier pl ots will be presented by  [CONTACT_3219] . Summaries of the number and percentage of 

Clinical Study Proto col -4.[ADDRESS_768232] withdrawn consent will be provided along with the median OS for each treatment.
[IP_ADDRESS] Overall survival in PD- L1 positive patients
OS in PD- L1 posi tive pati ents will  be analyzed using a stratified log -rank tests, using the same 
methodol ogy as described for the primary PFS endpoint. The effect of durvalumab + SoC 
CCRT versus placebo + SoC CCRT will be est imated by  [CONTACT_584260] p- value using the same methodology  as described for PFS. Kaplan -
Meier pl ots will be presented by  [CONTACT_3219] . Summaries of the number and percentage of 
patients who have died, those still in survival fo llow-up, those lost to follow -up, and those 
who have withdrawn consent will be provided along with the median OS for each treatment.
[IP_ADDRESS] Objective response rate
The ORR will be based on the programmat ically derived RECIST 1.[ADDRESS_768233] igator 
tumor assessments and histopathologic confirmat ion of local tumor progression. The ORR 
will be co mpared between durvalumab + SoC CCRT and placebo + SoC CCRT using logist ic 
regression models, adjust ing for the same factors as the primary endpo int. The resul ts of the 
analysis will be presented in terms of an odds ratio together with its associated profile 
likelihood CI and p -value (based on twice the change in log -likelihood result ing from the 
addition of  a treatm entfactor to the model). This analysis will be performed in the ITT 
popul ation.
Summaries will be produced that present the number and percentage of patients with a tumor 
response (CR/PR). Overall visit response data will be listed for all pat ients (ie, the FAS). For 
each treatment arm, best overall response (BoR) will be summarized by n (%) for each 
category  (CR, PR, SD, PD, and NE). No formal statist ical analyses are pl anned f or BoR.
[IP_ADDRESS] Complete response rate
The CR rate as obtained fro m complete responses will be co mpared between durvalumab + 
SoC CCRT and placebo + SoC CCRT using logist ic regression models, by [CONTACT_584261]. This analysis will be performed in the ITT 
popul ation. Summaries will be produced that pre sent the number and percentage of patients 
with a tum or response of CR.
[IP_ADDRESS] Incidence of Local Progression, Distant Disease Progression, and Secondary 
Malignancy 
The actual  number and percentage of patients with a progression free survival event will be 
presented by [CONTACT_584262] a 

Clinical Study Proto col -4.[ADDRESS_768234] secondary
malignancy, and t ime to death will be analyzed separately using KM plots. As discussed in 
Secti on [IP_ADDRESS] , distant di sease progressi on, secondary  malignancy , and death are consi dered 
to be compet ing risks for local progression. Patients with distant disease progression, 
secondary  malignancy, or death will be censored in the KM plot for local progression. Local 
progression and death are considered to be competing risks for distant disease recurrence and 
secondary  malignancy, patients with local progressio n or death will be censored in the KM 
plot for distant di sease progressi on or secondary  malignancy. 
The cumulat ive incidence of local progression, d istant disease progression or secondary  
malignancy, and deaths will be compared between the two treatment groups using co mpet ing 
risk analysis (Gray  test, Fine and Gray  1999). Death will be considered a compet ing risk for 
local progressi on and di stant di sease progression or secondary  malignancy. In addi tion, distant 
disease progressi on and secondary  malignancy  will be considered to be compet ing risks for 
local progressi on and l ocal progressi on will be consi dered to be a com peting risk for distant 
disease pr ogressi on and secondary  malignancy . Hazard rati os and 95% confidence intervals 
from compet ing risks regressio n analysis (Fine and Gray  1999) adj usted for treatm ent and 
stratificat ion factors will also be presented --more details o f the analysis will be gi ven in the 
SAP.
[IP_ADDRESS] Duration of complete response
Durati on of  response in pat ients who have a best object ive response of CR will be derived for 
each treatment arm based on the RECIST 1.1 Investigator assessments or phy sical exam and 
on histopathological confir mation of local tumour progression. Descript ive data will be 
provi ded by [CONTACT_584263], including the associated Kaplan -
Meier curves (without any  formal com parison of treatm ent arms or p -value attached).
[IP_ADDRESS] Patient -reported outcome s
All PRO analyses will be based on the FAS. For change fro m baseline summaries, evaluable 
patients will  have both a baseline and at least [ADDRESS_768235] -dose value recorded.
EORTC QLQ -C30
The m ean change in symptom  and functional scale and the global measure of h ealth 
status/QoL scale scores from baseline will be analyzed for each measure using a mixed model 
for repeated m easures. Full details of this and appropriate sensit ivity analyses will be 
described in full in the SAP.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 131Summaries of the original and the change fro m baseline values o f each symptom scale/item, 
the global healt h status/QoL score, and each functional domain will be reported by  [CONTACT_584264]. Graphical presentations may also be produced as appropriate. Summaries 
of the number an d percentage of pati ents in each response category  at each visit for each 
ordinal item will also be produced for each treatment arm.
EORTC -QLQ -CX24
The m ean change from  baseline will be analyzed for each EORTC -QLQ -CX24 score using a 
mixed model for repeate d measures. Full details of this and appropriate sensit ivity analyses 
will be described in full in the SAP.
Summaries of the original and the change fro m baseline values o f each symptom and 
funct ional do main will be reported by  [CONTACT_512217] . Graphical  presentati ons 
may also be produced as appropriate. Summaries of the number and percentage of patients in 
each response category  at each visit for each ordinal item will also be produced for each 
treatm ent arm .
PRO -CTCAE
PRO- CTCAE data will be p resented using summaries and descript ive statist ics. Further details 
will be provided in the SAP.
PGIC and PGIS
PGIC and PGIS data will be presented using summaries and descript ive statist ics. Further 
details will be provided in the SAP.
EQ-5D-5L
Descript ive statistics and graphs will be reported for health state utilit y index values (United 
Kingdo m base case).
To support future economic evaluations of the study treatment, addit ional appropriate analyses 
may be undertaken, for example, mean health state uti lity pre-and post -treatm ent, and pre -
and post -progression. These will be outlined in a separate Payer Analysis Plan.
[IP_ADDRESS] Health care resource use
The potential impact the disease and treatment has on healt h care resource use will be 
analysed for the purposes of submissio ns to pay ers. Descript ive statistics (as appropriate, 
including means, median, ranges or frequencies and percentages) will be provided for each 
arm on the different ty pes o f hospi [INVESTIGATOR_140754], the length of stay  of peopl e admitted in to 
hosp ital for at l east one overnight stay  and length of stay  of people admitted to intensive care / 
high dependency units, as well as the primary  sign or sym ptom  the pati ent presents wi th. To 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 132support submissions to pay ers, addi tional analyses may be undertaken and these will be 
outlined in a separate Pay er Analysis Plan. 
9.5.2 Safety analyses
Safety is a secondary endpo int in this study . All safety  analyses will be performed on the 
safet y popul ation. Safety  and tolerabilit y data will  be presented by  [CONTACT_584195] y popul ation. Safety  data will be summarized descript ively and will not be formally 
analyzed.
Data from all cycles of treatment will be co mbined in the presentation of safet y data. AEs 
(both in terms o f Medical Dictionary  for Regul atory  Acti vities [MedDRA] preferred terms 
and CTCAE grade) will be listed individually  by [CONTACT_73002]. The number of pat ients experiencing 
each AE will be summarized by [CONTACT_584265]. Addit ionally , data 
presentations of the rate of AEs per person -year at risk may  be produced. 
Other safet y data will be assessed in terms of AEs (including SAEs), physical examinat ions, 
laboratory  findings, vital signs, and exposure. Exposure to durvalumab + SoC CCRT and 
placebo + SoC CCRT will be summarized. Time on study , dose delays and dose reductions 
will also be summarized. At the end of the study , appropri ate summaries of all safet y data will 
be produced, as defined in the SAP.
9.5.[ADDRESS_768236] of its neutralizing properties on PK, 
pharmacodynamics, efficacy , and safet y may be eval uated, if the data allow. A detailed plan 
will be written by [CONTACT_584266].
9.5.5 Pharmacokinetic/phar macodynamic r elationships
If the data are suitable, the relationship between PK exposure and efficacy/safety parameters 
may be invest igated graphically or using an appropriate data modeling approach.

Clinical Study Proto col -4.[ADDRESS_768237] oratory  biomarkers to clinical 
outcom es (including but not restricted to) of PFS, and OS will be presented.
PD-L1 expression determined by [CONTACT_584267]. Summaries and analyses 
for expl oratory  biomarkers will be documented in a separate analysis plan and will be reported 
outsi de the CSR in a separate report.
9.5.7 Methods for multiplicity control
The m ultiple testing procedure (MTP) will define which significance levels should be applied 
to the interpretation of the raw p- values for th e primary  endpoint of PFS and the key  
secondary  endpoint of OS.
The overall 5% ty pe I error rate will first be allo cated to test the primary  endpoint of PFS for 
durvalumab + SoC CCRT versus placebo + SoC CCRT. If the primary  endpoint of PFS i s 
significant , 5% alpha will be recycled to the lower level I the hierarchy, where the 5% alpha 
will be used for the test of OS for durvalumab + SoC CCRT versus placebo + SoC CCRT. 
The primary endpoint of PFS will be tested once. The key  secondary  endpoint of OS will be 
tested at 2 timepo ints: 1 interim analysis and 1 final analysis. The tests including the interim 
and the final analysis that are for the comparison of durvalumab + SoC CCRT versus placebo 
+ SoC CCRT for the analyses of OS will be considered as one test family. As long as [ADDRESS_768238] in 
the family can be rejected, the family is rejected. Thus, the assigned total alpha to the family 
will be recycled to the next MTP level. Details of the interim analyses are provided in Section 
9.6.
The details o f the multiple testing procedure will be provided in the SAP.
9.6 Interim analyses 
No PFS interim analysis is planed in this study .
There will be an interim analys is performed for OS. The OS interim will occur at the time of 
the PFS analysis, if it is posit ive. It is ant icipated that approximately 86% of the OS events 
will be available for this OS IA (approximately 195 of 227 OS events). If exact ly 86% of  the 
target events are available at the time of the interim analysis, with overall 2 -sided alpha level 
of 5.0%, the 2- sided alpha to be applied at the interim analysis and final analysis would be 
3.1%and 4.1%, respectively.

Clinical Study Proto col -4.[ADDRESS_768239] patient, at which point OS will be retested. 
The SAP will desc ribe the planned interim analysis in greater detail.
9.6.1 Data monitoring committee
The safet y of all [COMPANY_008] clinical studies is clo sely monitored on an ongoing basis by 
[CONTACT_96784] y. Issues ident ified wil l be 
addressed; for instance, this could invo lve amendments to the study protocol and letters to 
Invest igators.
An IDMC co mposed of independent experts will be convened to confirm the safet y and 
tolerabilit y of the proposed dose and schedule of durvalumab + SoC CCRT. The first safet y 
review will take place when the first [ADDRESS_768240] ive o f whether or not the overall study  enrolment has been reached. It is 
anticipated that this target may not be met before the glo bal recruit ment of approximately 714 
is achieved. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 135A pat ient randomized in the China cohort will be included in both the global FAS and the 
China FAS. Per China Nat ional Medical Products Administration (NMPA) guidance, in 
addition to the evaluat ion of the overall data for primary, secondary and safet y objectives, 
evaluat ion of consistency in efficacy  and safety  in China and Asia populat ion is required to 
facilitate the benefit -risk assessment for Chinese patients.  Hence, the safet y and efficacy  data 
in China cohort will be analyzed separately where the same endpo int definit ions and analysis 
methods (as detailed in Sect ion 9.5) are applied.
Details o f this analysis will be in a China supplementary  SAP. 

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY [ZIP_CODE]. REFERENCES
FDA Guidance for Industry  (issued July  2009) “Drug -induced liver injury: Premarket ing 
clinical evaluat ion”
Aaronson et al 1993
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NK, et al. The European 
Organizat ion for Research and Treattment of Cancer QLQ -C30: a qualit y-of-life instrument 
for use in internat ional clinical tri als in onco logy. J Natl  Cancer I nst 1993;85:365 -76.
Alexandrov et al 2013
Alexandrov LB, Nik -Zainal S, Wedge DC, Aparicio SAJR, Behjat i S, Bl ankin AV, et al . 
Signatures of m utational processes in human cancer. Nature 2013;500:415 -21.
Antonia et al 2017
Antoni a SJ, Villegas A, Daniel D, V icente D, Murakami S, Hui R, et al. Durvalumab after 
chemoradiotherapy  in stage III non –small -cell lung cancer. N Engl  J Med 2017;377(20):1919-
29.
Banerjee and Kamrava 2014
Banerj ee R, Kam rava M. Brachy therapy  in the treatm ent of cervical cancer: a review. Int J 
Womens Health 2014;6:555 -
64.
Basch et al 2009
Basch E, Ji a X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting 
by [CONTACT_76470]: relat ionships wi th clinical outcom es. J Natl  Cancer Inst 
2009;101(23):[ADDRESS_768241] VB, Thomas CC, King J, Massetti GM, Doria -Rose VP, Saraiya M. Vital signs: 
cervical cancer incidence, mortalit y, and screening -[LOCATION_002], 2007 -2012. MMWR Morb 
Mortal  Wkly Rep 2014;63(44):1004 -09.
Benedetti -Panici et al 1996
Benedet ti-Panici P, Maneschi F, Scambia G, Greggi S, Cutillo G, D’Andrea G, et al. 
Lymphatic spread of cervical cancer: an anatomical and pathological study  based on 225 
radical hysterectomies wi th system atic pelvic and aortic lymphadenectomy. Gyneco l Onco l 
1996; 62(1):19 -24.
Berman et al 1984
Berm an ML, Keys H, Creasman W, DiSaia P, Bundy  B, Bl essing J. Survival and patterns of 
recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gyneco logic Oncol ogy 
Group study ). Gyneco l Onco l 1984;19(1):8 -16.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 137Brahmer et al 2012
Brahmer JR, Ty kodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safet y and activit y 
of anti-PD-L1 antibody  in pat ients with advanced cancer. N Engl J Med 2012;366(26):2455-
65.
Bruni et al 2016
Bruni L, Diaz M, Barrionuevo -Rosas L, He rrero R, Bray F, Bosch FX, et al. Global estimates 
of human papi[INVESTIGATOR_584171]: a pooled analysis. 
Lancet Glob Healt h 2016;4(7):e453-63.
Chen et al 2016
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray  F, et al . Cancer statistics in China, 
2015. CA Cancer J Clin 2016;66(2):115 -32.
Colombo et al 2012
Colombo N, Carinelli S, Colo mbo A, Marini C, Rollo D, Sessa C. Cervical cancer: ESMO 
Clinical pract ice guidelines for diagnosis, treatment and fo llow-up. Ann Onco l 
2012;23(7):vii27 -32.
Crosbie et al 2013
Crosbie EJ, Einstein MH, [LOCATION_009]schi S, Kitchener HC. Human papi[INVESTIGATOR_584172]. Lancet 2013;382(9895):889-99.
De Sanjose 2012
De Sanjose S, Serrano B, Castellsague X, Brotons M, Munoz J, Bruni L, et al . Hum an 
papi[INVESTIGATOR_358545] (HPV) and related cancers in the Glo bal Alliance for Vaccines and 
Immunizati on (GAVI) countri es. A WHO/ICO HPV Information Centre Report. Vaccine 
2012;30:D1 -83.
Dovedi et al [ADDRESS_768242] AL, Lipowska -Bhalla G, McKenna C, Jo nes S, Cheadle EJ, et al. Acquired 
resistance to fractionated radiotherapy  can be overcom e by [CONTACT_276279] -L1 blockade. 
Cancer Res 2014;74(19):[ADDRESS_768243] AL, Lipowska -Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acqui red 
resistance to fractionated radiotherapy  can be overcom e by [CONTACT_276279] -L1 blockade. 
Cancer Res 2014;74(19):[ADDRESS_768244]. The three Es of cancer immunoedit ing. Annu Rev Immuno l 
2004;22:329 -60.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 138Elit et al 2009
Elit L, Fyles AW, Devries MC, Oliver TK, Fung -Kee-Fung M. Fo llow-up for wom en after 
treatm ent for cervi cal cancer: a systemat ic review. Gyneco l Onco l 2009;114(3):528 -35.
Emeka et al 2017 
Emeka K Enwere, Elizabeth N Kornaga, Michelle Dean, Theodora A Koulis, Tien Phan, 
Mari a Kalantari an, Martin Köbel, Prafull Ghatage, Anthony  M Magli occo, Susan P Lees -
Miller & Corinne M Doll: Modern Pathology  2017; 30: 577 –586
EuroQol Group 1990
EuroQol  Group. EuroQol  -a new facilit y for the measurement of health
-related quali ty of life.
Health Policy  1990;16:199 -208.
EuroQol Group 2013
EuroQol  Group. EQ -5D- 5L User Guide: Basic information on how to use the EQ -5D-5L
instrum ent, Versi on 2.0, October 2013. Available from:
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/UserGuide_
EQ-5D- 5L_v2.0_October_2013.pdf.
Fairman et al 2014
Fairman D, Narwal R, Liang M, Robbins PB, Schneider A, Chavez C, et al. Pharmacokinet ics 
of durvalumab, a fully human a nti-PDL1 m onoclonal ant ibody , in pat ients with advanced 
solid tumours. J Clin Onco l, 2014 ASCO Annual Meet ing Abstracts;32(5s):(suppl; abstr 
2602).
Fayers et al 2001
Fayers P, Aaronson NK, Bjordal K, Curran D, Groenvo ld M on behalf o f the EORTC Qualit y 
of Life Study  Group. EORTC QLQ -C30 Scoring Manual: 3rd Edition 2001. Available on 
request.
FDA Guidance 2015
US Department of Health and Human Services Food and Drug Administration. Clinical Trial 
endpo ints for the approval of non -small  cell lung cancer drugs and bio logics: guidance for 
industry . 2015. Available fro m: URL: 
https://www.fda.gov/downloads/drugs/guidances/ucm259421.pdf. Accessed July 2018.
Formenti and Demaria 2013
Formenti SC and Demaria S. Combining radiotherapy  and cancer immunotherapy : a parad igm 
shift. J Natl Cancer Inst 2013;105(4):256- 65.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 139Ferlay et al 2013
Ferlay  J, Soerj omataram  I, Ervi k M, Di kshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 
v1.0, Cancer incidence and mortalit y worldwide: IARC CancerBase No. 11 [serial online] 
2013 [cited 20 18 March 17]. Available from: URL: http://globocan.iarc.fr.
Fuglsang et al 2015
Fuglsang K, Petersen LK, Blaakaer J. Addressing challenges in future surveillance after 
surgery  for early -stage cervical cancer. Int J Gynecol Cancer 2015;25(2):[ADDRESS_768245] ions between treatment effects and patient 
subsets. Bi ometrics 1985;41(2):361 -72.
Gien and Covens 2009
Gien LT and Covens A. Lymph node assessment in cervical cancer: prognostic and 
therapeuti c implicat ions. J Surg Oncol 2009;99(4):242-47.
Green et al 2001
Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and 
recurrence after concomitant chemotherapy  and radi otherapy  for cancer of the uterine cervix: 
a system atic review and meta -analysis. Lancet 2001;358(9284):781 -86.
Greimel et al 2006
Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S, et al, 
European Organizat ion for Research and Treatment of Cancer Qualit y-of-Life Group. The 
European O rganizat ion for Research and Treatment of Cancer (EORTC) Qualit y-of-Life 
questionnaire cervical cancer module: EORTC QLQ- CX24. Cancer. [ADDRESS_768246] 
15;107(8):1812 -22.
Gupta et al 2018
Gupta S, Maheshwari A, Parab P, Mahantshetty  U, Hawal dar R, Sastri  S, et al .Neoadj uvant 
chemotherapy fo llowed by  [CONTACT_584268]2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. 
JClin Onco l 2018;36(16):1548 -1555.
Haie -Meder et al 201 0
Haie-Meder C, Morice P, Castiglio ne M, EGW Group. Cervical cancer: ESMO Clinical 
practi ce guidelines for diagnosis, treatment and fo llow-up. Ann Oncol 2010;21(5):v37 -40.
Hanley et al 2015
Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccinat ion crisis in Japan. Lancet 
2015;385(9987): 2571.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 140Havrilesky et al 2004
Havrilesky LJ, Leath CA, Huh W, Calingaert B, Bent ley RC, Soper JT, et al. Radical 
hysterectomy and pelvic lymphadenectomy  for stage IB2 cervi cal cancer. Gynecol  Onco l 
2004;93(2):429 -34.
Hirano et a l 2005
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7 -H1 and 
PD-1 by [CONTACT_584269] y. Cancer Res 
2005;65(3):1089 -96.
Hollebecque et al 2017
Hollebecque A, Meyer T, Moore KN, Mac hiels JPH, Greve JD, López -Pi[INVESTIGATOR_584173], et al. An 
open -label, mult icohort, phase I/II study  of nivolumab in pat ients with virus -associ ated tum ors 
(CheckMate 358): Efficacy and safety  in recurrent or metastatic (R/M) cervical, vaginal, and 
vulvar cancers. J C lin Onco l 2017;35(15):5504.
Inoue et al 1990
Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical 
carcino ma stages IB, IIA, and IIB. Cancer 1990;65(9):1923- 7.
Iwai et al [ADDRESS_768247] immune system and tumor immunotherapy  by [CONTACT_4002] -L1 blockade. 
Proc Natl Acad Sci [LOCATION_003] 2002;99:[ZIP_CODE] -7.
Jin 2014
Jin J. JAMA pat ient page. Screening for cervical cancer. JAMA 2014;312(21):2302.
Juergens et al 2017
Juergens RA, Laurie SA, Ellis PM, Mates M, Bradbury P, Tehfe M, et al. Durvalumab ± 
tremelimumab wit h platinum -doublets in non -small  cell lung cancer: Canadian Cancer Trials 
Group Study  IND.226 (ID 8700). Presented at WCLC 2017; Octov er 17, 2017.
Karim et al 2009
Karim R, Jordanova ES, Pi[INVESTIGATOR_44822], Kenter GG, Chen L, Boer JM, et al. Tumor -expressed 
B7-H1 and B7 -DC in relat ion to PD -1+ T -cell Infiltration and survival o f patients with 
cervical carcino ma. Clin Cancer Res 2009;15(20):6341 -7.
Kasuya et al 2013
Kasuya G, Ogawa K, Iraha S, Nagai Y, Hirakawa M, Toita T, et al. Postoperative 
radiotherapy  for uterine cervical cancer: impact of lymph node and histological t ype on 
survival. Ant icancer Res 2013;33(5):2199 -204.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 141Katanyoo et al 2011
Katanyoo K, Tangji tgam ol S, Chongthanakorn M, Tant ivatana T, Manusirivit haya S, 
Rongsriyam K, et al. Treatment outcomes of concurrent weekly carboplat in with radiat ion 
therapy  in locally  advanced cervical  cancer pati ents. Gynecol  Oncol  2011;123(3):571 -6.
Keir et al 2008
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD -1 and i ts ligands in tol erance and immunit y. 
Annu Rev Immuno l 2008;26:677 -704.
Koh et al 2013
Koh WJ, Greer BE, Abu -Rustum  NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. 
JNatl Com pr Canc N etw 2013;11(3):320 -43.
Kokka et al 2015
Kokka F, Bry ant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy  or 
chemotherapy or both for women wit h locally advanced cervical cancer. Cochrane Database 
of Systematic Reviews 2015, Issue 4. Art. No.: CD010260. DOI: 
10.1002/14651858.CD010260.pub2.
Lai et al 1993
Lai CH, Chang HC, ChangTC, Hsueh S, Tang SG. Prognostic factors and impacts of adjuvant 
therapy  in early -stage cervical carcino ma wit h pelvic node metastases. Gynecol Onco l 
1993;51(3):[ADDRESS_768248] atin and pemetrexed wit h or without pembrolizumab for advanced, non -squamous 
non-small -cell lung cancer: a randomised, phase 2 cohort of the open -label KEYNOTE -
021 
study . Lancet Oncol  2016;17(11):1497-508.
Lan and DeMets 1983
Lan KKG, DeMets DL. Discrete sequent ial boundari es for clinical trials. Bio metrika 
1983;70:659 -63.
Lee et al 2006
Lee KB, Lee JM, Park CY, Lee KB, Cho HY, Ha SY. Lymph nod e metastasi s and lymph 
vascular space invasio n in microinvasive squamous cell carcino ma of the uterine cervix. Int J 
Gyneco l Cancer 2006;16(3):1184 -7.
Lepi[INVESTIGATOR_584153] 2009
Lepi[INVESTIGATOR_584174], Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages 
suppress ant itumor T cell responses. Clin Cancer Res 2009;15(13):[ADDRESS_768249] and patient 
assessments of health related qualit y of life in men with prostate cancer: resul ts of the 
CaPSURE database. J Urol 1998;159:[ADDRESS_768250] 
2016;116(5):1167 -73.
Macdonald et al 2009
Macdonald OK, Chen J, Dodson M, Lee CM, Gaffney DK. Prognos tic significance of 
histol ogy and posi tive lymph node invo lvement fo llowing radi cal hysterectomy in carcino ma 
of the cervix. Am J Clin Onco l 2009;32(4):[ADDRESS_768251] five years. Vaccine 2012;30(5):F139 -48.
Marth et al 2017
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez -Martin A, Colo mbo N, et al. 
Cervical cancer: ESMO Clinical pract ice guidelines for diagnosis, treatment and fo llow-up. 
Ann Onco l 2017;28(suppl_4):iv72 -83.Mauguen et al 2013
Maugen A, Pi[INVESTIGATOR_119603] J, Burdett S, Domerg C, Fisher D, Paulus R, et al . Surrogate endpoints 
for overall  survival in chemotherapy and radiotherapy  trials in operable and locally  advanced 
lung cancer: a re -analysis o f meta-analyses of individual patients’ data. Lancet Onco l 
2013;14(7):619 -26.
Mazeron et al 2016
Radiotherapy  and Oncol ogy 120 (2016) 460 –466 
http://dx.doi.org/10.1016/j.radonc.2016.07.010
Menderes et al 2016
Menderes G, Black J, S chwab CL, Sant in AD. Immunotherapy and targeted therapy for 
cervical cancer: an update. Expert Rev Ant icancer Ther 2016;16(1):[ADDRESS_768252] of pelvic 
and paraaortic lymphadenectomy in pat ients with stage IB and II cervical carcino ma. Gyneco l 
Onco l 1999;73(1):[ADDRESS_768253] 2013;18(7):843- 9.
Narwal et al 2013
Narwal  R, Roskos LK, Robbie GJ. Popul ation ph armacokinet ics of sifalimumab, an 
investigat ional ant i-interferonalpha m onocl onal antibody , in systemic lupus ery thematosus. 
Clin Pharmacokinet 2013;52:1017 -27.
NCCN 2020
NCCN guidelines versio n 1.2020, 
https://www.nccn.org/professio nals/physician_gls/pdf/cervical.pdf accessed April 13, 2020.
Ng et al 2006
Ng CM, Lum  BL, Gimenez V, Kelsey S, Alliso n D. Rati onale for fixed dosing of pertuzumab 
in cancer patients based on populat ion pharmacokinet ic analysis . Pharm  Res 2006;23(6):1275-
84.
Oemar and Oppe 2013
Oem ar M, Oppe M. EQ -5D- 3L User Guide: Basic informat ion on how to use the EQ -5D-3L
instrum ent V5.0 (October 2013). Available fro m:
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyer s/EQ -5D-
3L_UserGuide_2013_v5.0_October_2013.pdf.
Ojesina et al 2014
Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz -Rosshandler I, Pugh TJ, et al. 
Landscape of genomic alterat ions in cervical carcino mas. Nature 2014;506(7488):371 -5.
Okazaki et al 2007
Okazaki T, Honjo T. PD -1 and PD- 1 ligands: from discovery to clinical application. Int 
Immunol 2007;19(7):[ADDRESS_768254] in a mouse pancreatic cancer model. Int J Oncol 
2009;35(4):741 -9.
Osoba et al 1998
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in 
healt h-related qualit y-of-life scores. J Clin Onco l 1998;16(1):139 -44.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 144Pardoll 2012
Pardoll DM. The blockade of immune checkpo ints in cancer immunotherapy . Nat Rev Cancer 
2012;12:[ADDRESS_768255] 
2008;13(suppl 2):19 -21.
Pecorelli et al. 2009
Revised FIGO staging for carcinoma of the cervix. International Journal o f Gyneco logy and 
Obstetri cs 105 (2009) 107 –108.
Petereit et al. [ADDRESS_768256] in a patient with melano ma. N Engl J Med 2012;366(10):925 -
31.
Powles et al 2014
Powl es T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (ant i
-PD-L1) 
treatm ent leads to clinical act ivity in metastati c bladder cancer. Nature 2014;515(7528):558 -
62.
Qin et al 2016
Qin A, Coffey DG, Warren EH, Ramnath N. Mechanisms o f immune evasio n and current 
status of checkpo int inhibitors in non- small  cell lung cancer. Cancer Med 2016; 9:2169-70.
Qin et al [ADDRESS_768257] ivity is associated with human papi[INVESTIGATOR_584175]. Fr ont Immuno l 2017;8:689.
Quinn etal 2006
Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcino ma 
of the cervix uteri. Int J Gyneco l Obstet 2006;95(Suppl 1):43-103.
Rizvi et al [ADDRESS_768258] ivity of 
MEDI4736, an anti -programmed cell death -ligand -1 (PD -L1) antibody, in pat ients with 
nonsmall cell lung cancer (NSCLC). J Clin Onco l 2015;33:Abstract 8032.

Clinical Study Proto col -4.[ADDRESS_768259] -line treatment 
of advanced non -small -cell lung cancer. J Clin Oncol. 2016;34(25):2969 -79.
Ronco et al 2014
Ronco G, Dillner J, Elfstrom KM , Tunesi  S, Snijders PJ, Arbyn M, et al. Efficacy  of HPV -
based screening for prevent ion of invasive cervical cancer: fo llow-up of  four European 
rando mised controlled trials. Lancet 2014;383(9916):524 -32.
Rose et al 1999
Rose PG, Bundy  BN, Watkins EB, Thi gpen JT, Deppe G, Maiman MA, et al. Concurrent 
cisplatin -based radiotherapy  and chem otherapy  for locally  advanced cervical  cancer. N Engl  J 
Med 1999;340(15):1144 -53.
Sakuragi et al 1999
Sakuragi  N, Satoh C, [COMPANY_005] N, Harey ama H, [COMPANY_005] M, Yamamoto R, et al. Incidence and 
distribut ion pattern of pelvic and paraaortic lymph node metastasis in pat ients with Stages IB, 
IIA, and IIB cervical carcino ma treated with radical hysterectomy . Cancer 1999;85(7):1547 -
54.
Salama et al 2016
Salama AKS, Postow MA, Salama JK. Irradi ation and immunotherapy : from concept to the 
clinic. Cancer 2016;122(11):1659 -
71.
Samlal et al 1998
Samlal RA, Van Der Velden J, Van Eerden T, Schilt huis MS, Gonzalez D, Lammes FB. 
Recurrent cervical carcino ma after radical hysterectomy: an analysis of clinical  aspects and 
prognosi s. Int J Gynecol  Cancer 1998;8(1):78 -84.
Schellens et al 2017
Schellens JHM, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC. Pembrolizumab for 
previously treated advanced cervical squamous cell cancer: preliminary  resul ts from the phase 
2 KEYNOTE- 158 study . J Clin Oncol  2017;35(15):5514.
Segal et al 2015
Segal  NH, Ou S- HI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safet y and 
efficacy  of MEDI4736, an ant i-PD-L1 ant ibody , in pati ents fro m a squamous c ell carcino ma 
of the head and neck (SCCHN) expansio n cohort. J Clin Onco l 2015;33:Abstract 3011.
Sekine et al 2016
Sekine M, Kudo R, Adachi S, Yamaguchi M, Ueda Y, Takata T, et al. Japanese crisis of HPV 
vaccination. Int J Path Clin Res 2016;2(2).

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 146Sharabi etal 2014
Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francisca BJ, Velarde E, et al. Stereotactic 
radiation therapy  augments ant igen-specific pd-1- mediated ant i-tumor immune responses via 
cross -presentation of tumor antigen. Cancer Immuno l Res 2015;3( 4):345 –55.
Sharabi etal 2015
Sharabi AB, Tran PT, Lim M, Drake CG, DeWeese TL. Stereotactic radiotherapy  combined 
with immunotherapy : augmenting radiat ion’s rol e in l ocal and systemic treatm ent. Oncol ogy 
(Williston Park) 2015;29(5):331 -40.
Sprangers and A aronson 1992
Sprangers MA, Aaronson NK. The role of healt h care providers and significant others in 
evaluat ing the qualit y of life o f patients wi th chronic disease: a review. J Clin Epi[INVESTIGATOR_33408] l 
1992;45:743 -
60.
Song et al. 2013
Song et al. Cancer 2013;119:325 -31. DOI: 10.1002/cncr.[ADDRESS_768260] associated with 
a systemic ant i-melano ma immune response . Int J Radiat Oncol Bio l Phys 2013;85(2):[ADDRESS_768261] ic ant i-PD-L1 m onocl onal antibody . Cancer 
Immunol Res 2015;3(9):1052-62.
Sun and Chen 2010
Sun X, Chen C. Comparison of Finkelstein's method with the convent ional approach for 
interval -censored data analysis. Stat Biopharm Res 2010;2(1):[ADDRESS_768262] Rev 2014;(12):Cd010401.
Topalian et al 2012
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activit y, and immune correl ates of a nti-PD-1 antibody  in cancer. N Engl J Med 
2012;366:2443-54.

Clinical Study Proto col -4.[ADDRESS_768263], Sharfman WH et al. 
Survival, durable tumor remissio n, and lo ng-term safety in pat ients with advanced m elano ma 
receiv ing nivo lumab. J Clin Onco l 2014;32:1020 -30.
Twyman -Saint Victor et al 2015
Twyman -Saint Vi ctor C, Rech AJ, Mait y A, Rengan R, Pauken KE, Stelekat i E, et al . 
Radiation and dual checkpo int blockade activate non -redundant immune mechanisms in 
cancer. Nature 2015;520(7547):373- 7.
USPSTF 2016
US Prevent ive Services Task Force. Final update summary: cervical cancer: screening 
[online] 2016 [cited 2018 17 March]. Available from: URL: 
https://www.usprevent iveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervica
l-cancer -screening.
Valdivieso et al 2017
Valdivieso N, Am aro VP, Carretero CR, Nieto NP, Flores CJ, Chavez JFVet al. Which is 
better? Carboplat in versus cisplat in for locally advanced cervical cancer: Peruvian experience. 
J Clin Onco l 2017;35(15):e17004.
Wagenaar et al [ADDRESS_768264] RJ, Reiber JH, et al. 
Tumor diameter and volume assessed by  [CONTACT_584270] e for invasive cervical cancer. Gynecol Oncol 2001;82(3):474 -82.
Wang et al 2009
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body  size based dosing 
of monocl onal ant ibodies in adult clinical trials. J Cl in Pharm acol 2009;49(9):1012 -24.
Weichselbaum et al 2017
Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy  and immunotherapy : a beneficial 
liason? Nat Rev Clin Onco l 2017;14(6):365 -79.
Wiebe et al 2012
Wiebe E, Denny  L, Thom as G. Cancer of the cervix uteri. Int J Gynaecol  Obstet 
2012;119(2):S100 -9.
Yang et al 2017
Yang W, Lu YP, Yang YZ, Kang JR, Jin YD, Wang HW. Expressio ns of programmed death 
(PD) -1 and PD -1 ligand (PD -L1) in cervical intraepi[INVESTIGATOR_584176] e of prognosti c value and associated wi th human papi[INVESTIGATOR_584177]. J 
Obstet Gynaeco l Res 2013;43(10):1602-12.

Clinical Study Proto col -4.0 [COMPANY_008]
Durvalumab
CONFIDENTIAL AND PROPRIETARY 148Yarchoan et al 2017
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutatio nal burden and response rate to PD -1 
inhibit ion. N Engl J Med 2017;377(25): 2500-1.
Yoon et al [ADDRESS_768265] of concurrent chemotherapy  on uterine cervical 
cancer wi th para -aortic lymph node metastasis. Radiat Onco l2015;10:18.
Zhang et al 2008
Zhang C, Wu S, Xue X, Li M, Qin X, Li W, et al. Ant itumor immunotherapy  by [CONTACT_570471] -1/PD -L1 pathway with reco mbinant human PD -
1-IgV. Cy totherapy  2008;10(7):711 -9.
Zhang et al
2012
Zhang S, Shi R, Li C, Parivar K, Wan g DD. Fixed dosing versus body  size-based dosing of 
therapeuti c pept ides and proteins in adult s. J Clin Pharmaco l 2012;52(1):18 -28.
Zhou et al 2017
Zhou J, Wu SG, Sun JY, Liao XL, Li FY, Lin HX, et al. Incorporation of the number of 
positive lymph nodes le ads to better prognostic discrimination of node -positive early  stage 
cervical cancer. Oncotarget 2017;8(16):[ZIP_CODE] -65.

6,*1$785(3$*(
7KLVLVDUHSUHVHQWDWLRQRIDQHOHFWURQLFUHFRUGWKDWZDVVLJQHG
HOHFWURQLFDOO\DQGWKLVSDJHLVWKHPDQLIHVWDWLRQRIWKHHOHFWURQLFVLJQDWXUH
'RFXPHQW1DPHGFFVSY
'RFXPHQW7LWOH '&&OLQLFDO6WXG\3URWRFROYHUVLRQ
'RFXPHQW,'
9HUVLRQ/DEHO &855(17/$7(67$[ZIP_CODE]('
6HUYHU'DWH
GG000\\\\++PPµ87&¶=6LJQHGE\ 0HDQLQJRI6LJQDWXUH
0DU87& $XWKRU$SSURYDO
0DU87& &RQWHQW$SSURYDO
0DU87& &RQWHQW$SSURYDO
0DU87& &RQWHQW$SSURYDOCCI
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CCI